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Asymmetric transition-metal catalysis constitutes one of the most powerful strategies to construct 
non-racemic chiral molecules. This thesis deals with enantioselelctive catalysis of chiral-at-metal 
iridium and ruthenium complexes as well as a chiral mono-cyclometalated ruthenium complex. 
1) Kinetic resolution of racemic epoxides with CO2 catalyzed by a chiral-at-metal 
bis-cyclometalated iridium complex was accomplished, and s-factors between 6.4 and 16.6 were 
obtained for overall 21 monosubstituted epoxides containing diverse functional side chains. Notably, 
all reactions were performed at room temperature, and no copolymerization side reaction which 
occurred often in other catalytic systems was observed (Chapter 3.1). 
2) Enantioselective intramolecular benzylic C-H amination of primary aliphatic azides was 
achieved by using a chiral-at-metal bis(pyridyl-NHC) ruthenium complex in combination with 
tris(p-fluorophenyl)phosphine (both 1 mol%) to provide a vatiety of chiral -aryl pyrrolidines with 
enantioselectivities of up to 99% ee. In this unique case, the phosphine serves as a crucial nitrene 
transfer co-catalyst and activates the organic azide through the formation of an intermediate 
iminophosphorane. This methodology offers direct access to non-racemic -aryl pyrrolidines which 
are very important structural motifs in many bioactive compounds. (Chapter 3.2). 
3) A chiral cyclometalated ruthenium catalyst enabled direct enantioselective and highly 
diastereoselective oxidative homocoupling of 2-acyl imidazoles in the presence of one equivalent 
BrCCl3 to provide chiral symmetric 1,4-dicarbonyl compounds in 38-75% yield with 57-95% ee. Only 
one diastereomer was obtained for all the investigated substrates. Mechanistic experiments support a 
unique ruthenium catalyzed two-steps mechanism. The first step is a ruthenium catalyzed bromination 
of 2-acyl imidazole generating a brominated intermediate, followed by a ruthenium catalyzed 





Die asymmetrische Übergangsmetallkatalyse stellt eine der effektivsten Methoden zum Aufbau 
chiraler Moleküle dar. In dieser Arbeit wird sowohl die enantioselektive Katalyse mit chiral-at-metal 
Iridium- und Rutheniumkomplexen als auch mit chiralen mono-cyclometallierten 
Rutheniumkomplexen thematisiert.  
1) Eine kinetische Racematspaltung von racemischen Epoxiden mit CO2 katalysiert durch einen 
chiral-at-metal, bis-cyclometallierten Iridiumkomplex konnte erfolgreich durchgeführt werden, wobei 
s-Faktoren von 6.4 bis 16.6 für insgesamt 21 monosubstituierte Epoxide mit verschieden 
funktionalisierten Seitenketten erreicht werden konnten. Bemerkenswerterweise konnten alle 
Reaktionen bei Raumtemperatur durchgeführt werden. Hierbei wurde keine Copolymerisation als 
Nebenreaktion beobachtet, welche in anderen katalytischen Systemen häufig auftrat. (Kapitel 3.1). 
2) Die enantioselektive, intramolekulare, benzylische C-H-Aminierung von primären, 
aliphatischen Aziden wurde durch die Verwendung eines chiral-at-metal, 
bis(pyridyl-NHC)-Rutheniumkomplexes in Kombination mit Tris(p-fluorophenyl)phosphin (beide 1 
mol%) erfolgreich angewandt, um eine Vielzahl chiraler α-Arylpyrrolidine mit bis zu 99% ee zu 
synthetisieren. In diesem einzigartigen Fall dient das Phosphin als entscheidender 
Nitren-Transfer-Cokatalysator, der das organische Azid durch Bildung eines intermediären 
Iminophosphorans aktiviert. Diese Methode bietet somit einen direkten, synthetischen Zugang zu 
chiralen α-Arylpyrrolidinen, die ein wichtiges Strukturmotiv in vielen bioaktiven Wirkstoffen sind 
(Kapitel 3.2).  
3) Ein chiraler, cyclometallierter Ruthenium-Katalysator ermöglichte die direkte, enantioselektive 
und hochgradig diastereoselektive, oxidative Homokupplung von 2-Acylimidazolen in Anwesenheit 
eines Äquivalents BrCCl3, um chirale 1,4-Dicarbonylverbindungen mit einer Ausbeute von 38-75% 
und 57-95% ee zu erhalten. Bemerkenswerterweise wurde nur ein Diastereomer für alle untersuchten 
Substrate erhalten. Mechanistische Untersuchungen unterstützen einen einzigartigen 
Ruthenium-katalysierten Zwei-Stufen-Mechanismus. Der erste Schritt hierbei ist eine 
Ruthenium-katalysierte Bromierung der 2-Acylimidazole, welche das bromierte Produkt generiert, 
gefolgt von der Ruthenium-katalysierten, stereokontrollierten Radikal-Enolat Reaktion, die daraufhin 
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Chapter 1: Theoretical Part 
1.1 Introduction  
The importance of molecular chirality has been demonstrated for a long time. It is an essential 
objective for chemists to discover efficient methods for constructing non-racemic molecules.
1
 To date, 
different kinds of strategies have been developed to achieve this goal. Asymmetric catalysis represents 
one of the most economic methods to synthesize enantiopure compounds, which involves three main 
branches: transition-metal catalysis, organocatalysis and enzyme catalysis. The reactivity of transition 
metals can be easily tuned by the ligands around the metal center, thus making transition-metal 
catalysis a powerful and flexible tool to synthesize organic molecules. In 2001, the Nobel Prize in 
Chemistry was awarded to Knowles, Noyori, and Sharpless for their contributions to the asymmetric 
hydrogenation and oxidation,
2
 thereby recognizing the prominent role of asymmetric transition-metal 
catalysis. 
The work of this thesis is focused on asymmetric transition-metal catalysis including three 
sections: kinetic resolution of epoxides with CO2 catalyzed by a chiral-at-iridium complex, 
enantioselective intramolecular C-H amination of aliphatic azides by dual ruthenium and phosphine 
catalysis, and a ruthenium catalyzed asymmetric oxidative homocoupling of 2-acyl imidazoles. In the 
following, the theoretical part will introduce the background for these three topics. 
1.2 Kinetic Resolution of Epoxides with CO2 
The reaction of epoxides with CO2 to form cyclic carbonates has attracted much attention since 
CO2 constitutes a sustainable C1 feedstock.
3
 The reaction is highly atom economical, and the resulting 
cyclic carbonates are important synthetic building blocks.
4
 Although many efficient catalysts are 
known for the racemic reactions,
5
 the kinetic resolution of racemic epoxides with CO2 poses 
significant challenges.
6
 The selectivity factor s, which is defined as the ratio of the rate constants (kR 
and kS) for the reaction with the two individual enantiomers (s = kR/kS), is typically quite low (s < 10). 
The existing catalytic systems for the kinetic resolution normally consist of a chiral Lewis acid 
for activation of the epoxide in combination with a reversible nucleophile as co-catalyst for the 
epoxide ring opening (Figure 1).
5
 The enantiodifferentiation either already occurs during the 




formation of the Lewis acid-substrate complex I or in the subsequent reaction of the formation of the 
ring-opened alkoxide intermediate II upon the addition of nucleophile. 
 
Figure 1. General mechanism of a binary catalytic system for the kinetic resolution of epoxides with 
CO2. 
1.2.1 Metal Catalysts for the Kinetic Resolution of Epoxides with CO2 
The earliest study dates back to 1993.
7
 Vogt and co-workers reported the kinetic resolution of 
epoxides with CO2 by chiral titanium or vanadium-binol complexes, providing s-factors only up to 2.6 
(Scheme 1). 
 
Scheme 1. Kinetic resolution of styrene epoxide with CO2 catalyzed by Ti(OiPr)4/binol. 
In the following several years, chiral cobalt Schiff base complexes have been the most studied 
catalysts and showed the most successful results, which were firstly introduced by Lu and co-workers 
in 2004.
9
 In presence of 0.1 mol% Co
III
(salen)1 in combination with n-butylammonium chloride 
(nBu4NCl) as co-catalyst, s-factors of up to 9.0 at 40% conversion were obtained for propylene 
carbonate (Figure 2a). In their study, the nature of the co-catalyst had great influence on the s-factor. 




For example, the use of nBu4NCl was more beneficial for improving enantiomeric excess of the 
product compared with nBu4NBr and nBu4NI. The same year, Nguyen and co-workers reported a 
similar catalyst Co
III
(salen)2 (0.1 mol%) together with (R)-(+)-4-dimethylaminopyridinyl 
(pentaphenylcyclopentadienyl)iron (DMAP*) as co-catalyst, but s-factors of only 5.6 at very low 
conversion of 8% were obtained (Figure 2a).
8
 Further improvement was achieved by Berkessel and 





(salen)3) and employing bis-(triphenylphosphoranylidene)ammonium 
fluoride (PPNF) as co-catalyst, but the reaction was reacted at -40 °C for 5 days (Figure 2a).
10
  
Encouraged by these results, a number of modified chiral cobalt Schiff base catalysts were 
developed.
11,12
 Jing and co-workers made great contributions to this field.
11
 For example, they 
employed a polymer based catalyst Co
III
(salen)4 together with n-butylammonium fluorine (nBu4NF) 
as co-catalyst and obtained a good s-factor of 10.2 for propylene carbonate (Figure 2b).
11c
 This catalyst 
could be recovered and reused for more than ten times without loss of activity and enantioselectivity. 
In 2012, Lu and co-workers reported the most effective catalyst Co
III
(salen)5. With this particular 
catalyst and 200 equivalents of co-catalyst bis-(triphenylphosphoranyliden)ammonium 
2,4-dinitrophenoxide (PPN-DNP) (for the purpose of suppressing copolymerization side reaction), the 
reaction provided an impressive kinetic resolution with an s-factor of 75.8 at -25 °C but at a very low 





(salen) complexes, a series of ketoiminatocobalt(II) complexes developed by 
Yamada and co-workers also displayed good activities for this transformation.
14
 For example, 
Co
II
(salen)6 could catalyze the kinetic resolution of N-(2,3-epoxypropyl)diphenylamine with CO2 
providing s-factors of up to 43.5 (Figure 2c).
14b
 Unfortunately, this system suffered the 
copolymerization as side reaction for most of the investigated substrates. And the s-factor was 
sensitive to the nature of the epoxide. For example, the s-factor dramatically dropped to 2.2 for the 
substrate glycidyl phenyl ether. 
There are some problems associated with the kinetic resolution of epoxides with CO2 in spite of 
the encouraging results based on chiral cobalt Schiff base catalysts: the substrate was mainly focused 
on propylene epoxide, and the reaction had poor substrate tolerance. For example, although for 
propylene epoxide substrate Co
III
(salen)4 provided an s-fator of 10.2,
 
no kinetic resolution could be 
obtained (46% conversion with 0% ee) once the substrate was changed to glycidyl phenyl ether.
11c
  





Figure 2. Kinetic resolution of epoxides with CO2 catalyzed by chiral cobalt Schiff base catalysts.  




In addition to chiral cobalt Schiff base catalysts, a number of other salen-metal complexes were 
also explored for this transformation. In 2013, Jiang and co-workers reported a Ni(salen) complex 
incorporated within a MOF giving very modest s-factors of up to 3.2 for the kinetic resolution of 
propylene epoxide with CO2.
15b
 Two years later, North and co-workers demonstrated that both 
complexes Al(salen) and Cr(salen) could be employed as catalysts for the kinetic resolution of 
N-(2,3-epoxypropyl)diphenylamine with CO2 providing s-factors of up to 15.4 (Figure 3).
15c
 
Unfortunately, these salen-metal catalysts are also very sensitive to the nature of the epoxide. For 
example, the s-factor decreased to less than 5 when glycidyl phenyl ether was used as substrate. 
 
Figure 3. Kinetic resolution of N-(2,3-epoxypropyl)diphenylamine with CO2 catalyzed by Al(salen) 
and Cr(salen). 
1.2.2 Organocatalysts for the Kinetic Resolution of Epoxides with CO2 
Organocatalysts have recently also been investigated for the kinetic resolution of epoxides with 
CO2.
16
 In 2016, Shirakawa and co-workers designed a bifunctional quaternary phosphonium bromine 
catalyst for the kinetic resolution reaction (the upper reaction in Figure 4),
16a
 and the co-catalyst was 
not needed in this system. However, only two substrates with very low s-factors (less than 1.5) were 
presented. One year later, Ema and co-workers developed a series of chiral macrocyclic 
organocatalysts,
16b
 which performed well for the kinetic resolution of disubstituted epoxides with CO2 
providing s-factors of up to 13.0 (the bottom reaction in Figure 4). But for monosubstituted epoxides, 
the s-factors dropped to below 4.5. 





Figure 4. Kinetic resolution of epoxides with CO2 catalyzed by organocatalysts. 
1.3 Enantioselective C(sp
3
)-H Aminations through Metal-Imido Intermediates 
C-H amination represents an attractive strategy to activate C-H bonds and construct C-N bonds.
17
 
This method offers a way to synthesize nitrogen-containing molecules which constitute a prominent 
structural motif in many bioactive compounds.
18
 One important mechanism of C-H amination is the 
socalled ‘C-H insertion catalysis’ which proceeds through a metal-imido intermediate.
17f
 Generally, the 
catalytic process involves the formation of a metal-imido species through reaction between the metal 
catalyst and a suitable aminating reagent (such as amine, amide, imidoiodinane, organic azide and so 
on), followed by a C-H insertion to afford the target product (Figure 5). There are two mechanisms for 
the C-H insertion step: one is the direct C-H insertion (in a concerted way); another goes through a 
stepwise radical mechanism with H-atom abstraction, followed by radical recombination. Which 
mechanism is employed mainly relates to the nature of the catalyst. However, enantioselective 
C(sp
3
)-H aminations through the metal-imido intermediate are still underdeveloped. In the following, 
enantioselective inter- or intramolecular C(sp
3
)-H aminations via nitrene insertion catalyzed by 
transition-metal complexes and enzymes will be reviewed. 





Figure 5. General process of C-H amination through metal-imido intermediate. 
1.3.1 Catalytic Enantioselective Intramolecular C(sp
3
)-H Amination 
In 2002, Che and co-workers reported the first metalloporphyrin-catalyzed enantioselective 
intramolecular benzylic C-H amination.
19
 In the presence of 1.5 mol% chiral ruthenium porphyrin and 
PhI(OAc)2 as the oxidant, sulfamate esters could be transformed to cyclic sulfamidates with up to 87% 
ee (the upper reaction in Figure 6). Low reaction temperature was required for obtaining good 
enantioselectivity, but which sacrificed the reaction yield (less than 40% yields in some cases). Later 
in 2008, Blakey and co-workers developed a ruthenium pybox complex to catalyze the C-H amination 
of sulfamate esters in the presence of PhI(O2CtBu)2 , offering moderate to good ees (75-92%) in good 
yields (the middle reaction in Figure 6).
20
 Substrates investigated in this study are broader than Che’s 
report, which contain aromatic groups, one allylic group and even one alkyl group but with very poor 
yield of 14%. In the same year, Du Bois and co-workers reported the enantioselective intramolecular 
benzylic or allylic C-H amination of sulfamate esters by using the chiral dirhodium(II) complex 
Rh2(S-nap)4 as catalyst and PhIO as the oxidant (the bottom reaction in Figure 6).
21
 This catalytic 
system displayed unprecedented performance especially for sulfamate esters containing aromatic 
groups, and enantioselectivities of up to 99% ee could be obtained in up to 98% yield. For homoallyl 
sulfamate ester substrate, C-H amination product is favored and no aziridination product formed when 
employing Rh2(S-nap)4 as the catalyst.  





Figure 6. Transition-metal catalyzed enantioselective intramolecular C-H amination of sulfamate 
esters in the presence of stoichiometric amount of oxidant. 
The possible mechanism of above examples might be as follows: the sulfamate ester firstly 
reacted with the oxidant to form an iminoiodane species (PhI=NR), which then reacted with the metal 
catalyst affording the metal-imido intermediate, followed by intramolecular C-H insertion to afford the 
product. Stoichiometric amount of oxidant such as PhI(OAc)2 is required in the above systems, which 
is definitely a disadvantage. An obvious way forward is to choose organic azides as starting materials 
because no additional oxidant is required, and the only by-product is dinitrogen. In 2011, Katsuki and 




co-workers reported that iridium(III)-salen complexes served as efficient catalysts for asymmetric 
intramolecular C-H aminations of benzenesulfonyl azides providing high enantioselectivities of up to 
93% ee (the upper reaction in Figure 7).
22
 This is the first example of a highly enantioselective 
intramolecular C-H amination starting with organic azides. Most recently, Zhang and co-workers 
reported the enantioselective 1,6-C-H amination of sulfamoyl azides by a chiral Co(II)-porphyrin 
complex (the bottom reaction in Figure 7).
23
 A series of the six-membered cyclic sulfamides were 
obtained in high yields (up to 95%) with excellent enantioselectivities (up to 98% ee). The substrate 
scope of this system was very broad, consisting of benzylic, allylic and propargylic C-H bonds, also 
electron-deficient C-H bonds, and even non-activated C-H bonds. Mechanistic studies supported that 
this reaction went through a stepwise radical mechanism. 
 
Figure 7. Transition-metal catalyzed enantioselective intramolecular C-H amination of sulfonyl 
azides. 




To avoid using an oxidant, N-tosyloxycarbamate was also chosen as the starting compound for 
intramolecular C-H amination reported by Davies and co-workers in 2006 (Scheme 2).
24
 C-H 
amination of N-tosyloxycarbamate was achieved by the dirhodium(II) complex Rh2(S-TCPTAD)4 
providing enantioselectivities of up to 82% ee. In this case, a tosylate group served as the leaving 
group.  
 
Scheme 2. Enantioselective intramolecular C-H amination of N-tosyloxycarbamate catalyzed by 
Rh2(S-TCPTAD)4. 
In addition to transition-metal catalysts, enzymes have also been investigated for enantioselective 
intramolecular C-H amination.
25
 The first highly active enzyme catalysts was reported by Arnold and 
co-workers in 2013.
25a 
Serine-ligated P450s (called P411s) were employed to catalyze the 
enantioselective C-H amination of sulfamoyl azides, which displayed moderate reactivity with 
enantioselectivities of up to 89% ee (the upper reaction in Figure 8). One year later, Fasan and 
co-workers reported an alternative enzyme system, a cysteine-ligated P450s catalyzed intramolecular 
C(sp
3
)-H amination of arylsulfonyl azide providing enantioselectivities of up to 91% ee (the middle 
reaction in Figure 8).
25b
 The catalytic activities of the above two examples originated from the iron 
porphyrin moieties of the enzymes, which reacted with the organic azides to form iron(IV)-imido 
intermediates. In 2017, Hartwig and co-workers reported that P450s derived from a thermophilic 
organism and containing an iridium porphyrin cofactor (Ir(Me)-PIX) could catalyze enantioselective 
intramolecular C-H amination of sulfonyl azides with up to 98% yield and 90% ee (the bottom 
reaction in Figure 8).
25c
 This system offered not only better chemoselectivity (C-H amination product 




vs reduction of the azide) but also broader substrate scope compared with the above two reports which 
employed iron porphyrins containing enzymes as catalysts.  
 
Figure 8. Enantioselective intramolecular C-H amination of sulfonyl azides catalyzed by enzymes. 
Due to the high energy barrier for C-H activation especially for the C(sp
3
)-H bond, 
electron-deficient organic azides (such as sulfonyl azides) are generally used as substrates for the C-H 
amination. Enantioselective intramolecular C(sp
3
)-H aminations of aliphatic azides is only a recent 
accomplishment, which will be of great significance, because it enables to directly synthesize 
saturated chiral N-heterocyclic compounds. In 2017, de Bruin and co-workers reported the only 
example of a catalytic enantioselective C(sp
3
)-H amination of (4-azidobutyl)benzene by using a chiral 
cobalt(II) porphyrin as catalyst affording 46% ee in 22% yield (Scheme 3).
26
 Unfortunately, the 
enantioselectivity was low. 





Scheme 3. Enantioselective intramolecular C-H amination of (4-azidobutyl)benzene catalyzed by a 
chiral cobalt(II) porphyrin. 
1.3.2 Catalytic Enantioselective Intermolecular C(sp
3
)-H Amination  
Intermolecular C(sp
3
)-H aminations are more challenging than intramolecular versions although 
the intermolecular C(sp
3
)-H amination was reported earlier. Asymmetric intermolecular benzylic C-H 
amination of indane catalyzed by a chiral dirhodium(II) complex was demonstrated by the Müller 
group in 1997, but it provided very low enantioselectivity of only 31% ee (the upper reaction in Figure 
9).
27a
 In 1999, Che and co-workers reported that chiral ruthenium and manganese porphyrins could 
catalyze the enantioselective C-H amination of ethylbenzene and ethylnaphthalenes leading to 58% ee 
in moderate to good yields (the middle reaction in Figure 9).
27b
 Two years later, Katsuki and 
co-workers reported that a Mn(salen) complex acted as the catalyst for enantioselective C-H 
aminations resulting in up to 89% ee at -40 °C (the bottom reaction in Figure 9).
27c
 Not only benzylic 
C-H, but also allylic C-H bond could be aminated in their catalytic system. Moreover, allylic C-H 
amination occurred in preference to aziridination with respect to cycloalkenes. 





Figure 9. Transition-metal catalyzed enantioselective intermolecular C-H amination with 
[N-(p-toluenesulfonyl)imino] phenyliodinane (PhINTs) as the aminating reagent. 
[N-(p-toluenesulfonyl)imino]phenyliodinane (PhINTs) was selected as the aminating reagent in 
all the above examples. As introduced in Chaper 1.3.1, organic azides constitute atom-efficient 
aminating reagents. In 2003, Katsuki and co-workers demonstrated that intermolecular allylic C-H 
amination could be realized by using a Ru(salen) complex as the catalyst and tosyl azide (TsN3) as the 
aminating reagent, which provided a good enantioselectivity of 80% ee but in a poor yield of 17% (the 
upper reaction in Figure 10).
28a
 Ten years later, the same group reported an improved Ru(salen) 




catalyst together with 2-(trimethylsilyl)ethanesulfonyl azide (SES) as the aminating reagent could 
highly enantio- and regioselective aminate benzylic and allylic C-H bonds with up to 99% ee in up to 




Figure 10. Transition-metal catalyzed enantioselective intermolecular C-H amination with 
electron-deficient organic azides as the aminating reagents. 
In 2017, Arnold and co-workers reported an iron-containing enzymatic catalyst based on a 
cytochrome P450 monooxygenase for the highly enantioselective intermolecular benzylic C-H 
amination by using tosyl azide as the aminating reagent (Scheme 4).
29
 The turnover number (TON) of 
this biocatalyst could reach up to 1300 with very good enantioselectivities of up to >99% ee. This 
methodolody could be used for the synthesis of a variety of chiral benzylic amines.  





Scheme 4. Enantioselective intermolecular benzylic C-H amination catalyzed by an engineered 
iron-haeme enzyme. 
1.4 Asymmetric Oxidative Coupling of Carbonyl Compounds 
An oxidative coupling of two carbonyl compounds offers a direct and efficient way to construct 
molecules contain 1,4-dicarbonyl moieties,
30
 which are important synthetic intermediates. Actually, 
indirect methods for the oxidative coupling of two carbonyl compounds have been reported a long 
time ago (Figure 11a).
30b
 Normally, the first step is to transform the carbonyl compounds to 
electron-rich enolates or related carbonyl derivatives (like enol silanes and enamines), then undergo 
the coupling reaction in the presence of an oxidant. According to this general scheme, different kinds 
of methods have been developed for the indirect oxidative coupling of carbonyl compounds including 
coupling of lithium metal enolates, intramolecular oxidative coupling of silyl bis-enol ethers, and 
enamine catalysis.  
There are three kinds of mechanisms
30
 for the enolate coupling: radical-radical coupling, 
radical-enolate reaction, and SN2 reaction (Figure 11b). How to control stereoselectivity (diastereo- 
and enantioselectivity) of these coupling reactions has been a difficult task. Most enantioselective 
oxidative couplings mainly relied on the use of stoichiometric chiral reagents or substrates containing 
a chiral auxiliary, catalytic asymmetric versions have been very limited.  
Ideally, chiral 1,4-dicarbonyl compounds could directly form by oxidative coupling of two 
nucleophilic carbonyls (Figure 11c), although this is very challenging and until recently only one 
example is reported.
31
 In the following, enantioselective oxidative couplings of two carbonyl 
compounds will be discussed. 





Figure 11. a) General scheme for oxidative coupling of carbonyl compounds; b) Mechanisms for the 
formation of the coupling product; c) Ideal way for oxidative coupling of carbonyl compounds. 
1.4.1 Indirect Asymmetric Oxidative Coupling of Carbonyl Compounds 
The most popular strategy of oxidative coupling starts with lithium metal enolates, and early 
examples of enantioselective oxidative coupling mainly relied on the use of substrates containing 
chiral auxiliaries.
32
 For example in 1993, Porter and co-workers reported the enolization of optically 
pure butyryloxazolidine by using LDA as the base, then enantioselective oxidative homocoupling 
occurred in the presence of CuCl2. Almost only syn-product was obtained (50% yield with 97% ee) 
(Figure 12a).
32a
 Based on this result, different kinds of chiral auxiliaries have been investigated for the 
asymmetric oxidative coupling (Figure 12b). Both the diastereoselectivity and enantioselectivity 
depend on the chiral auxiliaries and reaction conditions. Importantly, this methodology has been 
successfully applied for the synthesis of natural products. For example, the synthesis of (-)-hinokinin 








Figure 12. Chiral auxiliary-mediated asymmetric oxidative enolate coupling. 
In 2001, Schäfer and co-workers reported the enantioselective oxidative homocoupling by using a 
stoichiometric chiral ligand as additive, instead of chiral auxiliary, and homocoupling of 
3-(2-phenylacetyl)oxazolidin-2-one was achieved with up to 76% ee (Scheme 5).
33
 Unfortunately, the 
anti-product (mesometic product) rather the syn-product was obtained as the major diastereomer.  





Scheme 5. Asymmetric oxidative enolate coupling in the presence of stoichiometric amounts of chiral 
ligand. 
Besides going through lithium enolates, a related oxidative enolate coupling reported by Thomson 
and co-workers proceeded via silyl bis-enol ethers (Scheme 6).
34
 This strategy allowed for the 
convergent and stereoselectively assembly of polycyclic molecules through cross-coupling of chiral 
substrates. 
 
Scheme 6. Oxidative enolate cross-coupling via silyl bis-enol ethers. 
All the examples described above required using of chiral substrates or stoichiometric amount of 
chiral ligands to achieve enantioselective transformations. The first report of catalytic enantioselective 
oxidative enolate coupling was disclosed by MacMillan and co-workers in 2007 through enamine 
catalysis (Scheme 7).
35
 The enamine generated by reaction of the aldehyde substrate and the chiral 
imidazolidinone catalyst underwent oxidative bond formation with enol silane in the presence of ceric 
ammonium nitrate (CAN), providing the coupling products in high yields (55-92%) with excellent 




enantioselectivities (86-96% ee). 
 
Scheme 7. Catalytic enantioselective enolate oxidative coupling via enamine catalysis. 
1.4.2 Direct Asymmetric Oxidative Coupling of Carbonyl Compounds 
The only example of direct asymmetric oxidative coupling of two carbonyl compounds was 
reported very recently by Jørgensen and coworkers (Scheme 8).
31
 The homocoupling of α-branched 
aldehydes with good yields and moderate to excellent enantioselectivities was achieved in the 
presence of 40 mol% chiral amine catalyst and Ag2CO3 as the oxidant. Diastereoselectivities and 
enantioselectivities were sensitive to the nature of the substrates. Electron-poor aromatic aldehydes 
performed better than electron-rich substrates. Mechanism studies indicated that the homocoupling 
proceeds through a radical cation intermediate. 
 
Scheme 8. Direct enantioselective oxidative homocoupling of aldehydes. 
1.5 Conclusions 
(1) The reported catalysts for the kinetic resolution of epoxides with CO2 are mainly Schiff base metal 
complexes. Almost all the reported systems display poor substrate tolerance, and no general catalytic 
system for a variety of different epoxide substrates exists. Another problem is the reaction suffers from 




copolymerization side reaction especially when cobalt Schiff base used as catalysts. Development of 
new updated catalysts is therefore of great interest. 
(2) Both transition metal complexes and enzymes can catalyze enantioselective C(sp
3
)-H aminations 
through metal-imido intermediates with excellent enantioselectivities using organic azides with 
electron-withdrawing groups like sulfonyl azides as the aminating reagents. However, enantioselective 
C-H aminations of primary aliphatic organic azides are apparently much more difficult and only one 
example was recently disclosed but with low enantioselectivity of only 46% ee. Therefore, the 
development of new catalytic systems for highly enantioselective C-H aminations of primary aliphatic 
organic azides is of high interest. 
(3) As one of the most efficient ways to construct 1,4-carbonyl moieties, oxidative coupling of 
carbonyl compounds has been achieved by different kinds of indirect strategies, such as the oxidative 
coupling of lithium enolates. These indirect strategies go through a two-steps procedure: the first step 
is the enolization, the second step is an oxidative coupling of the formed enolate. However, the direct 
enantioselective oxidative coupling of carbonyl compounds which provides a more direct access to 
chiral 1,4-carbonyl molecules has been much less addressed. It will be of great interest to explore new 
catalytic systems for the direct asymmetric coupling of carbonyl compounds.  
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Chapter 2: Aim of the Work 
As one of the most important strategies to synthesizing non-racemic compounds, asymmetric 
catalysis by chiral transition metal catalysts has been extensively studied in the past several decades.
1
 
Typically, the chiral transition metal catalyst contains at least one chiral ligand which is the origin of 
the chirality during the catalytic transformation. A variety of chiral ligands, such as heteroatom 
(phosphorus, nitrogen, oxygen, sulfur)-containing ligands, carbene ligands, cyclometalated ligands, 
and cyclopentadienyl ligands, have been successfully developed and applied in asymmetric catalysis. 
In a different and more or less neglected strategy, the chiral transition metal complex includes only 
achiral ligands, in which the origin of the chirality is solely from the stereogenic metal center 
generated upon the asymmetric coordination of the achiral ligands around the central metal (Figure 
13).
2
 Compared with transition metal catalysts with chiral ligands, those with only achiral ligands are 
much less studied and only a recent development especially by the Meggers group. “Chiral-at-metal” 
will be used as a term throughout the thesis to describe such complexes, referring to chiral metal 
complexes with only achiral ligands in which the chirality is the exclusive result of a stereogenic metal 
center. Over the last 5 years, the Meggers group developed a series of chiral-at-metal complexes 
(include iridium, rhodium, and ruthenium) which possess metal-centered Λ- (left-handed propeller) or 
Δ-configuration (righthanded propeller) derived from the propeller-type arrangement of the two 
bidentate achiral ligands (Figure 13).
3-5
 Importantly, this novel class of chiral-at-metal complexes has 
been demonstrated as efficient catalysts for a variety of transformations (like Michael additions, 
Friedel-Crafts reactions, cycloadditions, asymmetric transfer hydrogenation, light-activated 









Figure 13. Chiral transition metal catalysts with chiral or achiral ligand and representative 
chiral-at-metal catalysts developed by the Meggers group. 
Aim 1: Expanding the catalytic properties of chiral-at-metal iridium catalysts 
As mentioned above, the chiral-at-metal iridium and rhodium complexes developed by the 
Meggers group have been used as powerful Lewis acids for a variety of transformations. To get high 
enantioselectivity, the substrates employed in the catalytic reactions such as 2-acyl imidazole usually 
contain an auxiliary moiety for two-point binding.
2b
 There are notable exceptions, like an 
iridium-catalyzed enantioselective transfer hydrogenation of arylketones.
6
 In this respect, one can 
wonder if there are other types of enantioselective transformations that can be catalyzed by the 
chiral-at-metal Lewis acid catalysts without utilizing a bidentate coordination of the substrate. Thus, 
the author of this thesis is interested in investigating new catalytic properties of chiral-at-iridium 
Lewis acids using different coordination modes (Figure 14). 





Figure 14. Aim1: Expand the catalytic properties of chiral-at-metal iridium catalysts. 
Aim 2: Expanding the catalytic properties of chiral-at-metal ruthenium catalyst 
In 2017, former group member Yu Zheng synthesized a novel chiral-at-ruthenium complex 
coordinated by two N-(2-pyridyl)-substituted N-heterocyclic carbene (PyNHC) bidentate ligands in 
addition to two acetonitrile ligands in a C2-symmetric fashion.
5
 This ruthenium complex displayed 
high activity (up to 99% yield) and enantioselectivity (up to >99% ee) for the asymmetric alkynylation 
of trifluoromethyl ketones. It is well known that a variety of reactive intermediates can be generated 
through ruthenium complexes (like ruthenium-oxo, ruthenium-imido, ruthenium-hydride and so on). 
Further investigation of the catalytic properties of this type of chiral-at-ruthenium catalysts will be of 
high interest for our group, which is thus my aim of work (Figure 15). 
 
Figure 15. Aim 2: Expand the catalytic properties of chiral-at-metal ruthenium catalysts. 




Aim 3: Expanding the catalytic properties of chiral cyclometalated ruthenium catalysts 
The success of bis-cyclometalated chiral-at-metal iridium and rhodium complexes in asymmetric 
catalysis encouraged us to further investigate the catalytic property of other chiral cyclometalated 
transition metal complex, like ruthenium which is less reported.
7
 Cyclometalated ruthenium complexes 
are relatively electron-rich, which may be potentially good reducing agents. But asymmetric redox 
reactions catalyzed by cyclometalated ruthenium complexes are rare. Thus in this part, investigating 
the catalytic properties of chiral cyclometalated ruthenium complexes especially for redox reactions 
will be my aim of work (Figure 16).  
 
Figure 16. Aim 3: Expand the catalytic properties of chiral cyclometalated ruthenium catalysts. 
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Chapter 3: Results and Discussion 
3.1 Kinetic Resolution of Epoxides with CO2 Catalyzed by a Chiral-at-Iridium Complex  
3.1.1 Project Design and Research Background 





 complexes as a novel class of Lewis acids. These complexes contain only achiral 
ligands with the metal serving as the formal stereocenter (chiral-at-metal complex), which 
represent a new type of catalysts for many transformations providing excellent 
enantioselectivities with high activities.
3
 For example, both the chiral-at-metal iridium complexes 
Λ/Δ-IrO and the rhodium complex Λ/Δ-RhO could catalyze the Friedel-Crafts alkylation of 
α,β-unsaturated 2-acyl imidazoles with high yields and enantioselectivities (Figure 17a).
4
 In most of 
the previous studies,
 
substrates with two-point binding like 2-acyl imidazoles are necessary to obtain 
good asymmetric induction.
3
 There are also exceptions. For example, Λ/Δ-IrS has been demonstrated 
as an excellent catalyst for asymmetric transfer hydrogenations of ketones providing high 
enantioselectivities of up to 99% ee at low catalyst loadings down to 0.002 mol% in the presence of 
pyrazole co-ligand (Figure 17b).
5
 In this case, only simple ketones are used as substrates, and an 
iridium-hydride is proposed to be the key intermediate. It will be of high interest for our group to 
develop other asymmetric transformations without the need for two-point binding substrates. With this 
expectation, my co-worker Dr. Vladimir Larionov found that a modified chiral-at-iridium 
complex -IrO(Carb) could serve as the catalyst for the kinetic resolution of epoxides with 
CO2 to afford cyclic carbonate with a moderate conversion of 23% and enantioselectivity of 
71% ee (Figure 17c). This reflects an s-factor of 7.3. 




Figure 17. a) Enantioselective Friedel-Crafts alkylation of substrate with two-point binding; b) ATH 
reaction of substrate with one-point binding; c) Kinetic resolution of epoxide with CO2. 
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As described in Chapter 1.2, the kinetic resolution of epoxides with CO2 is of great interest 
because it features a perfect atom economy. Moreover, chiral cyclic carbonates are important 
synthetic intermediates.
6
 However, the kinetic resolution of epoxides with CO2 is still 
underdeveloped to date.
7
 Low s-factors (s < 10) are typical in most of the reported catalytic systems. 
Another problem is the poor substrate tolerance. Almost all the reported catalytic systems are very 
sensitive to the nature of the substrate.  
In theory, there is a real possibility to get good s-factors for this kinetic resolution reaction 
with the chiral-at-metal iridium or rhodium catalysts if the coordination of the epoxide and later 
ring opening occur around the metal center. The primary s-factor of 7.3 obtained by Dr. Vladimir 
Larionov is comparable with other reported Lewis acid catalysts.
8-12
 Encouragingly, the author of this 
thesis decided to further investigate this kinetic resolution reaction with the chiral-at-metal complexes 
as catalysts to improve the s-factor. 
3.1.2 Initial Experiments and Optimization of Reaction Conditions 
The investigation was started by testing a number of bis-cyclometalated chiral-at-iridium 
and chiral-at-rhodium Lewis acid complexes for the kinetic resolution of racemic glycidyl 
benzyl ether (4a) with CO2. All reactions shown in Table 1 were performed at 25 °C with CO2 
pressure of 20 bar in the presence of 1 mol% chiral Lewis acid catalyst. Using the benzoxazole 
rhodium catalyst -RhO together with nBu4NBr as the co-catalyst provided the cyclic 
carbonate 5a with 8% conversion and 47% ee, which relates to an s-factor of 2.9 (entry 1). The 
related benzothiazole rhodium catalyst -RhS displayed a higher catalytic activity with 26% 
conversion after 24 hours but an unchanged s-factor (entry 2). The analogous iridium 
complexes -IrO and -IrS provided better results (entries 3 and 4). Especially -IrO 
provided an s-factor of 6.0 (entry 3). A further slight improvement was achieved with the 
iridium catalyts -IrO(Carb) functionalized with two carbazole moieties which provided an 
s-factor of 6.3 (entry 5). The role of the carbazole moiety is unclear. However, our group
13a
 and 
independently the Kang group
13b
 found that for related bis-cyclometalated catalysts the 
functionalization of the phenyl moiety at this position with an aryl moiety can sometimes have 
a positive effect on the stereocontrol.  
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Catalyst -IrO(Carb) was used to optimize the reaction conditions next. First the 
co-catalyst was optimized (entries 6-12), and it was found that bromide was optimal as a 
nucleophile in combination with tetraethylammonium cation to provide an s-factor of 7.6 
(entry 11). This was different from the result of the Co
III
(salen) complex system which 
provided better s-factor with co-catalyst bearing bulky cation.
8b
 With respect to the amount of 
the nucleophilic co-catalyst Et4NBr (entries 13-16), the highest s-factor of 8.7 (entry 15) was 
observed at a catalyst loading of 1.5 mol%. It should be noted here that there is totally no 
catalytic activity in the presence of 1.0 mol% co-catalyst (entry 16). Under solvent-free 
conditions the s-factor decreased to 5.4 (entry 17), but testing some other solvents (entries 
18-21) revealed that 1,4-dioxane was the solvent of choice providing an s-factor of 10.8 (entry 
21). It is noteworthy that doubling the loadings of catalyst and co-catalyst leads to a higher 
conversion but also decreases the enantiomeric excess of the cyclic carbonate and reduces the 
s-factor (entry 22). Finally, control experiments verified that neither the Lewis acids nor 
Et4NBr alone can catalyze this transformation (entries 23 and 24). Notably, selectivities for the 
cyclic carbonate product were perfect in all cases, and no copolymerization side reaction was 
observed, which is often encountered for the chiral cobalt Schiff base catalysts.
8b,9
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1 -RhO (1.0) nBu4NBr (2.0) Tol 8 47 2.9 
2 -RhS (1.0) nBu4NBr (2.0) Tol 26 43 2.9 
3 -IrO (1.0) nBu4NBr (2.0) Tol 16 68 6.0 
4 -IrS (1.0) nBu4NBr (2.0) Tol 20 50 3.4 
5 -IrO(Carb) (1.0) nBu4NBr (2.0) Tol 14 70 6.3 
6 -IrO(Carb) (1.0) nBu4NI (2.0) Tol 26 43 2.9 
7 -IrO(Carb) (1.0) nBu4NCl (2.0) Tol 8 70 6.0 
8 -IrO(Carb) (1.0) nBu4NDNP (2.0)
e
 Tol 2 - - 
9 -IrO(Carb) (1.0) nBu4NOBz (2.0) Tol 2 - - 
10 -IrO(Carb) (1.0) nOctyl4NBr (2.0) Tol 13 63 4.9 
11 -IrO(Carb) (1.0) Et4NBr (2.0) Tol 15 74 7.6 
12 -IrO(Carb) (1.0) Me4NBr (2.0) Tol trace - - 
13 -IrO(Carb) (1.0) Et4NBr (4.0) Tol 18 73 7.5 
14 -IrO(Carb) (1.0) Et4NBr (8.0) Tol 22 65 5.6 
15 -IrO(Carb) (1.0) Et4NBr (1.5) Tol 14 77 8.7 
16 -IrO(Carb) (1.0) Et4NBr (1.0) Tol trace - - 
17 -IrO(Carb) (1.0) Et4NBr (1.5) no solvent 21 64 5.4 
18 -IrO(Carb) (1.0) Et4NBr (1.5) DCE 9 63 4.7 
19 -IrO(Carb) (1.0) Et4NBr (1.5) THF 14 71 6.6 
20 -IrO(Carb) (1.0) Et4NBr (1.5) nBu2O 13 77 8.6 
21
f
 -IrO(Carb) (1.0) Et4NBr (1.5) 1,4-dioxane 14 81 10.8 
22
f
 -IrO(Carb) (2.0) Et4NBr (3.0) 1,4-dioxane 28 71 7.5 
23
f
 -IrO(Carb) (1.0) no cocat. 1,4-dioxane 0 - - 
24
f
 no cat. Et4NBr (1.5) 1,4-dioxane <1 - - 
a
Reaction conditions: 4a (32.8 mg, 0.2 mmol), catalyst and co-catalyst in the indicated solvent 




H NMR. No other 
products formed. 
c
Determined by HPLC on chiral stationary phase. 
d
Calculated as (ln[1 - c(1 + 
ee)])/(ln[1 - c(1 - ee)]) where c is the conversion and ee is the enantiomeric excess of the cyclic 
carbonate product. 
e
DNP = 2,4-dinitrophenoxide. 
f
Reaction time was 30 h. 
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3.1.3 Substrate Scope 
Using the optimized conditions with the chiral Lewis acid -IrO(Carb) at 1 mol% and the 
co-catalyst Et4NBr at 1.5 mol% in 1,4-dioxane at room temperature with 20 bar CO2, the substrate 
scope was next investigated starting with a variety of glycidyl ethers (Figure 18). Glycidyl phenylether 
gave the carbonate 5b with 20% conversion and 82% ee (s = 12.3). A comparable s-factor of 10.7 at a 
conversion of 43% was obtained with Lu’s binol-functionalized Co(salen) complex.
8b
 Methyl groups 
in para- and meta-position did not affect the outcome (5c and 5d) but a methyl group in ortho-position 
of the phenyl moiety somewhat decreased the conversion (5e). Glycidyl phenylethers with electron 
donating and electron accepting groups in the phenyl moiety were well tolerated (cyclic carbonates 
5f-h) with s-factors of 10.1-11.5. Glycidyl (2-naphthyl)ether afforded the carbonate 5i with 22% 
conversion and 80% ee (s = 11.2). A variety of other glycidyl ethers provided the cyclic carbonates 
5j-m with s = 7.5-11.8. For glycidyl ethers, our chiral-at-metal catalyst provided much higher s-factors 
compared with most of other catalytic systems.
9b,10f,12c
 To further evaluate effect of the nature of 
epoxide side chain on the s-factor, substrates 4n-t were tested. Replacing the ether side chain with an 
ester group gave the carbonate 5n with 15% conversion and 74% ee (s = 7.6), for which only a s-factor 
of 2.1 was obtained with the ketoiminatocobalt(II) catalytic system.
9b
 A phenylethyl side chain led to a 
decreased conversion with an s-factor of 9.0 (5o), while a butyl side chain provided carbonate 5p with 
an s-factor of 8.5, and an ethyl side chain provided the carbonate 5q with an s-factor of 6.4. For 
substrate 4q, Lu’s catalyst is superior, providing cyclic carbonate 5q with an s-factor of 31.5.
8b
 To our 
delight, a benzyl substituent afforded the carbonate 5r with 21% conversion and 86% ee, which 
reflected an s-factor of 16.6 and a p-methoxybenzyl substituent the cyclic carbonate 5s with 80% ee at 
40% conversion (s = 15.3). A chloromethyl group gave a better conversion of 40% but a decreased 
s-factor of 8.9 (cyclic carbonate 5t). For this chloromethyl cyclic carbonate 5t most studies reported 
moderate to low s-factors below 6.0, except for Lu’s system which provided an s-factor of 13.2 at a 
conversion of 41%.
8b
 An epoxide with a quartenary carbon center 4u did not show any reactivity. 
Finally, styrene oxide 4v afforded the cyclic carbonate 5v with an s-factor of 7.3, compared to an 
s-factor of 5.4 in Lu’s catalytic system.
8b
 It should be noted that no detectable signal of polycarbonate 
side product was observed in the 
1
H NMR spectrums for all presented substrates. This is consistent 
with determined mass balances of >99% for several reactions (for 4b, 4g and 4i). 




Figure 18. Asymmetric coupling of various epoxides with CO2. 
a
MB = mass balance. 
 b
Reaction time 
was 70 h. 
c
2 mol% nBu4NBr, 1 mol% -IrO(Carb) and 45 h were used instead. 
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To give a better indication of the performance of the chiral-at-iridium catalyst for this kinetic 
resolution of epoxides, s-factors of selected substrates (4b-d, 4g) were determined at higher 
conversions (around 40%), resulting in slightly reduced s-factors (Table 2). For an example, the 
s-factor of glycidyl phenylether 4b decreased from 12.3 (at 20% conversion) to 10.5 (at 41% 
conversion). 
Table 2. Catalytic results of selected epoxides at high conversions
a
 







1 4b 41 73 10.5 
2 4c 40 73 10.3 
3 4d 39 74 10.6 
4 4g 45 70 10.0 
a
Reaction conditions: Epoxides (0.3 mmol), nBu4NBr (1.9 mg, 0.006 mmol, 2 mol%), -IrO(Carb) 
(3.8 mg, 0.003 mmol, 1 mol%) in 1,4-dioxane (86 µL, 3.5 M) were stirred at room temperature at 20 




H NMR. Selectivity for the cyclic carbonate product were 
all >99%. 
c
Determined by HPLC on chiral stationary phase. 
d
Calculated as (ln[1 - c(1 + ee)])/(ln[1 - 
c(1 - ee)]) where c is the conversion and ee is the enantiomeric excess of the cyclic carbonate product. 
3.1.4 Additional Experiments 
Next, a few mechanistic experiments were performed. To verify that there is a 
stereochemical match and mismatch between the metal-centered configuration of the iridium 
catalyst and the stereochemistry of the chiral epoxide, the enantiomerically pure (S)-glycidyl 
phenyl ether (>99% ee) was used as substrate in the CO2-coupling reaction catalyzed by the 
individual enantiomeric catalysts -IrO(Carb) and -IrO(Carb) (Figure 19a). As a result, 
after 20 hours at room temperature a conversion of 20% was observed for catalyst 
-IrO(Carb), while under the same conditions -IrO(Carb) only provided a conversion of 
2%, thus demonstrating a strong preference of (S)-4b for -IrO(Carb) over -IrO(Carb). 
Furthermore, the cyclic carbonate product (R)-5b was formed under complete retention of the 
configuration, which is in accordance to the established mechanism.
14
 Figure 19b features the 
correlation between conversion and enantiomeric excess of the formed cyclic carbonate. As 
expected, with a progress in conversion the enantiomeric excess declines. However, it is 
surprising that the s-factor also decreases gradually with increasing conversion. The 
explanation for this unusal effect is unclear at this stage, but it is possible that the formed 
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cyclic carbonate interferes with the catalysis of just increases the overall polarity of the solvent. 
Finally, the direct reaction of nBu4NBr with the catalyst was investigated (Figure 19c). An 
immediate color change from yellow to orange was observed when mixing the catalyst 
-IrO(Carb) with one equivalent of nBu4NBr with a disappearance of an acetonitrile signal, 
which indicates that the bromide replaced one acetonitrile ligand by directly coordinating to 
the iridium and providing a neutral complex. This explains why a slight excess of co-catalyst 
over the iridium complex is necessary for observing catalytic activity. 
 
Figure 19. Additional experiments. a) Investigation of match and mismatch of chiral catalyst 
and epoxide substrate. b) Dependence of enantioselectivity and s-factor on the conversion. 
Reaction conditions: glycidyl ether 4b (0.2 mmol) with -IrO(Carb) (2.0 mol%), Et4NBr (3.0 
mol%) in 1,4-dioxane (57 µL) at room temperature under 20 bar CO2. c) Stoichiometric 
reaction of -IrO(Carb) with nBu4NBr. 
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Based on previous reports
7
 and our mechanistic experiments, the catalytic cycle shown in Figure 
20 is proposed. The catalyst -IrO(Carb) first reacts with one equivalent nBu4NBr to replace one 
MeCN ligand with bromide and to form the neutral iridium complex I. Replacement of the second 
MeCN ligand with the epoxide substrate then leads to complex II. The observed enantiodifferentiation 
either already occurs during the formation of this iridium-substrate complex II or the subsequent 
reaction with bromide to form the ring-opened alkoxide intermediate III. The nucleophilic alkoxide 
then reacts with CO2 to form the short-lived carbonate intermediate IV which undergoes a ring-closing 
intramolecular SN2 reaction to generate the catalyst bound cyclic carbonate product. Dissociation of 
the product and new coordination of substrate finally initiates a new catalytic cycle. 
 
Figure 20. Proposed mechanism for the kinetic resolution of epoxides with CO2. 
3.1.5 Conclusions 
In summary, bis-cyclometalated iridium complexes are demonstrated to be a new and promising 
class of chiral catalysts for the kinetic resolution of racemic epoxides with CO2. Significant s-factors 
of up to 16.6 are achieved for a variety of monosubstituted epoxides including epoxides with aliphatic 
side chains, glycidyl ethers, styrene epoxide, and a glycidyl ester. It is noteworthy that all reactions 
were performed at room temperature and no polymerization side reaction was detected. 
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3.2 Enantioselective Intramolecular C-H Amination of Aliphatic Azides by Dual 
Ruthenium and Phosphine Catalysis  
3.2.1 Project Design and Research Background  
As discussed in Chapter 3.1, the Meggers group developed the bis-cyclometalated iridium(III) 
and rhodium(III) complexes as a novel class of chiral Lewis acids, which showed excellent 
asymmetric induction for a variety of transformations.
1
 Most recently, former group member Yu Zheng 
synthesized a new class of chiral-at-metal ruthenium catalysts
2
 which displayed high activity (up to 
99% yield) and enantioselectivity (up to 99% ee) for the alkynylation of trifluoromethyl ketones 
(Scheme 9). Ruthenium complexes are well known to exhibit diverse reactivities, especially 
generating a variety of highly reactive ruthenium-bound intermediates. The author of this thesis holds 
a great interest in investigating new catalytic properties of this class of chiral-at-metal ruthenium 
catalysts. 
 
Scheme 9. Enantioselective alkynylation of trifluoromethyl ketones catalyzed by chiral-at-metal 
ruthenium complex. 
At the onset of the study, the author of this thesis focused on transformations involving ruthenium 
imido intermediates which have been well demonstrated in the literature.
3
 A number of interesting 
transformations like aziridination and C-H amination had been realized through the reactive ruthenium 
imido intermediate (Figure 21).
4
 In particular, C-H amination represents one of the most effective 
methodologies to construct nitrogen-containing molecules.
5
 Organic azide was chosen as the testing 
substrate because it has been well reported to react with ruthenium complexes forming ruthenium 
imido intermediates.
3
 Furthermore, organic azides are attractive functionalities for C-H amination 
because no additional oxidant is required and molecular nitrogen is the only by-product.
6 




Figure 21. Transformations via the ruthenium imido intermediate. 
With the above idea in mind, the literature of C-H aminations of organic azides was reviewed 
carefully. As introduced in Chapter 1.3, the amination of saturated C(sp
3
)-H bonds with aryl, sulfonyl, 
acyl and phosphoryl azides has been well established,
7
 but the use of non-activated, aliphatic azides is 
only a recent accomplishment.
8,12,15-18
 In addition to their lower reactivity, a major pitfall for C(sp
3
)-H 
aminations of primary aliphatic azides constitutes a competing unproductive 1,2-hydride shift of the 
intermediate alkyl nitrenoid intermediate leading to the irreversible formation of undesirable imines 
(Figure 22a).
9,10
 Betley and co-workers introduced an elegant dipyrrinato-iron(II)-catalyzed 
ring-closing C(sp
3
)-H amination of aliphatic azides but the reported turnover numbers were modest 




 offers a direct access to saturated cyclic amines.
14 





 and cobalt(II) porphyrin
17
 catalysts by Lin, van der Vlugt, and de Bruin, 
respectively, provided improved catalytic performances for this challenging transformation. Finally, 
Che and co-workers very recently reported an N-heterocyclic carbene iron(III) porphyrin complex 
exhibiting high activity for this transformation under microwave conditions.
18
 However, cyclic amines 
like pyrrolidines as part of bioactive compounds are typically chiral but only a single example of a 
catalytic enantioselective reaction has been reported using a chiral cobalt(II) porphyrin achieving low 
yields and very low enantiomeric excess (Figure 22c).
17,19
 Apparently, it is difficult to get both high 
enantioselectivity and good catalytic turnover number. 




Figure 22. Previous work on ring-closing C(sp
3
)-H aminations of primary aliphatic azides. 
Ruthenium complexes are well-established for catalyzing C(sp
3
)-H aminations of organic azides 
such as aryl, acyl, and sulfonyl azides,
7
 but applying simple primary aliphatic azides has remained 
elusive and this has been attributed at least in parts to a very efficient 1,2-hydrogen shift of the 
intermediate Ru-imido complexes.
9
 And this reactivity was also reported for other metal complexes 
when encountering aliphatic azide with α-C-H.
10
 
Intrigued by these studies, the author of this thesis wondered if the chiral-at-ruthenium complex 
with suitable ligand environment is capable of activating primary aliphatic azides like 
(4-azidobutyl)benzene for intramolecular C-H amination instead of 1,2-hydride shift. Another 
expectation was that asymmetric induction which is challenging to date may be realized by the 
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3.2.2 Initial Optimization 
The study was initiated by investigating the intramolecular C-H amination of 
4-azidobutylbenzene (9a) to Boc-protected 2-phenylpyrrolidine (10a) with rac-Ru1 as the catalyst. 
The reaction highly depends on the solvent (Table 3, entries 1-6). Toluene gave the best yield of 22% 
at a conversion of 52% in the presence of one equivalent of Boc2O at 85 °C. At the same time, the 
Boc-protected amine 11 was detected as a side-product in 9% NMR yield. Temperature was optimized 
next (entries 7-10), and it was found that 95 °C was optimal. The substrate 9a was kept intact at 60 °C 
after 40 hours. Further optimization of the amount of Boc2O and the concentration of the reaction did 
not obviously improve the yield of 10a (entries 11-15).  
























1 DMF 85 1.0 0 0 0 
2 1,4-dioxane 85 1.0 49 18 8 
3 Toluene 85 1.0 52 22 9 
4 DCE 85 1.0 48 15 12 
5 iPrOH 85 1.0 43 0 20 
6 3-Pentanone 85 1.0 48 9 24 
7 Toluene 60 1.0 0 0 0 
8 Toluene 75 1.0 17 5 5 
9 Toluene 95 1.0 57 26 14 
10 Toluene 105 1.0 59 25 15 
11 Toluene 95 1.2 58 25 15 
12 Toluene 95 2.0 57 20 18 
13 Toluene 95 4.0 65 16 21 
14
c
 Toluene 95 1.0 22 10 6 
15
d
 Toluene 95 1.0 65 27 18 
a
Reaction conditions: 9a (17.5 mg, 0.1 mmol, 1 equiv), rac-Ru1 catalyst (2.8 mg, 0.002 mmol, 2 
mol%) and Boc2O in indicated solvent (0.25 mL, 0.4 M) were stirred at indicated temperature for 40 h 




H NMR of the crude products using Cl2CHCHCl2 
as internal standard. 
c
0.4 mL toluene (0.25 M) was used instead. 
d
0.1 mL toluene (1.0 M) was used 
instead. 
To our surprise, the reaction was fastly improved when performed in the presence of catalytic 
amounts of PPh3, providing 10a in 44% yield with 79% conversion (Table 4, entry 1). Even slightly 
better yields were obtained with tris(4-fluorophenyl)phosphine, while other phosphines and pyridine 
provided inferior results (entries 2-9).  








Entry Additive Conversion (%)
b
 Yield of 10a (%)
b
 Yield of 11 (%)
b
 
1 P(Ph)3 79 44 17 
2 P(OPh)3 65 15 10 
3 P(cy)3 58 20 11 
4 P(4-MeO-Ph)3 64 18 15 
5 P(4-F-Ph)3 81 46 18 
6 P(Pentafluoropheny)3 77 31 16 
7 P(4-CF3-Ph)3 78 35 17 
8 P(2-Me-Ph)3 60 20 15 
9 Pyridine 39 8 5 
a
Reaction conditions: 9a (17.5 mg, 0.1 mmol, 1 equiv), rac-Ru1 catalyst (2.8 mg, 0.002 mmol, 2 
mol%), indicated additive (0.002 mmol, 2 mol%) and Boc2O (23 µL, 0.1 mmol, 1 equiv) in toluene 





NMR of the crude products using Cl2CHCHCl2 as internal standard. 
With this result in hand, the amount of the phosphine was further investigated, and it was found 
that 1 mol% provided the optimal result (Table 5, entries 1-4). In addition, decrease the catalyst 
loading from 2 mol% to 1 mol% almost did not affect the yield of 10a (entry 5 vs 2), but increase the 
catalyst loading to 4 mol% led to worse result (entry 6). It has to be noted that none of the reactions 
proceed to full conversion. To understand if this is due to the catalyst deactivation, experiments in 
which the fresh catalyst and optionally also additional phosphine ligand was added after a reaction 
time of 30 hours were performed but did only slightly improve the yields (entries 7-10).  
 























1 2 0.5 75 40 16 
2 2 1 80 47 17 
3 2 2 81 46 18 
4 2 5 89 40 17 
5 1 1 81 46 18 
6 4 1 75 40 19 
7
c
 1 1 79 46 15 
8
c,d
 2 1 83 48 17 
9
c,e
 1 2 84 43 16 
10
c,f
 2 2 82 48 17 
a
Reaction conditions: 9a (17.5 mg, 0.1 mmol, 1 equiv), rac-Ru1 catalyst, P(4-F-Ph)3 and Boc2O (23 
µL, 0.1 mmol, 1 equiv) in toluene (0.25 mL, 0.4 M) were stirred at 95°C for 40 h under an 




H NMR of the crude products using Cl2CHCHCl2 as 
internal standard. 
c
1,2-dichlorobenzene as the solvent. 
d
1 mol% Ru catalyst was added initially, and 
another 1 mol% catalyst was added after 30 h of the reaction. The new mixture was stirred for 
another 20 h.
 e
1 mol% P(4-F-Ph)3 was added initially, and another 1 mol% P(4-F-Ph)3 was added 
after 30 h of the reaction. The new mixture was stirred for another 20 h. 
f
1 mol% Ru catalyst and 
P(4-F-Ph)3 were added initially, and another 1 mol% Ru catalyst and P(4-F-Ph)3 were added after 30 
h of the reaction. The new mixture was stirred for another 20 h. 
 
Although the yield was only modest, an encouraging enantioselectivity of 82% ee was obtained 
with -Ru1 as the catalyst (Table 6, entry 1). Next, the optimization of the ruthenium catalyst for this 
transformation was performed to improve the enantioselectivity (Note: 1,2-dichlorobenzene was 
finally used as the solvent for this reaction due to the solubility problem of the ruthenium catalyst. 
Some of the Ru catalysts (e.g. Ru2-4 and Ru7) were later found soluble in 1,2-dichlorobenzene but 
not in toluene, and the reactivity was similar in both solvents). The initial experiments were carried out 
with the chiral-at-ruthenium catalyst -Ru1 which bears two very bulky 3,5-di(tert-butyl)phenyl 
substituents at the coordinating pyridine ligands. Interestingly, -Ru2 with less bulky 
3,5-(dimethyl)phenyl substituents at the pyridyl moieties provided an even higher enantioselectivity of 
89% ee (entry 2). The phenyl-modified catalyst -Ru3 afforded a further slightly increased 
enantioselectivity of 90% ee (entry 3), whereas the plain catalyst devoid of additional substituents 
(-Ru4) yielded the Boc-protected pyrrolidine with reduced 87% ee (entry 4). Furthermore, a 
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trimethylsilyl (TMS)-functionalized ruthenium complex -Ru5 did not provide better results here 
(entry 5). Adding a tBu-moiety at the 4-position of the phenyl groups (-Ru6) decreased the 
enantioselectivity to 80% ee (entry 6). However, the best result was obtained with a 4-(CF3)Ph 
modification (-Ru7) which afforded (R)-10a in 54% NMR yield at 77% conversion and with 95% ee 
(entry 7). Interestingly, even at a catalyst loading of just 0.5 mol%, the Boc-protected pyrrolidine 
(R)-10a was still formed with 42% yield (65% conversion) and 94% ee, reflecting a turnover number 
of 84 (entry 8). Thus, a careful optimization of steric and electronic effects provided a ruthenium 
catalyst (-Ru7) which, in the presence of tris(4-fluorophenyl)phosphine, effectively discriminates 
between the two benzylic C-H bonds of 4-azidobutylbenzene to provide the corresponding chiral 
pyrrolidine with outstanding enantioselectivity. 
Control experiments revealed that tris(4-fluorophenyl)phosphine is crucial for obtaining a 
satisfactory yield. In its absence, the yield diminished to merely 12% even after an extended reaction 
time, while the enantioselectivity was not affected, thus implying that the phosphine is not involved in 
the stereocontrolling step (entry 9). Finally, Boc2O is also required for this reaction to proceed (entry 
10). 




















 -Ru1 P(4-F-Ph)3 81 46 18 82 
2 -Ru2 P(4-F-Ph)3 77 46 18 89 
3 -Ru3 P(4-F-Ph)3 79 44 16 90 
4 -Ru4 P(4-F-Ph)3 75 44 20 87 
5 -Ru5 P(4-F-Ph)3 70 43 17 89 
6 -Ru6 P(4-F-Ph)3 65 23 18 80 
7 -Ru7 P(4-F-Ph)3 77 54 (51)
e
 18 95 
8 -Ru7
f
 P(4-F-Ph)3 65 42 16 94 
9 -Ru7 no 45 12 14 95 
10
g









Standard conditions: 9a (35 mg, 0.2 mmol, 1 equiv), Boc2O (46 µL, 0.2 mmol, 1 equiv), catalyst 
(0.002 mmol, 1 mol%), and additive (0.002 mmol, 1 mol%) in 1,2-dichlorobenzene (0.5 mL) at 95
o
C 




H NMR of crude products using 
Cl2CHCHCl2 as internal standard. 
c
Determined by HPLC of crude main product on a chiral stationary 
phase. 
d
Reaction time was 40 h. 
e
Isolated yield in parentheses. 
f





Refers to cpds without Boc-protection. 
i
n.a. = not applicable. 
At last, to understand if these chiral-at-metal ruthenium complexes are unique for this 
transformation, several commercially available ruthenium complexes were tested. However, none of 
them can catalyze this transformation providing Boc-protected pyrrolidine product no matter in the 
presence or absence of tris(4-fluorophenyl)phosphine (Table 7). This suggests that the ligand 
environment of ruthenium complex is very important for the success of the C-H amination. 



















no 87 0 
yes 80 0 
2 [Ru(p-cymene)Cl2]2 
no 80 0 
yes 85 0 
3 [RuCp*(CH3CN)3]PF6 
no 0 0 
yes 0 0 
4 Cp*RuCl(cod) 
no <5 0 
yes <5 0 
5 CpRuCl[bis(diphenylphosphino)methane] 
no 0 0 
yes 0 0 
a
Reaction conditions: 9a (35.0 mg, 0.2 mmol, 1 equiv), 2 mol% Ru catalyst, P(4-F-Ph)3 (1.3 mg, 0.004 
mmol, 2 mol%) and Boc2O (46 µL, 0.2 mmol, 1 equiv) in 1,2-dichlorobenzene (0.5 mL, 0.4 M) were 




H NMR of the crude 
products using Cl2CHCHCl2 as internal standard. 
3.2.3 Scope Investigations 
With the optimized catalyst -Ru7 and reaction conditions in hand (1 equiv Boc2O and 1 mol% 
P(4-F-Ph)3 in 1,2-dichlorobenzene at 95 °C), the substrate scope of this transformation was 
investigated. As shown in Figure 23, methyl groups in para or meta position of the benzene moiety are 
well tolerated (pyrrolidines 10b,c), but a sterically demanding ortho-methyl group leads to vastly 
diminished yield of 15%. Electron-donating groups appear to be beneficial (pyrrolidines 10e-i). For 
example, a para-methoxy functionalized benzene provides the Boc-protected pyrrolidine in 53% yield 
and with excellent 99% ee. Interestingly, potentially coordinating group on the benzene moiety (10h,i) 
do not affect the formation of pyrrolidine product. A bulky phosphite substituent (10j) and benzoxy 
group (10k) with active C-H lead to a decreased yield but still with good enantioselectivities of 92% 
ee. In contrary, electron-withdrawing groups like fluorine substituent leads to a decreased yield of 40% 
with 94% ee (product 10l) and a chlorine to a yield of 45% with 95% ee (product 10m). The phenyl 
moiety can also be replaced by a naphthyl (pyrrolidine 10n) and by heteroaromatic moieties 
(pyrrolidines 10o-s). For example, a carbazole moiety provides the Boc-protected pyrrolidine 10s in 
52% yield and 93% ee. Further substrates including aryl moieties in the bridge could also be 
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transformed to pyrrolidine products (10t,u) with 80% and 94% ee respectively. 
 
Figure 23. Substrate scope for the enantioselective intramolecular C-H amination of aliphatic azide 
with isolated yield. 
a
Recovered starting materials were showed in parentheses. 
b
0.1 M 
1,2-dichlorobenzene and 85 °C were used instead. 
However, replacing the aryl group with alkyl group (9v) totally suppresses the C-H amination 
reaction even after an increased reaction temperature to 105 °C (Table 8, entry 1). Further variation of 
9w with an alkynyl group only provided <5% yield of the product under the standard reaction 
conditions (entry 2). Substrate 9x with an alkenyl group was also tested, but it totally decomposed 
even at 85 °C (entry 3). Finally, a racemic substrate with a tertiary C-H group only provided a very 
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modest kinetic resolution (entry 4).  





Reaction conditions: Organic azide substrate (0.2 mmol), -Ru7 (0.002 mmol, 1 mol%), P(4-F-Ph)3 
(0.002 mmol, 1 mol%) and Boc2O (0.2 mmol, 1 equiv) in 1,2-dichlorobenzene (0.5 mL, 0.4 M) were 
stirred at 95°C for 60 h under an atmosphere of nitrogen. 
b
NMR yield with Cl2CHCHCl2 as internal 
standard. 
c
Determined by HPLC of crude main product on a chiral stationary phase. 
d
The substrate 9v 
was kept infact even at 105°C for 10 h. 
e
Organic azide 9x is not stable at 95°C, which is decomposed 
under the reaction conditions. 
f
Reaction time was 35 h. n.a. = not applicable. 
Overall, enantioselectivities of 76-99% ee were observed and isolated yields of 15-57%. However 
it has to be noted that none of the reactions proceed to full conversion and thus allow to reisolated 
unreacted starting materials (Figure 23). Nevertheless, it is remarkable that within this substrate scope, 
chiral α-aryl pyrrolidines with enantioselectivities of up to 99% ee can be obtained. Importantly, chiral 
α-aryl pyrrolidines are prominent structural motifs in bioactive compounds.
20
 For example, pyrrolidine 





Figure 24. Synthesis of anti-tumor alkaloid (R)-(+)-crispine A from pyrrolidine (R)-10g. 
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3.2.4 Mechanism Study 
Some experiments were performed to gain insight into the mechanism and started with the 
unusual function of the phosphine. The role of phosphine as co-catalyst to activate the organic azide is 
advocated by the well-established reactivity of organic azides towards phosphines.
21 
Indeed, 
P(4-F-Ph)3 starts to react with (4-azidobutyl)benzene already at room temperature and full conversion 
is obtained at 95 °C for 2 hours to form the corresponding iminophosphorane 12 (Figure 25a). The 
iminophosphorane 12 was also confirmed catalytically competent by itself (Figure 25b). Interestingly, 
although such a role of phosphines in the activation of organic azides towards C-H amination has not 
been reported to our knowledge, the opposite reaction namely the phosphine-induced extraction of a 






Next, experiments of comparing (4-azidobutyl)benzene and benzyl azide as substrates at a 
temperature where C-H amination does not yet occur was performed to gain insight into the competing 
1,2-hydride shift. As a result, only benzyl azide provided significant amounts of the imine product 
which can be traced back to the higher activity of the benzylic C-H bond in the ruthenium imido 
intermediate towards 1,2-H shift (Figure 25c). This is consistent with a recent report by Park who 
showed that the degree of 1,2-H shift correlates with the nature of the -C-H bond.9 
To understand the reactivity of ruthenium nitrene, initial C-H amination rates of electronically 
distinct substrates 9e and 9l were determined. Reaction rate of electron-rich 9e is 1.7 times faster than 
electron-deficient 9l suggesting the electrophilic nature of the ruthenium nitrene (Figure 25d). This is 
in consistent with the substrate scope that electron-rich substrates provide better yields compared with 
electron-deficient substrates. The C-H amination with mono-deuterated substrate 9a' using racemic 
catalyst provided an intramolecular kinetic isotope effect (KIE) of 1.3 (Figure 25e), which is much 




 catalytic systems. This might suggest that the 
C-H amination appears to occur by a concerted-insertion mechanism or a hydrogen abstraction 
mechanism with fast radical recombination.
18
 However, the interpretation of the intramolecular KIE is 
complicated by the fact that the ruthenium catalyst is intrinsically chiral, although used as a racemic 
mixture for this experiment, and the monodeuterated substrate 9a' as well. Indeed the cyclization of 
the chiral substrate (R)-9y to (R)-10y but not (S)-9y to (S)-10y demonstrates the high stereospecificity 
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of the C-H amination (Figure 25f). Finally, a pronounced (noncompetitive) intermolecular KIE value 
of 3.1 was determined by measuring initial C-H amination rates of non-deuterated (9a) and 
bis-deuterated (9a'') substrates (Figure 25e). Using alternatively a 1:1 mixture of non-deuterated (9a) 
and bis-deuterated substrate (9a'') provides a (competitive) intermolecular KIE of 3.9 (see the 
Experimental Part 5.3.4). An observation of a significant intermolecular KIE reveals that the C-H 
amination is the rate limiting step in the overall process.
 




Figure 25. Mechanism studies for the enantioselective intramolecular C-H amination of aliphatic 
azide. 
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Based on previous work on the ring-closing C-H amination of (4-azidobutyl)arenes
12,15-17
 and all 
the mechanism studies, the following catalytic cycle is proposed (Figure 26). P(4-F-Ph)3 activates the 
organic azide to form an intermediate iminophosphorane (I) through the well-known Staudinger 
reaction, which then transfers a nitrene to the ruthenium center to afford a ruthenium imido complex 
(intermediate II), followed by a stereo-controlled insertion of the nitrene moiety into the -C-H bond 
(transition state III) to provide a ruthenium-coordinated pyrrolidine (intermediate IV). However, a 
stepwise process through H-atom transfer cannot be totally excluded at this point. Finally, the product 
is released after Boc-protection. 
 
Figure 26. Proposed mechanism for the enantioselective intramolecular C-H amination of aliphatic 
azide. 
3.2.5 Conclusions 
In summary, a highly enantioselective catalytic ring-closing benzylic C(sp
3
)-H amination of 
primary aliphatic azides to provide chiral 2-aryl pyrrolidines by combining of chiral-at-metal transition 
metal catalysis with nucleophilic phosphine catalysis is presented here. In this unique dual catalysis 
system, the phosphine activates the organic azide and transfers a nitrene to the ruthenium complex, 
which then executes the enantioselective C-H amination. This combination of ruthenium catalysis and 
Staudinger reaction introduces a novel direction for C-H amination of unactivated aliphatic azides 
which are very desirable but challenging substrates for this transformation. 
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3.3 Ruthenium Catalyzed Asymmetric Oxidative Homocoupling of 2-Acyl Imidazoles  
3.3.1 Project Design and Research Background 
Bis-cyclometalated chiral-at-metal iridium and rhodium complexes have been successfully 
employed as catalysts for a variety of transformations by the Meggers group,
1
 especially light-induced 
enantioselective reactions.
2
 The efficiency of this kind of catalysts is attributed at least in parts to the 
strong σ donating effect of the cyclometalated ligands, which makes the ligand exchange fast in the 
overall catalytic process. The author of this thesis is quite interested in the asymmetric catalysis of 
chiral cyclometalated ruthenium complexes.
3
 Compared with iridium and rhodium complexes, 
bis-cyclometalated ruthenium complexes are less reported for catalysis,
4
 maybe because they are too 
electron-rich to be stable. After a literature research, it was found that Nishiyama and co-workers 
reported a chiral mono-cyclometalated ruthenium complex
3a
 which contains one chiral cyclometalated 
bis-oxazolinyl ligand, one bidentate acetylacetonato ligand in addition to one CO ligand. This complex 
has been demonstrated to be stable under air. Furthermore, it has been applied for the asymmetric 
hydrogenation of ketones
3a
 and asymmetric alkynylation of aldehydes
3c
 providing excellent 
enantioselectivities (Figure 27). 
 
Figure 27. Asymmetric transformations catalyzed by chiral cyclometalated ruthenium complex 
(Phebox-Ru1). 
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Both the bis-cyclometalated chiral-at-metal iridium and rhodium complexes have been employed 
as single electron reductants in light-induced photoredox transformations.
2a,b,d,f
 For example, a 
chiral-at-metal iridium (IrS) catalyzed enantioselective trichloromethylation of 2-acyl imidazoles and 
2-acyl pyridines with enantioselectivities of ≥99% ee was reported in 2015 (Scheme 10).
2b
 The author 
of this thesis wondered if the cyclometalated ruthenium complex could also serve as a single electron 
reductant. The study was initiated with testing the catalytic performance of mono-cyclometalated 
ruthenium complex Phebox-Ru1 for the trichloromethylation of 2-acyl imidazoles. 
 
Scheme 10. Visible-light-activated enantioselective trichloromethylation of 2-acyl imidazoles 
catalyzed by Λ-IrS. 
3.3.2 Reaction Development and Initial Experiments 
Under the established reaction conditions of the above report from the Meggers group,
2b
 only 
10% of the trichloromethylation product 14 with 74% ee was obtained after 18 hours in the presence 
of 2 mol% of Phebox-Ru1 (Table 8, entry 1). Control experiment indicated that light was not 
necessary for the formation of the product (entry 2). Interestingly, the homocoupling product 15c was 
isolated as the major product in 55% yield with 93% ee when the reaction was performed at 40 
o
C 
(entry 3). This surprising homocoupling product has never been observed in the transformations 
catalyzed by the chiral-at-metal iridium (IrS) complex. Furthermore, the product containing a 
1,4-dicarbonyl motif is an important synthetic building block, and the direct oxidative α-coupling of 
carbonyl compounds constitutes a direct way to construct 1,4-dicarbonyl moiety which has been 
reported rarely.  








Entry Light T (
o
C) 
      Yield (%)
b
       ee (%)
c
 
14 15c 14 15c 
1 CFL (20 W) 25 10 0 74 n.a. 
2 No 25 10 0 73 n.a. 
3 No 40 trace 55 n.a 93 
a
Standard conditions: 13c (26.2 mg, 0.1 mmol, 1 equiv), NaHCO3 (9.2 mg, 0.11 mmol, 1.1 equiv), 
Phebox-Ru1 (1.3 mg, 0.002 mmol, 2 mol%) and BrCCl3 (29.4 µL, 0.3 mmol, 3 equiv) in MeOH/THF 
(0.2 mL, the volume ratio of MeOH and THF is 3: 1) were stirred at indicated temperature under 




Determined by HPLC of crude main product on a chiral stationary 
phase. n.a. = not applicable. 
As introduced in Chapter 1.4, although different indirect methods (Figure 28a), like the coupling 
of pre-formed lithium enolates, have been developed for the oxidative α-coupling of carbonyl 
compounds,
5
 catalytic asymmetric versions are very limited.
6
 The ideal way to construct chiral 
1,4-dicarbonyl compounds is the direct asymmetric oxidative α-coupling of carbonyl compounds, 
which is only a recent accomplishment. Jørgensen and coworkers reported the direct enantioselective 
oxidative homocoupling of α-branched aldehydes with good yields (28-79%) and excellent 
enantioselectivities (6-96% ee) in the presence of 40 mol% chiral amine catalyst (Figure 28b).
7
 All 
these facts give necessary impetus for the author of this thesis to further investigate this catalytic 
asymmetric transformation. 




Figure 28. a) General strategy for oxidative homocoupling of carbonyl compounds; b) Previous report 
on direct asymmetric oxidative homocoupling of carbonyl compounds. 
The optimization of the reaction conditions is performed in the presence of 2 mol% ruthenium 
catalyst and started with testing the substrates with different imidazole moieties. Both the yield and 
enantioselectivity were improved to 73% and 94% respectively when increasing the size of the 
substituents from methyl to phenyl (Table 9, entries 1-3). Interestingly, the reaction is very sensitive to 
the solvent. None of the other investigated solvents (THF, DMF, CH3CN, and CH2Cl2) except 
methanol could give the homocoupling product (entries 4-8). Next, the base was optimized. Using 
other bases instead of sodium bicarbonate (NaHCO3) provided decreased yields, even totally supressed 
the reaction in some cases (entries 9-13). Increase the reaction temperature to 50 or 60 
o
C led to worse 
results (entries 14,15 vs 3). In addition, screening the amount of BrCCl3 indicated that one equivalent 
provided the best result (entries 16,17 vs 3). Finally, using Phebox-Ru2 with isopropyl groups as the 
catalyst instead of Phebox-Ru1 led to a decreased yield and ee (entry 18).  
Control experiments confirmed that ruthenium catalyst, base as well as BrCCl3 are all essential 
for this coupling reaction (entries 19-21). Furthermore, air could obviously suppress the product 
formation (entry 22). For comparison, the chiral-at-metal complexes -RhS and -IrS which have 
been known to activate 2-acyl imidazole could not catalyze this transformation (entries 23,24). It is 
noteworthy that only syn-products can be observed in all cases. 























1 NaHCO3 1.0 40 MeOH/THF 13a 47 45 
2 NaHCO3 1.0 40 MeOH/THF 13b 41 67 
3 NaHCO3 1.0 40 MeOH/THF 13c 73 94 
4 NaHCO3 1.0 40 MeOH 13c 62 93 
5 NaHCO3 1.0 40 THF 13c 0 - 
6 NaHCO3 1.0 40 DMF 13c 0 - 
7 NaHCO3 1.0 40 CH3CN 13c 15 n.d. 
8 NaHCO3 1.0 40 CH2Cl2 13c 0 - 
9 Na2HPO4 1.0 40 MeOH/THF 13c trace n.a. 
10 K3PO4 1.0 40 MeOH/THF 13c 62 90 
11 Et3N 1.0 40 MeOH/THF 13c trace n.a. 
12 Lutidine 1.0 40 MeOH/THF 13c 32 n.d. 
13 K2HPO4 1.0 40 MeOH/THF 13c trace n.a. 
14 NaHCO3 1.0 50 MeOH/THF 13c 63 86 
15 NaHCO3 1.0 60 MeOH/THF 13c 43 86 
16 NaHCO3 0.5 40 MeOH/THF 13c 52 90 
17 NaHCO3 2.0 40 MeOH/THF 13c 47 86 
18
e 
NaHCO3 1.0 40 MeOH/THF 13c 69 92 
19 - 1.0 40 MeOH/THF 13c 0 - 
20
f
 NaHCO3 1.0 40 MeOH/THF 13c 0 - 
21
g
 NaHCO3 1.0 40 MeOH/THF 13c 0 - 
22
h
 NaHCO3 1.0 40 MeOH/THF 13c 7 n.d. 
23
i
 NaHCO3 1.0 40 MeOH/THF 13c 0 - 
24
j
 NaHCO3 1.0 40 MeOH/THF 13c 7 n.d. 
a
Reaction conditions: 13a-c (0.1 mmol), base (1.1 equiv), Phebox-Ru1 (1.3 mg, 0.002 mmol, 2 mol%) 
and BrCCl3 in indicated solvent (0.2 M) were stirred at indicated temperature under nitrogen for 45 h. 
b





Determined by HPLC on chiral stationary phase. n.d. = not determined. 
e
Phebox-Ru2 was 






In the air. 
i
-IrS was used instead of 
Phebox-Ru1. 
j
-RhS was used instead of Phebox-Ru1. 
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To obtain the absolute configuration of the homocoupling product, 15c was transformed to 
2,3-diphenylbutane-1,4-diol (19) in two steps (Scheme 11). The optical rotation of 19 is determined as 
[]D
20




= +47 (c 
= 0.25, CHCl3) for (2S,3S)-19}. This suggests that the homocoupling product is (2R,3R)-15c. 
 
Scheme 11. Determination of the absolute configuration of the homocoupling product. 
3.3.3 Substrate Scope 
With the optimized reaction conditions in hand, we investigated the scope of this ruthenium 
catalyzed homocoupling transformation (Figure 29). Substrates with a methyl group at the meta- or 
para-position of the phenyl moiety were successfully transformed to the homocoupling products with 
good yields and enantioselectivities (15d,e), but a sterically demanding ortho-methyl group totally 
suppressed the reaction. Electronic property of the phenyl group has great influence on both of the 
yield and enantioselectivity of this transformation. Typically, substrates with electron-donating groups 
(13g,i) gave higher enantioselectivities but lower yields compared with substrates with 
electron-withdrawing groups (13j-l). For example, enantioselectivity of 94% ee with a low yield of 
35% was obtained for 13i with a methoxy group, while a good yield of 72% with a decreased 
enantioselectivity of 75% ee was provided for 13l containing a chlorine. Finally, phenyl can also be 
replaced with other aromatic groups like naphthyl (13n) or thiophenyl (13o). Importantly, 
diastereoselectivities were extremely high for all presented substrates, and only syn-products were 
detected in the 
1
H NMR spectra of the crude reaction mixtures. 




Figure 29. Substrate scope of direct asymmetric oxidative homocoupling of 2-acyl imidazoles with 
isolated yields. 
3.3.4 Mechanism Study  
A number of experiments were performed to understand the mechanism. Firstly, ruthenium 
enolate 16 which was proposed to be the key intermediate was isolated in 70% yield after the 
stoichiometric reaction of Phebox-Ru1 and 2-acyl imidazole 13l (Figure 30a). The accurate structure 
of 16 was also demonstrated by single crystal X-ray diffraction. Moreover, the chiral ruthenium 
enolate 16 was confirmed catalytically competent by itself for the homocoupling reaction (Figure 30b). 
Thus, the chiral ruthenium enolate 16 is a key intermediate which provides the crucial asymmetric 
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induction in the reaction. 
 
Figure 30. a) Preparation of the chiral ruthenium enolate intermediate; b) The chiral ruthenium enolate 
intermediate as the catalyst for the homocoupling of 13l. 
Next, monitoring the reaction by 
1
H NMR indicated that a new species was formed initially and 
disappeared at the end of the reaction, which was demonstrated to be the brominated compound 17 
(Figure 31a). This suggests that the brominated compound 17 is the reaction intermediate. Further 
verification was offered by the crosscoupling reaction between 17 and 2-acyl imidazole 13c in the 
absence of BrCCl3, providing the coupling product 15c in 54% yield with 94% ee (Figure 31b). 
Interestingly, three coupling products were obtained in 56% yield when 2-acyl imidazole 13d was 
used instead of 13c under the same reaction conditions (Figure 31b). This could be explained by the 
bromide-transfer reaction between the bromide-containing compound with the ruthenium enolate 
intermediate (see the proposed mechanism below).  




Figure 31. a) Monitor the reation by 
1
H NMR; b) Heterocoupling of 17 with 13c or 13d. 
When the standard catalytic reaction was monitored by electron paramagnetic resonance (EPR) 
using 5,5-dimethyl-1-pyrroline N-oxide (DMPO) as a free radical spin trapping agent, one radical 
signal was clearly observed (Figure 32a). The exact same signal was also observed for the reaction 
between 17 and 13c, which was proposed to be α-carbonyl carbon radical generated from 17. 
Furthermore, the catalytic reaction using 17 as the substrate in the absence of BrCCl3 afforded the 
homocoupling product 15c in 12% yield (Figure 32b). This also implies that radical species can be 
formed from 17 in the presence of the ruthenium complex Phebox-Ru1.  




Figure 32. a) EPR experiment; b) Catalytic reaction with 17 as the substrate. 
Based on all the observations and previous reports,
5
 the following radical-enolate reaction 
mechanism is proposed (Figure 33). The ruthenium catalyst initially reacts with the substrate affording 
the electron-rich ruthenium enolate I, followed by reaction with BrCCl3 providing brominated 
intermediate 17, which is the key to form the free radical II. This radical species (II) reacts with 
ruthenium enolate I in a stereo-controlled manner providing intermediate III, which can be further 
oxidized by brominated intermediate 17 to afford the product-coordinated ruthenium species IV. 
Finally, the product is released together with regenerating the catalyst. However, the radical-radical 
coupling mechanism cannot be totally excluded at this stage. 




Figure 33. Proposed mechanism for the homocoupling of 2-acyl imidazoles. 
3.3.5 Conclusions 
In conclusion, the first ruthenium catalyzed asymmetric direct oxidative homocoupling of 2-acyl 
imidazole providing 1,4-dicarbonyl compounds in good yields with moderate to high 
enantioselectivities was reported here. To be noted, only one diastereomer is formed for all presented 
substrates. Moreover, mechanism studies support a two-steps catalytic process, first the bromination of 
the 2-acyl imidazole, followed by ruthenium catalyzed radical-enolate coupling to afford the final 
product. This methodology represents a rare example of the catalytically direct synthesis of symmetric 
chiral 1,4-dicarbonyl compounds. 
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Chapter 4: Summary and Outlook 
4.1 Summary 
1) Kinetic resolution of epoxides with CO2 catalyzed by a chiral-at-iridium complex 
Chiral-at-metal bis-cyclometalated iridium(III) complexes were introduced as a new class of 
catalysts for the reaction of epoxides with CO2 to form cyclic carbonates under conditions of kinetic 
resolution (Figure 34). Reactions were typically performed at room temperature in the presence of 1 
mol% iridium catalyst and 1.5 mol% tetraethylammonium bromide as the nucleophilic co-catalyst to 
provide selectivity factors of up to 16.6. Compared with reported catalytic systems, this system is 
tolerant of a variety of monosubstituted epoxides including styrene epoxide, epoxides with aliphatic 
side chains, glycidyl ethers, and a glycidyl ester, and no polymerization side reaction was observed for 
any of the investigated substrates. Moreover, only sample epoxides were used as substrates in this case. 
This is different from most of our group’s previous reports in which two-point binding substrates are 
necessary to obtain good asymmetric induction. 
 
Figure 34. Kinetic resolution of epoxides with CO2 catalyzed by -IrO(Carb). 
Chapter 4. Summary and Outlook 
74 
 
2) Enantioselective intramolecular C(sp
3
)-H amination of aliphatic azides by dual ruthenium 
and phosphine catalysis 
The previously elusive catalytic enantioselective ring-closing C(sp
3
)-H amination of unactivated 
aliphatic azides affording chiral pyrrolidines has been achieved through dual catalysis with a 
chiral-at-metal bis(pyridyl-NHC) ruthenium catalyst in combination with 
tris(p-fluorophenyl)phosphine (both 1 mol%) to provide enantioselectivities of up to 99% ee (Figure 
35). A number of experiments have been performed, which support a unique catalytic cycle. The 
phosphine activates the organic azide to form an intermediate iminophosphorane through the 
well-known Staudinger reaction, which then transfers a nitrene to the ruthenium center to afford a 
ruthenium imido complex, followed by the stereo-controlled C-H amination. 
The application of chiral-at-ruthenium complexes in enantioselective C(sp
3
)-H activation 
demonstrates its interesting reactivity. The high enantioselectivity obtained for this transformation also 
indicated that the configuration of the chiral-at-ruthenium complex is stable even at a high temperature. 
This methodology is of significant synthetic value due to the importance of chiral α-aryl pyrrolidines 
as structural motifs in bioactive compounds. 




Figure 35. Enantioselective intramolecular C-H amination of aliphatic azides by dual ruthenium and 
phosphine catalysis. 
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3) Ruthenium catalyzed asymmetric direct oxidative homocoupling of 2-acyl imidazoles 
Enantioselective direct oxidative homocoupling of 2-acyl imidazoles is achieved in the presence of 
2 mol% of a mono-cyclometalated ruthenium complex and one equivalent BrCCl3 as the oxidant, 
providing moderate to excellent enantioselectivities (Figure 36). Furthermore, almost only one 
diastereomer was obtained for all of the investigated substrates, which is difficult for most of the 
reported catalytic systems. Interestingly, a unique two-steps mechanism is proposed for this catalytic 
transformation. First is the ruthenium catalyzed bromination of 2-acyl imidazole affording the key 
intermediate brominated product, followed by the ruthenium catalyzed stereo-controlled 
radical-enolate reaction to provide the final product. This methodology represents a rare examples of 
catalytically synthesizing chiral 1,4-dicarbonyl molecules from carbonyl compounds. 




Figure 36. Asymmetric direct oxidative homocoupling of 2-acyl imidazole catalyzed by 
cyclometalated ruthenium complex. 
4.2 Outlook 
This thesis displays the versatile catalytic properties of previously established chiral-at-metal 
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iridium and ruthenium complexes and a cyclometalated ruthenium complex. In particular, the 
enantioselective intramolecular C-H amination of aliphatic azides demonstrates the attractive catalytic 
property of our chiral-at-ruthenium complex. Accordingly, further investigations as follows can be 
considered in the future: 
1) Developing new ruthenium complexes with other types of ligands instead of pyridyl-NHC: 
The chiral-at-metal bis(pyridyl-NHC) ruthenium catalysts displayed high activity and excellent 
stereocontrol for intramolecular C-H amination of aliphatic azides, but it could not activate 
electro-deficient organic azides. The study in this thesis also indicated that ligands surrounding the 
metal center had a great influence on the catalytic activity of the ruthenium complex. Therefore, it is 
supposed that ruthenium complexes containing other types of ligands (like cyclometalated ligands) 
which make the metal center more electron-rich is worthy of further development. New ruthenium 
complexes offer the opportunity to catalyze C-H aminations of other types of organic azides or other 
precursors, thus making this strategy more general to construct C-N bonds. The precise design of the 
ligand is necessary when synthesizing electron-rich ruthenium complexes because of the stability 
problem. Both the steric and electronic effects on the ligand should be considered.  
2) Developing new transformations based on nitrene or carbene insertion catalysis: Ruthenium 
imido complexes are the key intermediate in our catalytic enantioselective C-H animations. The 
formation of the ruthenium imido intermediate depends on the nature of the ruthenium catalyst and the 
nitrene precursors employed. The C-H amination of aliphatic azides presented in this thesis was 
limited to the activation of the benzylic C-H bond. It will be of high significance to achieve the C-H 
amination of saturated and completely unactivated C-H bonds. Except for the development of new 
catalysts, testing other aminating reagents is an alternative, for an example using 
N-tosyloxycarbamates. In addition to the nitrene insertion, C-H functionalization through carbene 
insertion using our chiral-at-metal ruthenium catalysts is also interesting. Analogously, different kinds 
of carbene precursors should be carefully screened to achieve the transformation.
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Chapter 5: Experimental Part 
5.1 Materials and Methods 
All reactions were carried out under an atmosphere of nitrogen with magnetic stirring unless indicated 
ortherwise. The catalytic reactions were performed by using standard Schlenk glassware techniques. 
 
Solvents and Reagents 
Solvents were distilled under nitrogen from calcium hydride (CHCl3, CH2Cl2 and CH3CN) or 
sodium/benzophenone (Et2O and THF) or sodium (toluene). Extra dry DMF, 1,4-dioxane and 
1,2-dichlorobenzene were purchased from Acros. HPLC grade solvents, such as 2-methoxyethanol, 
methanol and ethanol were used directly without further drying. All reagents were purchased from 




The course of the reactions and the column chromatographic elution were monitored by thin layer 
chromatography (TLC) [Macherey-Nagel (ALUGRAM®Xtra Sil G/UV254)]. Flash column 
chromatography was performed with silica gel from Merck (particle size 0.040-0.063 mm). 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1
H NMR, proton decoupled 
13
C NMR, and proton coupled 
19
F NMR spectra were recorded on Bruker 
Avance 300 system (
1
H NMR: 300 MHz, 
13
C NMR: 75 MHz, 
19
F NMR: 282 MHz) spectrometers or 
Bruker AM (1H NMR: 500 MHz) spectrometers at ambient temperature. Chemical shifts are given 
in ppm on the  scale, and were determined after calibration to the residual signals of the solvents, 
which were used as an internal standard. NMR standards were used are as follows: 
1
H NMR 
spectroscopy:  = 7.26 ppm (CDCl3),  = 5.32 ppm (CD2Cl2),  = 1.96 ppm (CD3CN),  = 7.16 ppm 
(C6D6); 
13
C-NMR spectroscopy:  = 77.0 ppm (CDCl3),  = 53.8 ppm (CD2Cl2),  = 118.26, 1.32 ppm 
(CD3CN),  = 206.26,  = 128.06 ppm (C6D6). 
19
F NMR spectroscopy:  = 0 ppm (CFCl3). The 
characteristic signals were specified from the low field to high field with the chemical shifts (δ in 
ppm). 
1
H NMR spectra peak multiplicities indicated as singlet (s), doublet (d), doublet of doublet (dd), 
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doublet of doublet of doublet (ddd), triplet (t), doublet of triplet (dt), quartet (q), multiplet (m). The 
coupling constant J indicated in Hertz (Hz).  
 
High-Performance Liquid Chromatography (HPLC) 
Chiral HPLC was performed with an Agilent 1200 Series, Agilent 1260 Series HPLC System or 
Shimadzu Lc-2030c. All the HPLC conditions were detailed in the individual procedures. The type of 
the columns, mobile phase and the flow rate were specified in the individual procedures. 
 
Gas Chromatography (GC) 
Chiral GC chromatography was performed with an Agilent 7890B GC system. All the GC conditions 
were detailed in the individual procedures. 
 
Infrared Spectroscopy (IR) 
IR measurements were recorded on a Bruker Alpha-P FT-IR spectrometer. The absorption bands were 
indicated a wave numbers v (cm
1
). All substances were measured as films or solids. 
 
Mass Spectrometry (MS) 
High-resolution mass spectra were recorded on a Bruker En Apex Ultra 7.0 TFT-MS instrument using 
ESI or APCI or FD technique. Ionic masses are given in units of m/z for the isotopes with the highest 
natural abundance. 
 
Electron Paramagnetic Resonance (EPR) 
The EPR spectrometer is from Bruker (model esp300), with a modified Varian rectangular X-band 
cavity and the modulation frequency was set to 100 kHz, the modulation amplitude was 0.1 mT. 
 
Circular Dichroism Spectroscopy (CD) 
CD spectra were recorded on a JASCO J-810 CD spectropolarimeter. The parameters we used as 
follows: from 600 nm to 200 nm; data pitch (0.5 nm); band with (1 nm); response (1 second); 
sensitivity (standard); scanning speed (50 nm/min); accumulation (5 times). The concentration of the 
compounds for the measurements was 0.2 mM. The formula for converting θ to ε is shown as below. 












C = concentration of the sample; L = thickness of the measurement vessel 
 
Crystal Structure Analysis 
Crystal X-ray measurements and the crystal structure analysis were carried out by Dr. Klaus Harms 
(Chemistry Department, Philipps University of Marburg). X-ray data were collected with a Bruker 3 
circuit D8 Quest diffractometer with MoKa radiation (microfocus tube with multilayer optics) and 
Photon 100 CMOS detector. Scaling and absorption correction was performed by using the SADABS 
software package of Bruker. Structures were solved using direct methods in SHELXS and refined 
using the full matrix least squares procedure in SHELXL-2013 or SHELXL-2014. The Flack 
parameter is a factor used to estimate the absolute configuration of the coumounds. The hydrogen 
atoms were placed in calculated positions and refined as riding on their respective C atom, and Uiso(H) 
was set at 1.2 Ueq(Csp
2
) and 1.5 Ueq(Csp
3
). Disorder of PF6 ions, solvent molecules or methylene 
groups was refined using restraints for both the geometry and the anisotropic displacement factors. 
 
Optical Rotation Polarimeter 





 values reported in degrees with concentrations reported in g/100 mL.  
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5.2 Kinetic Resolution of Epoxides with CO2 Catalyzed by a Chiral-at-Iridium Complex 
5.2.1 Synthesis of Iridium Catalysts -IrO(Carb) and -IrO(Carb) 
a) Synthesis of ligand 
 
A solution of 2-amino-4-tert-butylphenol (0.43 g, 2.58 mmol) and 2-(9H-carbazol-9-yl)benzaldehyde
1
 
(0.7 g, 2.58 mmol) in m-xylene (9 mL) was stirred at 120 °C for 1 h. After cooling to r.t., 
4-methoxy-TEMPO (24.0 mg, 0.13 mmol) was added to the mixture which was then stirred at 120 °C 
overnight under an oxygen atmosphere (1 atm O2 gas in a balloon). After cooling to room temperature, 
all volatiles were removed in vacuo. The residue was purified by flash chromatography on silica gel 
(n-hexane/EtOAc 20:1) to afford the desired product 1 (1.02 g, 2.45 mmol, 95%) as a white solid.
 
1
H NMR (300 MHz, CDCl3) δ 8.56 (dd, J = 7.6, 1.8 Hz, 1H), 8.25-8.15 (m, 2H), 7.82-7.68 (m, 2H), 
7.67-7.56 (m, 2H), 7.35-7.21 (m, 4H), 7.20-7.08 (m, 3H), 6.80 (d, J = 8.7 Hz, 1H), 1.30 (s, 9H).  
13
C NMR (75 MHz, CDCl3) δ
 
161.2, 148.8, 147. 9, 142.0, 141.2, 136.4, 132. 6, 132.0, 130.9, 129.0, 
126.9, 126.1, 123.7, 123.0, 120.3, 119.8, 116.5, 109.64, 109.61, 34.9, 31.8.  
IR (film): ν (cm
1
) 3056, 2959, 2869, 1591, 1544, 1452, 1315, 1270, 1229, 1197, 1118, 1065, 1029, 
908, 842, 812, 720, 640, 425.  
HRMS (ESI, m/z) calcd. for C29H24N2ONa [M+Na]
+
: 439.1786, found: 439.1781. 
b) Synthesis of iridium dimer complex  
 
A solution of compound 1 (500 mg, 1.20 mmol) and iridium chloride hydrate (254 mg, 0.72 mmol) in 
Chapter 5. Experimental Part 
83 
 
2-ethoxyethanol (24 mL) was purged with nitrogen gas for 15 min and then stirred at 130 °C for 24 h 
under nitrogen atmosphere. After cooling to room temperature, all volatiles were removed in vacuo 
and the residue was purified by flash chromatography on silica gel (n-hexane/CH2Cl2 1:4 to CH2Cl2) 
to afford the desired product Ir-dimer2 (553 mg, 0.26 mmol, 87%) as a yellow solid. 
1
H NMR (300 MHz, CD2Cl2) δ 8.27-8.13 (m, 12H), 7.52-7.41 (m, 8H), 7.38-7.31 (m, 4H), 7.20-7.14 
(m, 4H), 7.12-7.06 (m, 4H), 7.03-6.94 (m, 8H), 6.79-6.72 (m, 4H), 6.62-6.58 (m, 4H), 6.32-6.20 (m, 
8H), 0.62 (s, 36H).  
13
C NMR could not be measured because of the low solubility.  
IR (film): ν (cm
1
) 3055, 2962, 2869, 2034, 1573, 1481, 1453, 1424, 1364, 1314, 1275, 1231, 1193, 
1147, 1109, 965, 929, 888, 808, 749, 719, 646, 425.  
HRMS (LIFDI, m/z) calcd. for C116H92Cl2Ir2N8O4: 2116.5887, found: 2116.5921. 
c) Synthesis of iridium auxiliary complex 
 
A mixture of dimer complex Ir-dimer2 (0.5 g, 0.24 mmol), the chiral auxiliary Aux4a (125.4 mg, 
0.57 mmol), AgOTf (146 mg, 0.57 mmol) and Na2CO3 (375 mg, 3.54 mmol) in 2-ethoxyethanol (15 
mL) was stirred at 80 
o
C for 20 h under nitrogen atmosphere. After cooling to room temperature, all 
volatiles were removed in vacuo. The residue was dissolved in CH2Cl2 and filtered through celite to 
remove all unsoluble solid. The filtrate was then concentrated under reduced pressure and purified by 
flash chromatography on silica gel (n-hexane/CH2Cl2 4:1 to 2:1) to get the two diastereomers. The first 
eluting diastereomer (236 mg, 0.19 mmol, 40%) was assigned as Λ-(S)-Ir3 and the second eluting 
diastereomer as Δ-(S)-Ir3 (174 mg, 0.14 mmol, 30%). 
Λ-(S)-Ir3:  
1
H NMR (300 MHz, CD2Cl2) δ 8.35-8.15 (m, 4H), 7.92 (s, 1H), 7.51-7.21 (m, 16H), 7.20-7.05 (m, 
5H), 6.99-6.86 (m, 3H), 6.82 (d, J = 8.7 Hz, 1H), 6.71 (d, J = 7.5 Hz, 1H), 6.37-6.27 (m, 1H), 4.97 (d, 
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J = 8.7 Hz, 1H), 3.46 (t, J = 10.8 Hz, 1H), 3.09 (d, J = 12.5 Hz, 1H), 1.39 (s, 9H), 1.11 (s, 9H), 
0.80-0.65 (m, 1H), 0.48 (d, J = 6.7 Hz, 3H), 0.02 (d, J = 6.6 Hz, 3H).  
13
C NMR (75 MHz, CD2Cl2) δ 176.8, 176.4, 168.9, 167.7, 154.7, 154.0, 150.8, 150.5, 148.7, 148.3, 
143.0, 142.4, 142.3, 142.2, 138.6, 138.3, 136.5, 136.0, 135.8, 134.1, 133.9, 133.1, 132.4, 131.8, 130.4, 
129.8, 126.7, 126.5, 126.4, 126.3, 124.9, 124.4, 124.3, 124.03, 123.96, 123.8, 123.6, 122.9, 121.9, 
121.0, 120.9, 120.7, 120.6, 120.4, 120.3, 120.3, 119.2, 118.6, 115.2, 114.0, 113.1, 111.1, 110.8, 110.7, 
110.6, 110.4, 85.6, 35.9, 35.5, 32.2, 31.8, 31.7, 28.4, 19.8, 14.2.  
IR (film): ν (cm
1
) 2960, 2869, 1562, 1522, 1452, 1362, 1273, 1232, 1194, 1151, 1013, 965, 930, 846, 
814, 749, 647.  
HRMS (ESI, m/z) calcd. for C70H61IrN5O3S [M+H]
+
: 1244.4124, found: 1244.4124.  








H NMR (300 MHz, CD2Cl2) δ 8.31-8.18 (m, 4H), 7.89 (d, J 1.7 Hz, 1H), 7.43-7.01 (m, 22H), 6.92 (d, 
J 8.9 Hz, 1H), 6.80 (dd, J 7.7, 5.5 Hz, 2H), 6.62 (d, J 7.8 Hz, 1H), 6.29 (t, J 6.9 Hz, 1H), 3.64 (d, J 
10.0 Hz, 1H), 2.93 (dd, J 11.3, 2.2 Hz, 1H), 2.57 (t, J 10.6 Hz, 1H), 2.38-2.22 (m, 1H), 1.15 (s, 9H), 
1.08 (s, 9H), 1.05 (d, J 6.9 Hz, 3H), 0.35 (d, J 7.0 Hz, 3H).  
13
C NMR (75 MHz, CD2Cl2) δ 177.3, 177.1, 168.3, 167.6, 154.9, 154.0, 151.0, 149.9, 148.9, 148.3, 
142.9, 142.8, 142.2, 142.2, 139.0, 137.9, 136.5, 136.1, 133.7, 132.8, 132.8, 132.6, 132.4, 129.8, 129.3, 
126.6, 126.6, 126.4, 126.3, 124.5, 124.4, 124.2, 124.1, 123.9, 123.9, 123.7, 122.8, 122.1, 121.0, 120.9, 
120.8, 120.7, 120.4, 120.3, 120.2, 119.9, 114.9, 114.1, 113.7, 110.9, 110.5, 110.3, 83.1, 35.6, 35.4, 
32.2, 32.0, 31.6, 30.1, 20.8, 17.1.  
IR (film): ν (cm
1
) 2954, 2922, 2856, 1593, 1563, 1450, 1419, 1359, 1339, 1312, 1274, 1231, 1194, 
1146, 928, 813, 746, 718, 640.  
HRMS (ESI, m/z) calcd. for C70H61IrN5O3S [M+H]
+
: 1244.4121, found: 1244.4121.  




) 470 (+10), 424 (+1), 412 (+3), 387 (-5), 378 (-3), 331 (-41), 299 
(+40), 274 (+9), 238 (-37), 215 (+42). 
d) Synthesis of enantiopure iridium complex 




A round flask was charged with Λ-(S)-Ir3 (142 mg, 0.11 mmol), then evacuated and purged with 
nitrogen gas, and CH3CN (6 mL) was added. After stirring for 5 min, trifluoromethanesulfonic acid  
(29 µL, 0.33 mmol) was added. The resulting mixture was stirred for 1 h at room temperature under 
nitrogen atmosphere. Then all volatiles were removed in vacuo and the residue was purified by flash 
chromatography on silica gel (CH2Cl2/CH3CN 20:1 to 3:1) to give catalyst Λ-IrO(Carb) (125.4 mg, 
0.099 mmol, 90%) as a yellow solid. According to the same procedure, catalyst Δ-IrO(Carb) (121.6 
mg, 0.097 mmol, 88%) was got as a yellow solid. 
Λ-IrO(Carb):  
1
H NMR (300 MHz, CD3CN) δ 8.30 (d, J = 7.5 Hz, 4H), 7.92 (d, J = 1.7 Hz, 2H), 7.55 (dd, J = 8.9, 
1.9 Hz, 2H), 7.46-7.15 (m, 14H), 7.01 (d, J = 8.9 Hz, 2H), 6.90 (d, J = 7.1 Hz, 2H), 6.64 (dd, J = 7.4, 
1.1 Hz, 2H), 2.39 (s, 6H), 1.40 (s, 18H).  
13
C NMR (75 MHz, CD2Cl2) δ 175.5, 151.5, 148.6, 145.3, 142.5, 142.1, 137.7, 136.4, 133.8, 132.9, 
128.6, 126.6, 126.5, 125.4, 124.8, 124.3, 124.2, 121.7, 121.0, 121.0, 120.7, 120.6, 113.0, 111.9, 110.2, 
110.1, 35.8, 31.9, 4.4.  
IR (film): v~ (cm-1) 3053, 2961, 2871, 1575, 1453, 1423, 1366, 1313, 1266, 1230, 1195, 1151, 1028, 
969, 930, 817, 747, 636, 571, 518, 423.  




: 1105.3776, found: 1105.3780.  




) 448 (-6), 338 (+31), 412 (+3), 293 (-46), 235 (+54), 217 (-11), 207 
(+39). 








) 448 (+6), 338 (-31), 412 (-3), 293 (+46), 235 (-54), 217 (+11), 207 
(-39).  
All other spectroscopic data of Δ-IrO(Carb) were in agreement with Λ-IrO(Carb). 
5.2.2 Synthesis of Epoxides 
Procedure A: 
 
To a solution of ROH (1 equiv), 40% NaOH aqueous (17 equiv) and nBu4NBr (0.05 equiv) in water 
(0.6 M) was added 2-(chloromethyl)oxirane (4 equiv) in a flask. After being stirred at room 
temperature for 24 hours, the reaction mixture was extracted three times with diethyl ether. The 
combined organic phases were dried over Na2SO4. After removal of the solvent under reduced 
pressure, the crude mixture was purified by flash column chromatography on silica gel column 
resulted in the desired epoxides. 
Procedure B: 
 
To a solution of alkene (1.0 equiv) in CH3CN/CH3CH2OH (2.1 M, volume ratio = 1: 5), H2O2 solution 
(2.0 equiv) containing KHCO3 (0.3 equiv) was added slowly. The resulting mixture was stirred at 
room temperature for 24 hours. Another portion of H2O2 solution (0.5 equiv) was added and the 
resulting mixture was stirred at room temperature for another 24 hours. The reaction was quenched by 
saturated Na2S2O3 solution slowly, and the product was extracted three times with diethyl ether. The 
combined organic phases were dried over Na2SO4. After removal of the solvent under reduced 
pressure, the crude mixture was purified by flash column chromatography on silica gel column 
resulted in the desired epoxides. 
2-((Benzyloxy)methyl)oxirane (4a) 
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Compound 4a (985 mg, 6.0 mmol) was synthesized from phenylmethanol (1.08 g, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 60%. 
1
H NMR (300 MHz, 
CDCl3) δ 7.42-7.27 (m, 5H), 4.69-4.50 (m, 2H), 3.77 (dd, J = 11.4, 3.1 Hz, 1H), 3.45 (dd, J = 11.4, 5.8 
Hz, 1H), 3.19 (ddd, J = 7.0, 5.8, 2.9 Hz, 1H), 2.88-2.75 (m, 1H), 2.62 (dd, J = 5.0, 2.7 Hz, 1H). 
2-((p-Tolyloxy)methyl)oxirane (4c) 
 
Compound 4c (969 mg, 5.9 mmol) was synthesized from p-cresol (1.08 g, 10 mmol) according to the 
above Procedure A and obtained as a colorless oil. Yield: 59%. 
1
H NMR (300 MHz, CDCl3) δ 7.08 (d, 
J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 4.18 (dd, J = 11.0, 3.2 Hz, 1H), 3.95 (dd, J = 11.0, 5.5 Hz, 
1H), 3.35 (s, 1H), 2.90 (t, J = 4.5 Hz, 1H), 2.75 (dd, J = 4.9, 2.6 Hz, 1H), 2.29 (s, 3H). 
2-((m-Tolyloxy)methyl)oxirane (4d) 
 
Compound 4d (903 mg, 5.5 mmol) was synthesized from m-cresol (1.08 g, 10 mmol) according to the 
above Procedure A and obtained as a colorless oil. Yield: 55%. 
1
H NMR (300 MHz, CDCl3) δ 7.17 (t, 
J = 7.7 Hz, 1H), 6.76 (dd, J = 17.8, 8.0 Hz, 3H), 4.19 (dd, J = 11.0, 3.3 Hz, 1H), 3.97 (dd, J = 11.0, 5.5 




Compound 4e (969 mg, 5.9 mmol) was synthesized from o-cresol (1.08 g, 10 mmol) according to the 
above Procedure A and obtained as a colorless oil. Yield: 59%. 
1
H NMR (250 MHz, CDCl3) δ 
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7.22-7.08 (m, 2H), 6.93-6.75 (m, 2H), 4.23 (dd, J = 11.1, 3.1 Hz, 1H), 3.99 (dd, J = 11.1, 5.4 Hz, 1H), 
3.38 (ddt, J = 5.6, 4.1, 3.0 Hz, 1H), 2.99-2.85 (m, 1H), 2.79 (dd, J = 5.0, 2.7 Hz, 1H), 2.26 (s, 3H). 
2-((4-Methoxyphenoxy)methyl)oxirane (4f) 
 
Compound 4f (1.17 g, 6.5 mmol) was synthesized from 4-methoxyphenol (1.24 g, 10 mmol) according 
to the above Procedure A and obtained as a colorless oil. Yield: 65%. 
1
H NMR (250 MHz, CDCl3) δ 
6.97-6.73 (m, 4H), 4.17 (dd, J = 11.1, 3.3 Hz, 1H), 3.92 (dd, J = 11.1, 5.6 Hz, 1H), 3.77 (s, 3H), 
3.42-3.27 (m, 1H), 2.98-2.83 (m, 1H), 2.74 (dd, J = 5.0, 2.7 Hz, 1H). 
2-((4-Bromophenoxy)methyl)oxirane (4j) 
 
Compound 4j (1.40 g, 6.1 mmol) was synthesized from 4-bromophenol (1.73 g, 10 mmol) according 
to the above Procedure A and obtained as a colorless oil. Yield: 61%. 
1
H NMR (250 MHz, CDCl3) δ 
7.46-7.30 (m, 2H), 6.90-6.73 (m, 2H), 4.21 (dd, J = 11.0, 3.0 Hz, 1H), 3.91 (dd, J = 11.0, 5.7 Hz, 1H), 
3.34 (ddt, J = 5.7, 4.1, 2.9 Hz, 1H), 2.97-2.83 (m, 1H), 2.75 (dd, J = 4.9, 2.6 Hz, 1H). 
2-((4-Chlorophenoxy)methyl)oxirane (4h) 
 
Compound 4h (1.09 g, 5.9 mmol) was synthesized from 4-chlorophenol (1.29 g, 10 mmol) according 
to the above Procedure A and obtained as a colorless oil. Yield: 59%. 
1
H NMR (300 MHz, CDCl3) δ 
7.36-7.16 (m, 2H), 6.97-6.80 (m, 2H), 4.23 (dd, J = 11.0, 3.0 Hz, 1H), 3.94 (dd, J = 11.0, 5.7 Hz, 1H), 
3.36 (ddd, J = 6.9, 5.8, 2.9 Hz, 1H), 2.93 (t, J = 4.5 Hz, 1H), 2.77 (dd, J = 4.9, 2.6 Hz, 1H). 
2-((Naphthalen-2-yloxy)methyl)oxirane (4i) 




Compound 4i (981 mg, 4.9 mmol) was synthesized from naphthalen-2-ol (1.44 g, 10 mmol) according 
to the above Procedure A and obtained as a colorless oil. Yield: 49%. 
1
H NMR (300 MHz, CDCl3) δ 
7.85-7.66 (m, 3H), 7.44 (dd, J = 11.0, 4.1 Hz, 1H), 7.35 (t, J = 6.9 Hz, 1H), 7.22-7.12 (m, 2H), 4.35 
(dd, J = 11.0, 3.2 Hz, 1H), 4.09 (dd, J = 11.0, 5.7 Hz, 1H), 3.43 (dt, J = 9.8, 3.0 Hz, 1H), 3.01- 2.91 (m, 
1H), 2.82 (dd, J = 4.9, 2.7 Hz, 1H). 
2-(Phenethoxymethyl)oxirane (4j) 
 
Compound 4j (1.16 g, 6.5 mmol) was synthesized from 2-phenylethan-1-ol (1.22 g, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 65%. 
1
H NMR (250 MHz, 
CDCl3) δ 7.38-7.26 (m, 2H), 7.25-7.15 (m, 3H), 3.02-2.91 (m, 1H), 2.91-2.66 (m, 3H), 2.48 (dd, J = 
5.0, 2.7 Hz, 1H), 2.01-1.73 (m, 2H). 
2-((Benzhydryloxy)methyl)oxirane (4k) 
 
Compound 4k (1.44 g, 6.0 mmol) was synthesized from diphenylmethanol (1.84 g, 10 mmol) 
according to the above Procedure A and obtained as a white solid. Yield: 60%. 
1
H NMR (300 MHz, 
CDCl3) δ 7.47-7.20 (m, 10H), 5.48 (s, 1H), 3.76 (dd, J = 11.4, 3.1 Hz, 1H), 3.49 (dd, J = 11.4, 5.7 Hz, 
1H), 3.24 (ddt, J = 5.7, 4.0, 3.0 Hz, 1H), 2.81 (dd, J = 5.0, 4.2 Hz, 1H), 2.63 (dd, J = 5.1, 2.7 Hz, 1H). 
2-((Oxiran-2-ylmethoxy)methyl)furan (4l) 




Compound 4l (693 mg, 4.5 mmol) was synthesized from furan-2-ylmethanol (981 mg, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 45%. 
1
H NMR (300 MHz, 
CDCl3) δ 7.54-7.31 (m, 1H), 6.34 (s, 2H), 4.67-4.38 (m, 2H), 3.75 (dd, J = 11.5, 3.1 Hz, 1H), 3.44 (dd, 




Compound 4m (953 mg, 5.6 mmol) was synthesized from thiophen-2-ylmethanol (1.14 g, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 56%. 
1
H NMR (250 MHz, 
CDCl3) δ 7.30 (dd, J = 5.0, 1.3 Hz, 1H), 7.00 (ddd, J = 8.4, 3.9, 2.0 Hz, 2H), 4.87-4.61 (m, 2H), 3.77 
(dd, J = 11.4, 3.1 Hz, 1H), 3.45 (dd, J = 11.4, 5.8 Hz, 1H), 3.18 (ddt, J = 5.8, 4.1, 2.9 Hz, 1H), 
2.89-2.76 (m, 1H), 2.62 (dd, J = 5.0, 2.7 Hz, 1H). 
2-Phenethyloxirane (4o) 
 
Compound 4o (934 mg, 6.3 mmol) was synthesized from but-3-en-1-ylbenzene (1.32 g, 10 mmol) 
according to the above Procedure B and obtained as a colorless oil. Yield: 63%. 
1
H NMR (250 MHz, 
CDCl3) δ 7.38-.26 (m, 2H), 7.25-7.15 (m, 3H), 3.02-2.91 (m, 1H), 2.91-2.66 (m, 3H), 2.48 (dd, J = 5.0, 
2.7 Hz, 1H), 2.01-1.73 (m, 2H). 
2-Benzyloxirane (4r) 




Compound 4r (671 mg, 5.0 mmol) was synthesized from allylbenzene (1.18 g, 10 mmol) according to 
the above Procedure B and obtained as a colorless oil. Yield: 50%. 
1
H NMR (250 MHz, CDCl3) δ 




Compound 4s (969 mg, 5.9 mmol) was synthesized from 1-allyl-4-methoxybenzene (1.48 g, 10 mmol) 
according to the above Procedure B and obtained as a colorless oil. Yield: 59%. 
1
H NMR (250 MHz, 
CDCl3) δ 7.23-7.11 (m, 2H), 6.93-6.79 (m, 2H), 3.80 (s, 3H), 3.12 (tdd, J = 5.5, 3.9, 2.7 Hz, 1H), 
2.96-2.70 (m, 3H), 2.53 (dd, J = 5.0, 2.7 Hz, 1H). 
5.2.3 Ir-Catalyzed Kinetic Resolution of Epoxides with CO2 
A 1.5 mL glass vial with stirrer bar was charged with the Et4NBr (0.9 mg, 0.0045 mmol, 1.5 
mol%), Λ-IrO(Carb) (3.8 mg, 0.003 mmol, 1.0 mol%), the corresponding epoxide (0.3 mmol, 1.0 
equiv) and 1,4-dioxane (86 µL, 3.5 M). The glass vial was placed into a 300 mL stainless steel 
autoclave with suitable stainless steel module. The autoclave was closed and then subjected to three 
cycles of pressurization and depressurization with carbon dioxide, before final stabilization of the 
pressure to 20 bar. The autoclave was left stirring at room temperature for 30 hours. At the end of the 
reaction an aliquot of the resulting mixture was taken and the conversion was determined by means of 
1
H NMR spectroscopy using CDCl3 as the solvent. The analytically pure cyclic carbonate product was 









Starting from 4a (49.2 mg, 0.3 mmol) according to the general procedure to give 5a in 14% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
81%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 17.3 
min, tr (major) = 22.3 min. 
1
H NMR (300 MHz, CDCl3) δ 7.42-7.27 (m, 5H), 4.86-4.76 (m, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.56 
(d, J = 12.0 Hz, 1H), 4.48 (t, J = 8.3 Hz, 1H), 4.38 (dd, J = 8.3, 6.1 Hz, 1H), 3.71 (dd, J = 10.9, 4.0 
Hz, 1H), 3.71 (dd, J = 10.9, 3.8 Hz, 1H) ppm.  
13





Starting from 4b (45.0 mg, 0.3 mmol) according to the general procedure to give 5b in 20% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
82%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 24.0 
min, tr (major) = 31.8 min. 
1
H NMR (300 MHz, CDCl3) δ 7.35-7.26 (m, 2H), 7.02 (t, J = 7.4 Hz, 1H), 6.91 (d, J = 7.8 Hz, 2H), 
5.07-4.97 (m, 1H), 4.65-4.57 (m, 1H), 4.56-4.49 (m, 1H), 4.24 (dd, J = 10.6, 4.2 Hz, 1H), 4.14 (dd, J 
= 10.6, 3.6 Hz, 1H) ppm.  
13
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Starting from 4c (49.2 mg, 0.3 mmol) according to the general procedure to give 5c in 20% conversion. 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 82%. HPLC 
conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile phase 
n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 16.1 min, 
tr (major) = 29.6 min. 
1
H NMR (300 MHz, CDCl3) δ 7.15-7.05 (m, 2H), 6.85-6.77 (m, 2H), 5.06-4.95 (m, 1H), 4.65-4.48 
(m, 2H), 4.22 (dd, J = 10.6, 4.3 Hz, 1H), 4.12 (dd, J = 10.6, 3.7 Hz, 1H), 2.29 (s, 3H).  
13





Starting from 4d (49.2 mg, 0.3 mmol) according to the general procedure to give 5d in 20% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
82%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 18.2 
min, tr (major) = 28.1 min. 
1
H NMR (300 MHz, CDCl3) δ 7.18 (t, J = 7.8 Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 6.76-6.67 (m, 2H), 
5.06-4.95 (m, 1H), 4.64-4.48 (m, 2H), 4.21 (dd, J = 10.7, 4.2 Hz, 1H), 4.12 (dd, J = 10.7, 3.7 Hz, 1H), 
2.33 (s, 3H) ppm.  
13






Starting from 4e (49.2 mg, 0.3 mmol) according to the general procedure to give 5e in 12% conversion. 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 80%. HPLC 
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conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile phase 
n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 22.5 min, 
tr (major) = 24.2 min. 
1
H NMR (300 MHz, CDCl3) δ 7.21-7.12 (m, 2H), 6.92 (t, J = 7.5 Hz, 1H), 6.82-6.75 (m, 1H), 
5.09-5.00 (m, 1H), 4.67-4.52 (m, 2H), 4.26 (dd, J = 10.7, 3.6 Hz, 1H), 4.13 (dd, J = 10.7, 3.1 Hz, 1H), 
2.22 (s, 3H) ppm.  
13





Starting from 4f (54.0 mg, 0.3 mmol) according to the general procedure to give 5f in 17% conversion. 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 80%. HPLC 
conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile phase 
n-hexane/isopropanol = 70:30, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 15.1 min, 
tr (major) = 27.0 min. 
1
H NMR (300 MHz, CDCl3) δ 6.90-6.78 (m, 4H), 5.04-4.93 (m, 1H), 4.63-4.47 (m, 2H), 4.18 (dd, J = 
10.7, 4.1 Hz, 1H), 4.09 (dd, J = 10.7, 3.6 Hz, 1H), 3.76 (s, 3H) ppm.  
13





Starting from 4g (68.7 mg, 0.3 mmol) according to the general procedure to give 5g in 24% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
80%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 19.4 
min, tr (major) = 24.0 min. 




H NMR (300 MHz, CDCl3) δ 7.47-7.34 (m, 2H), 6.85-6.75 (m, 2H), 5.07-4.96 (m, 1H), 4.62 (t, J = 
8.5 Hz, 1H), 4.51 (dd, J = 8.6, 5.9 Hz, 1H), 4.21 (dd, J = 10.6, 4.1 Hz, 1H), 4.11 (dd, J = 10.6, 3.6 Hz, 
1H) ppm.  
13





Starting from 4h (55.4 mg, 0.3 mmol) according to the general procedure to give 5h in 23% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
78%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 18.6 
min, tr (major) = 22.5 min. 
1
H NMR (300 MHz, CDCl3) δ 7.30-7.22 (m, 2H), 6.88-6.80 (m, 2H), 5.06-4.97 (m, 1H), 4.61 (t, J = 
8.5 Hz, 1H), 4.51 (dd, J = 8.6, 5.9 Hz, 1H), 4.21 (dd, J = 10.6, 4.0 Hz, 1H), 4.11 (dd, J = 10.6, 3.6 Hz, 
1H) ppm.  
13





Starting from 4i (60.0 mg, 0.3 mmol) according to the general procedure to give 5i in 22% conversion. 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 80%. HPLC 
conditions: Chiralpak IG column (4.6  250 mm), UV detection at 254 nm, mobile phase 
n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 20.1 min, 
tr (major) = 21.3 min. 
1
H NMR (300 MHz, CDCl3) δ 7.85-7.68 (m, 3H), 7.51-7.43 (m, 1H), 7.42-7.34 (m, 1H), 7.20-7.10 
(m, 2H), 5.15-5.04 (m, 1H), 4.71-4.54 (m, 2H), 4.36 (dd, J = 10.6, 4.3 Hz, 1H), 4.27 (dd, J = 10.6, 3.7 
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Hz, 1H) ppm.  
13
C NMR (75 MHz, CDCl3) δ 155.9, 154.7, 134.4, 130.0, 129.7, 127.9, 127.0, 126.9, 124.5, 118.5, 
107.3, 74.2, 67.1, 66.4 ppm. 
(R)-4-(Phenethoxymethyl)-1,3-dioxolan-2-one (5j) 
 
Starting from 4j (53.4 mg, 0.3 mmol) according to the general procedure (70 h was used instead) to 
give 5j in 16% conversion. Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 82%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection 
at 216 nm, mobile phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 
25 °C, tr (minor) = 15.4 min, tr (major) = 19.7 min. 
1
H NMR (300 MHz, CDCl3) δ 7.34-7.26 (m, 2H), 7.25-7.17 (m, 3H), 4.81-4.70 (m, 1H), 4.42 (t, J = 
8.3 Hz, 1H), 4.29 (dd, J = 8.3, 6.1 Hz, 1H), 3.81-3.64 (m, 3H), 3.58 (dd, J = 11.0, 3.6 Hz, 1H), 2.89 (t, 
J = 6.8 Hz, 2H) ppm.  
13
C NMR (75 MHz, CDCl3) δ 155.0, 138.6, 129.0, 128.5, 126.5, 75.1, 72.9, 69.9, 66.3, 36.3 ppm.  
IR (film): ν (cm
1
) 2922, 2863, 1787, 1486, 1455, 1393, 1362, 1167, 1128, 1105, 1045, 749, 701, 576, 
499.  
HRMS (ESI, m/z) calcd. for C12H14O4Na [M+Na]
+
: 245.0784, found: 245.0780. 
(R)-4-((Benzhydryloxy)methyl)-1,3-dioxolan-2-one (5k) 
 
Starting from 4k (72.2 mg, 0.3 mmol) according to the general procedure (70 h was used instead) to 
give 5k in 12% conversion. Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 82%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection 
at 216 nm, mobile phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 
25 °C, tr (minor) = 24.2 min, tr (major) = 35.9 min. 




H NMR (300 MHz, CDCl3) δ 7.38-7.25 (m, 10H), 5.42 (s, 1H), 4.90-4.78 (m, 1H), 4.57-4.39 (m, 
2H), 3.74 (dd, J = 10.9, 3.9 Hz, 1H), 3.61 (dd, J = 10.8, 3.6 Hz, 1H) ppm.  
13
C NMR (75 MHz, CDCl3) δ 155.0, 141.3, 141.2, 128.8, 128.7, 128.1, 128.0, 127.1, 127.0, 84.6, 
75.1, 68.0, 66.5 ppm.  
IR (film): ν (cm
1
) 2925, 2873, 1779, 1486, 1452, 1393, 1331, 1168, 1124, 1097, 1033, 973, 919, 845, 
793, 747, 696, 656, 625, 593, 524, 469.  
HRMS (ESI, m/z) calcd. for C17H16O4Na[M+ Na]
+





Starting from 4l (46.2 mg, 0.3 mmol) according to the general procedure to give 5l in 13% conversion. 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 74%. HPLC 
conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile phase 
n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 14.7 min, 
tr (major) = 15.8 min. 
1
H NMR (300 MHz, CDCl3) δ 7.47-7.38 (m, 1H), 6.42-6.30 (m, 2H), 4.84-4.73 (m, 1H), 4.61-4.42 
(m, 3H), 4.34 (dd, J = 8.4, 6.2 Hz, 1H), 3.70 (dd, J = 10.9, 4.4 Hz, 1H), 3.64 (dd, J = 10.9, 3.9 Hz, 1H) 
ppm.  
13
C NMR (75 MHz, CDCl3) δ 154.9, 150.8, 143.3, 110.5, 110.2, 75.0, 68.6, 66.4, 65.4 ppm. 
(R)-4-((Thiophen-2-ylmethoxy)methyl)-1,3-dioxolan-2-one (5m) 
 
Starting from 4m (51.0 mg, 0.3 mmol) according to the general procedure to give 5m in 11% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
76%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 19.4 
min, tr (major) = 22.3 min. 




H NMR (300 MHz, CDCl3) δ 7.32 (dd, J = 4.9, 1.4 Hz, 1H), 7.06-6.95 (m, 2H), 4.85-4.68 (m, 3H), 
4.47 (t, J = 8.3 Hz, 1H), 4.36 (dd, J = 8.4, 6.1 Hz, 1H), 3.70 (dd, J = 10.8, 4.2 Hz, 1H), 3.63 (dd, J = 
10.8, 3.8 Hz, 1H) ppm.  
13
C NMR (75 MHz, CDCl3) δ 154.9, 139.7, 127.3, 127.0, 126.6, 75.0, 68.4, 68.1, 66.4 ppm.  
IR (film): ν (cm
1
) 2918, 2857, 1786, 1392, 1360, 1166, 1098, 1040, 845, 771, 710.  
HRMS (ESI, m/z) calcd. for C9H10O4SNa [M+Na]
+





Starting from 4n (53.4 mg, 0.3 mmol) according to the general procedure to give 5n in 15% 
conversion. Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 
74%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 216 nm, mobile 
phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 17.2 
min, tr (major) = 19.1 min. 
1
H NMR (300 MHz, CDCl3) δ
 
 8.06-7.98 (m, 2H), 7.64-7.56 (m, 1H), 7.51-7.42 (m, 2H), 5.11-5.00 
(m, 1H), 4.67-4.55 (m, 2H), 4.51 (dd, J = 12.6, 3.9 Hz, 1H), 4.42 (dd, J = 8.8, 5.7 Hz, 1H) ppm.  
13





Starting from 4o (29.6 mg, 0.2 mmol) according to the general procedure (reaction time is 70 h) to 
give 5o in 12% conversion. Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 78%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection 
at 216 nm, mobile phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 
25 °C, tr (minor) = 21.5 min, tr (major) = 24.2 min. 
1
H NMR (300 MHz, CDCl3) δ 7.36-7.16 (m, 5H), 4.73-4.62 (m, 1H), 4.47 (t, J = 8.1 Hz, 1H), 4.04 
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(dd, J = 8.4, 7.2 Hz, 1H), 2.93-2.81 (m, 1H), 2.80-2.68 (m, 1H), 2.23-2.09 (m, 1H), 2.05-1.91 (m, 1H) 
ppm.  
13





Starting from 4p (21.5 µL, 0.2 mmol) according to the general procedure (1 mol% -IrO(Carb), 2 
mol% nBu4NBr and 45 h were used instead) to give 5p in 25% conversion. Enantiomeric excess was 
determined by GC analysis on a chiral stationary phase, ee = 74%. GC conditions: BGB column (30 m 
 0.25 mm), column temperature 115 C, isothermal, tr (minor) = 12.1 min, tr (major) = 12.4 min. 
1
H NMR (300 MHz, CDCl3) δ 4.70 (ddd, J = 14.8, 7.4, 5.5 Hz, 1H), 4.52 (t, J = 8.1 Hz, 1H), 4.07 (dd, 
J = 8.3, 7.2 Hz, 1H), 1.90-1.60 (m, 2H), 1.50-1.29 (m, 4H), 0.93 (dd, J = 8.8, 5.3 Hz, 3H) ppm.  
13





Starting from 4q (26.1 µL, 0.3 mmol) according to the general procedure (1 mol% -IrO(Carb), 2 
mol% nBu4NBr and 45 h were used instead) to give 5q in 23% conversion. Enantiomeric excess was 
determined by GC analysis on a chiral stationary phase, ee = 68%. GC conditions: BGB column (30 m 
 0.25 mm), column temperature 110 C, isothermal, tr (minor) = 5.6 min, tr (major) = 5.7 min. 
1
H NMR (300 MHz, CDCl3) δ 4.65 (dt, J = 13.5, 7.0 Hz, 1H), 4.51 (t, J = 8.1 Hz, 1H), 4.07 (dd, J = 
8.3, 7.0 Hz, 1H), 1.88-1.67 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H) ppm. 
13
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Starting from 4q (26.8 mg, 0.2 mmol) according to the general procedure (1 mol% -IrO(Carb), 2 
mol% nBu4NBr and 45 h were used instead) to give 5q in 21% conversion. Enantiomeric excess was 
determined by HPLC analysis on a chiral stationary phase, ee = 86%. HPLC conditions: Chiralpak 
OD-H column (4.6  250 mm), UV detection at 216 nm, mobile phase n-hexane/isopropanol = 80:20, 
flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 18.7 min, tr (major) = 20.1 min. 
1
H NMR (300 MHz, CDCl3) δ 7.41-7.27 (m, 3H), 7.25-7.19 (dd, J = 7.6, 1.7 Hz, 2H), 4.93 (td, J = 
13.5, 6.7 Hz, 1H), 4.50-4.39 (m, 1H), 4.17 (dd, J = 8.6, 6.9 Hz, 1H), 3.17 (dd, J = 14.2, 6.2 Hz, 1H), 
2.99 (dd, J = 14.2, 6.7 Hz, 1H) ppm.  
13
C NMR (75 MHz, CDCl3) δ 154.9, 134.0, 129.5, 129.2, 127.8, 77.0, 68.6, 39.8 ppm. 
(S)-4-(4-Methoxybenzyl)-1,3-dioxolan-2-one (5s) 
 
Starting from 4s (32.8 mg, 0.2 mmol) according to the general procedure (1 mol% -IrO(Carb), 2 
mol% nBu4NBr and 45 h were used instead) to give 5s in 40% conversion. Enantiomeric excess was 
determined by HPLC analysis on a chiral stationary phase, ee = 80%. HPLC conditions: Chiralpak 
OD-H column (4.6  250 mm), UV detection at 216 nm, mobile phase n-hexane/isopropanol = 80:20, 
flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 15.7 min, tr (major) = 18.0 min. 
1
H NMR (300 MHz, CDCl3) δ 7.13 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.98-4.81 (m, 1H), 
4.42 (t, J = 8.2 Hz, 1H), 4.15 (dd, J = 8.5, 7.0 Hz, 1H), 3.79 (s, 3H), 3.08 (dd, J = 14.3, 6.0 Hz, 1H), 
2.93 (dd, J = 14.3, 6.6 Hz, 1H) ppm. 
13
C NMR (75 MHz, CDCl3) δ 159.2, 154.9, 130.6, 125.8, 114. 6, 77.1, 68.5, 55.4, 38.8 ppm. 
HRMS (ESI, m/z) calcd. for C11H12O4Na [M+Na]
+





Starting from 4r (23.6 µL, 0.3 mmol) according to the general procedure (1 mol% -IrO(Carb), 2 
mol% nBu4NBr and 45 h were used instead) to give 5r in 40% conversion. Enantiomeric excess was 
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determined by GC analysis on a chiral stationary phase, ee = 70%. GC conditions: BGB column (30 m 
 0.25 mm), column temperature 110 C, isothermal, tr (minor) = 12.8 min, tr (major) = 13.0 min. 
1
H NMR (300 MHz, CDCl3) δ 4.96 (dtd, J = 8.2, 5.6, 4.3 Hz, 1H), 4.59 (t, J = 8.5 Hz, 1H), 4.41 (dd, 
J = 8.9, 5.8 Hz, 1H), 3.85-3.67 (m, 2H) ppm.  
13





Starting from 4v (24.0 mg, 0.20 mmol) according to the general procedure (reaction time was 70 h) to 
give 5v as a white solid in 10% conversion. Enantiomeric excess was determined by HPLC analysis 
on a chiral stationary phase, ee = 74%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), 
UV detection at 216 nm, mobile phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (minor) = 13.0 min, tr (major) = 15.7 min. 
1
H NMR (300 MHz, CDCl3) δ 7.48-7.41 (m, 3H), 7.40-7.33 (m, 2H), 5.67 (t, J = 8.0 Hz, 1H), 4.80 (t, 
J = 8.4 Hz, 1H), 4.38-4.30 (m, 1H) ppm.  
13
C NMR (75 MHz, CDCl3) δ 154.9, 136.0, 129.9, 129.4, 126.0, 78.1, 71.3 ppm. 
5.2.4 Reaction of nBu4NBr with Iridium Catalyst Λ-IrO(Carb) 
 
A NMR tube was charged with iridium catalyst Λ-IrO(Carb) (20 mg, 0.016 mmol), nBu4NBr (5.2 mg, 
0.016 mmol, 1 equiv) and CD2Cl2 (0.5 mL). The mixture was left at room temperature for 1 h, and 
then analyzed by 
1
H NMR. See the change of the corresponding spectrum below. Free acetonitrile 
signal could be clearly observed after mixing iridium catalyst Λ-IrO(Carb) and
 
nBu4NBr, which 
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might result from the coordination of bromide to the iridium metal center. 
 
 
5.2.5 Single Crystal X-Ray Diffraction Study of -IrO(Carb) 
Crystals of -IrO(Carb) was obtained by slow diffusion from a solution of the compound in CH2Cl2 
layered with n-hexane at room temperature for several days. 
Crystal data and details of the structure determination are presented in Table 10. Data was collected 
with an STOE STADIVARI diffractometer equipped with with CuKa radiation, a graded multilayer 
mirror monochromator (l = 1.54178 Å) and a DECTRIS PILATUS 300K detector using an oil-coated 
shock-cooled crystal at 100(2) K. Absorption effects were corrected semi-empirical using 
multiscanned reflexions (STOE LANA, absorption correction by scaling of reflection intensities.). 
Cell constants were refined using 522626 of observed reflections of the data collection. The structure 
was solved by direct methods by using the program XT V2014/1 (Bruker AXS Inc., 2014) and refined 
by full matrix least squares procedures on F
2
 using SHELXL-2018/3 (Sheldrick, 2018). The 
non-hydrogen atoms have been refined anisotropically, carbon bonded hydrogen atoms were included 
at calculated positions and refined using the ‘riding model’ with isotropic temperature factors at 1.2 
times (for CH3 groups 1.5 times) that of the preceding carbon atom. CH3 groups were allowed to rotate 
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about the bond to their next atom to fit the electron density. Nitrogen or oxygen bonded hydrogen 
atoms were located and allowed to refine isotropically. 
 
Figure 37. Crystal structure of -IrO(Carb). ORTEP drawing with 50% probability thermal ellipsoids.
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Table 10 Crystal data and details of the structure determination of -IrO(Carb). 
Empiric formula C67H60Cl8F3IrN6O5S 
Formula weight 1594.07 
Crystal system, space group Tetragonal, P41 
a, b, c (Å) 27.8771(1), 27.8771(1), 38.0822(2) 





Crystal size (mm) 0.30 x 0.20 x 0.10 
Data collection software X-Area Pilatus3_SV 1.31.127.0 (STOE, 2016)
3
 
Cell refinement software X-Area Recipe 1.33.0.0 (STOE, 2015)
4
 
Data reduction software 
X-Area Integrate 1.71.0.0 (STOE, 2016)
5
 
X-Area LANA 1.68.2.0 (STOE, 2016)
6
 
Tmax, Tmin 0.2441, 0.0522 
No. of measured, independent and 
observed [I > 2 (I)] reflections 








), S 0.0579, 0.1582, 1.054 
No. of used reflections 60310 
No. of parameters 3459 
No. of restraints 2130 
max, min (e Å
-3
) 4.366, -1.393 
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5.3 Enantioselective Intramolecular C-H Amination of Aliphatic Azides by Dual 
Ruthenium and Phosphine Catalysis 
5.3.1 Synthesis of Ruthenium Catalysts 
1) Synthesis of imidazolium ligands 
 
Compound 7b was synthesized by following a published procedure.
1  
Compound 7a was synthesized according to the published procedure with slight modifications.
1 
A 
mixture of 2-bromo-5-iodopyridine (1.42 g, 5 mmol), (3,5-di(tert-butyl)phenyl)boronic acid (1.17 g, 5 
mmol), Pd(PPh3)4 (289 mg, 0.25 mmol) and K2CO3 ( 2.07 g, 15 mmol) in THF (8.6 mL) and water 
(4.3 mL) in a round bottomed flask was allowed to heat at 70 °C for 1 day. After cooling to room 
temperature, the layers were separated and aqueous layer was extracted with CH2Cl2 (3×15 mL). The 
combined organic layers were washed with water, dried with Na2SO4 and concentrated under reduced 
pressure. The crude mixture was purified by flash column chromatography on a silica gel column 
resulted in the compound 7a (693 mg, 2.0 mmol, 40% yield) as a white solid.  
1
H NMR (300 MHz, CDCl3) δ 8.57 (d, J = 2.2 Hz, 1H), 7.73 (dd, J = 8.2, 2.6 Hz, 1H), 7.54 (d, J = 
8.2 Hz, 1H), 7.51 (t, J = 1.8 Hz, 1H), 7.34 (d, J = 1.8 Hz, 2H), 1.38 (s, 18H).  
13
C NMR (75 MHz, CDCl3) δ 152.0, 148.9, 140.7, 137.4, 137.4, 136.1, 128.0, 122.8, 121.6, 35.2, 
31.6.  
IR (film): ν (cm
1
) 3050, 2956, 2866, 1593, 1553, 1456, 1426, 1391, 1358, 1249, 1203, 1126, 1093, 
1068, 1017, 929, 900, 869, 828, 799, 738, 705, 639, 615, 568, 541, 493, 403.  
HRMS (ESI, m/z) calcd. for C19H25NBr [M+H]
+
: 346.1165, 348.1146, found: 346.1174, 348.1154. 
Following the above procedure, compound 7c (606 mg, 2.1 mmol, 41% yield) was obtained as a white 
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solid from (4-(tert-butyl)phenyl)boronic acid (890 mg, 5 mmol).  
1
H NMR (300 MHz, CDCl3) δ 8.58 (dd, J = 2.6, 0.5 Hz, 1H), 7.73 (dd, J = 8.3, 2.6 Hz, 1H), 
7.55-7.47 (m, 5H), 1.36 (s, 9H).  
13
C NMR (75 MHz, CDCl3) δ 152.0, 148.6, 140.7, 136.9, 136.0, 133.7, 128.1, 126.8, 126.4, 34.8, 
31.4.  
IR (film): ν (cm
1
) 2957, 2864, 1572, 1543, 1444, 1401, 1359, 1268, 1112, 1083, 1031, 995, 931, 851, 
822, 776, 738, 707, 631, 572, 528, 441, 414.  
HRMS (ESI, m/z) calcd. for C15H17NBr [M+H]
+
: 290.0539, 292.0520, found: 290.0547, 292.0527. 
Following the above procedure, compound 7d (1.28 g, 4.2 mmol, 84% yield) was obtained as a white 
solid from (4-(trifluoromethyl)phenyl)boronic acid (950 mg, 5 mmol).  
1
H NMR (300 MHz, CDCl3) δ 8.60 (d, J = 2.3 Hz, 1H), 7.79-7.57 (m, 6H).  
13
C NMR (75 MHz, CDCl3) δ 148.7, 142.1, 140.2, 137.1, 134.8, 131.5, 131.1, 130.6, 130.2, 128.4, 
127.5, 126.4, 126.4, 126.3, 126.3, 122.3.  
19
F NMR (282 MHz, CDCl3) δ -63.51.  
IR (film): ν (cm
1
) 3028, 2955, 2867, 1592, 1534, 1477, 1418, 1376, 1329, 1244, 1093, 1052, 1007, 
825, 754, 730, 663, 627, 576, 541, 502, 438, 405.  
HRMS (ESI, m/z) calcd. for C12H8BrF3N [M+H]
+
: 301.9787, 303.9767, found: 301.9795, 303.9774. 
Compound 8a was synthesized following the reported procedure.
2 
Mesitylimidazole (391 mg, 2.1 
mmol) and 2-bromo-5-(3,5-di-tert-butylphenyl)pyridine (7a) (693 mg, 2.0 mmol) were stirred in a 
sealed tube at 170 °C for 30 h. After cooling to room temperature, the resulting brown solid was 
washed with diethyl ether for several times until no starting materials were visible by TLC, and then 
the solvent was removed to give 8a as a light brown solid (905 mg, 1.7 mmol, 85% yield).  
1
H NMR (300 MHz, CDCl3) δ 11.47 (t, J = 1.5 Hz, 1H), 9.40 (d, J = 8.5 Hz, 1H), 8.94 (t, J = 1.8 Hz, 
1H), 8.73 (d, J = 2.0 Hz, 1H), 8.34 (dd, J = 8.6, 2.4 Hz, 1H), 7.55 (t, J = 1.7 Hz, 1H), 7.44 (d, J = 1.7 
Hz, 2H), 7.36 – 7.30 (m, 1H), 7.07 (s, 2H), 2.37 (s, 3H), 2.22 (s, 6H), 1.39 (s, 18H).  
13
C NMR (75 MHz, CDCl3) δ 151.4, 146.5, 144.1, 140.6, 138.9, 138.2, 134.9, 134.7, 133.4, 130.1, 
129.3, 124. 5, 122.5, 120.9, 119.9, 115.3, 34.4, 30.9, 20.5, 17.3.  
IR (film): ν (cm
1
) 3037, 2957, 2867, 1595, 1535, 1483, 1443, 1367, 1327, 1248, 1088, 1049, 1027, 
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963, 929, 849, 743, 711, 662, 626, 574, 555, 517, 480, 412.  
HRMS (ESI, m/z) calcd. for C31H38N3 [M-Br]
+
: 452.3060, found: 452.3064. 
Following the above procedure, compound 8b (673 mg, 1.6 mmol, 80% yield) was obtained as a light 
brown solid from 7b (468 mg, 2.0 mmol).  
1
H NMR (300 MHz, CDCl3) δ 11.78 (s, 1H), 9.38 (d, J = 8.5 Hz, 1H), 8.95 (s, 1H), 8.72 (d, J = 2.0 
Hz, 1H), 8.27 (dd, J = 8.5, 2.2 Hz, 1H), 7.60 (d, J = 6.9 Hz, 2H), 7.55-7.43 (m, 4H), 7.04 (s, 2H), 2.34 
(s, 3H), 2.21 (s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 146.8, 145.1, 141.5, 139.0, 138.6, 136.9, 136.0, 134.1, 130.8, 130.1, 
129.4, 129.0, 127.2, 124.0, 120.0, 116.3, 21.2, 17.8.  
IR (film): ν (cm
1
) 1592, 1535, 1473, 1451, 1383, 1242, 1148, 1088, 1031, 997, 968, 914, 857, 767, 
724, 699, 666, 635, 575, 515, 489, 409.  
HRMS (ESI, m/z) calcd. for C23H22N3 [M-Br]
+
: 340.1808, found: 340.1816. 
Following the above procedure, compound 8c (754 mg, 1.6 mmol, 79% yield) was obtained as a light 
brown solid from 7c (580 mg, 2.0 mmol).  
1
H NMR (300 MHz, CDCl3) δ 11.29 (s, 1H), 9.23 (d, J = 8.5 Hz, 1H), 8.99 (s, 1H), 8.75 (d, J = 1.6 
Hz, 1H), 8.28 (dd, J = 8.5, 1.9 Hz, 1H), 7.56 (d, J = 7.8 Hz, 5H), 7.05 (s, 2H), 2.36 (s, 3H), 2.22 (s, 
6H), 1.40 (s, 9H).  
13
C NMR (75 MHz, CDCl3) δ 152.3, 146.7, 144.6, 141.5, 138.5, 138.4, 135.7, 134.0, 132.9, 130.6, 
130.0, 126.7, 126.3, 124.3, 120.3, 116.1, 34.7, 31.2, 21.1, 17.8.  
IR (film): ν (cm
1
) 3028, 2955, 2867, 1592, 1534, 1477, 1418, 1376, 1329, 1244, 1093, 1052, 1007, 
825, 754, 730, 663, 627, 576, 541, 502, 438, 405.  
HRMS (ESI, m/z) calcd. for C27H30N3 [M-Br]
+
: 396.2434, found: 396.2444. 
Following the above procedure, compound 8d (930 mg, 1.9 mmol, 95% yield) was obtained as a light 
brown solid from 7d (604 mg, 2.0 mmol).  
1
H NMR (300 MHz, CDCl3) δ 11.39 (t, J = 1.4 Hz, 1H), 9.39 (d, J = 8.6 Hz, 1H), 8.93 (t, J = 1.8 Hz, 
1H), 8.74 (d, J = 2.2 Hz, 1H), 8.32 (dd, J = 8.6, 2.4 Hz, 1H), 7.75 (q, J = 8.4 Hz, 4H), 7.38 (t, J = 1.7 
Hz, 1H), 7.05 (s, 2H), 2.35 (s, 3H), 2.20 (s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 147.0, 145.6, 141.9, 139.5, 139.5, 137.4, 136.4, 134.1, 131.5, 131.0, 
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130.7, 130.2, 127.7, 126.6, 126.5, 126.5, 126.4, 125.8, 124.1, 122.2, 120.3, 116.9, 21.3, 18.0.  
19
F NMR (282 MHz, CDCl3) δ -62.65.  
IR (film): ν (cm
1
) 3018, 1595, 1533, 1479, 1381, 1323, 1245, 1164, 1115, 1066, 1009, 964, 830, 728, 
671, 603, 510, 435.  
HRMS (ESI, m/z) calcd. for C24H21F3N3 [M-Br]
+
: 408.1682, found: 408.1691. 
2) Synthesis of racemic ruthenium catalysts 
 
Racemic ruthenium catalyst rac-Ru1 was synthesized following the published procedure with slight 
modifications.
2
 A solution of RuCl3•xH2O (25.0 mg, 0.12 mmol) and compound 8a (128 mg, 0.24 
mmol) in ethylene glycol (2.4 mL) was heated at 200 °C for 6 h. The reaction mixture was treated with 
saturated aqueous NH4PF6 after cooling down to room temperature. A yellow precipitate was formed, 
which was extracted by CH2Cl2 for three times. The combined organic layers were washed with water 
and concentrated under reduced pressure to obtain an orange solid, which was dissolved in CH3CN (3 
mL) followed by adding AgPF6 (38 mg, 0.15 mmol). The mixture was stirred at 60 °C overnight. After 
cooling to room temperature, the mixture was filtered, and the filtrate was collected, evaporated to 
dryness and purified by column chromatograph on silica gel (CH2Cl2/CH3CN = 100:1 to 20:1) to give 
rac-Ru1 (139 mg, 0.10 mmol, 84% yield for two steps) as a pale yellow solid.  
1
H NMR (300 MHz, CD2Cl2) δ 8.51 (d, J = 1.9 Hz, 2H), 8.15 (dd, J = 8.7, 2.1 Hz, 2H), 8.08 (d, J = 
2.3 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 7.62 (t, J = 1.6 Hz, 2H), 7.43 (d, J = 1.7 Hz, 4H), 6.97 (d, J = 
2.3 Hz, 2H), 6.65 (s, 2H), 6.60 (s, 2H), 2.25 (s, 6H), 2.10 (s, 6H), 1.89 (s, 6H), 1.54 (s, 6H), 1.45 (s, 
36H).  
13
C NMR (75 MHz, CD2Cl2) δ 189.2, 152.9, 152.3, 149.0, 140.7, 136.8, 136.1, 135.1, 134.4, 134.3, 
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134.2, 130.4, 129.4, 125.8, 124.5, 124.2, 121.0, 118.3, 112.0, 35.7, 31.9, 21.0, 17.9, 17.5, 4.0.  
19
F NMR (235 MHz, CD2Cl2) δ -71.22, -74.25.  
IR (film): ν (cm
1
) 2957, 1604, 1499, 1436, 1367, 1307, 1250, 1154, 1106, 1034, 931, 833, 702, 628, 
589, 555, 423. 
Following the above procedure, rac-Ru3 (102 mg, 0.09 mmol, 74% yield for two steps) was obtained 
as a yellow solid from compound 8b (252 mg, 0.6 mmol).  
1
H NMR (300 MHz, CD2Cl2) δ 8.53 (d, J = 2.0 Hz, 2H), 8.08 (dd, J = 8.6, 2.1 Hz, 2H), 8.02 (d, J = 
2.3 Hz, 2H), 7.65-7.52 (m, 12H), 6.93 (d, J = 2.3 Hz, 2H), 6.60 (d, J = 6.3 Hz, 4H), 2.31 (s, 6H), 2.01 
(s, 6H), 1.97 (s, 6H), 1.52 (s, 6H).  
13
C NMR (75 MHz, CD2Cl2) δ 189.6, 152.4, 149.2, 140.6, 137.1, 135.6, 135.3, 135.1, 134.3, 134.2, 
130.2, 130.2, 129.8, 129.6, 127.0, 126.0, 125.0, 118.0, 111.8, 21.1, 17.7, 17.5, 4.0.  
19
F NMR (282 MHz, CD2Cl2) δ -71.32, -73.84.  
IR (film): ν (cm
1
) 2922, 2852, 1511, 1483, 1453, 1422, 1290, 1247, 1142, 1081, 1036, 952, 930, 835, 
764, 745, 696, 678, 620, 591, 556, 542, 488, 457, 434, 388. 
Following the above procedure, rac-Ru6 (212 mg, 0.17 mmol, 56% yield for two steps) was obtained 
as a yellow solid from compound 8c (286 mg, 0.6 mmol).  
1
H NMR (300 MHz, CD2Cl2) δ 8.51 (d, J = 1.9 Hz, 2H), 8.07 (dd, J = 8.6, 2.1 Hz, 2H), 8.02 (d, J = 
2.3 Hz, 2H), 7.68 - 7.52 (m, 10H), 6.93 (d, J = 2.3 Hz, 2H), 6.60 (s, 4H), 2.31 (s, 6H), 2.03 (s, 6H), 
1.95 (s, 6H), 1.51 (s, 6H), 1.41 (s, 18H).  
13
C NMR (75 MHz, CD2Cl2) δ 189.3, 153.0, 151.9, 148.7, 140.3, 136.5, 135.2, 135.0, 134.0, 134.0, 
131.9, 130.0, 129.4, 127.0, 126.4, 125.6, 124.7, 117.8, 111.7, 35.1, 31.4, 20.8, 17.5, 17.2, 3.7.  
19
F NMR (282 MHz, CD2Cl2) δ -72.21, -74.73.  
IR (film): ν (cm
1
) 3138, 2959, 1611, 1490, 1425, 1373, 1309, 1258, 1103, 1033, 932, 834, 738, 629, 
588, 554, 434.  
Following the above procedure, rac-Ru7 (348 mg, 0.27 mmol, 89% yield for two steps) was obtained 
as a yellow solid from compound 8d (293 mg, 0.6 mmol).
  
1
H NMR (300 MHz, CD2Cl2) δ 8.57 (d, J = 1.9 Hz, 2H), 8.10 (dd, J = 8.7, 2.1 Hz, 2H), 8.03 (d, J = 
2.3 Hz, 2H), 7.89 (d, J = 8.3 Hz, 4H), 7.78 (d, J = 8.2 Hz, 4H), 7.67 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 
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2.3 Hz, 2H), 6.64 (s, 2H), 6.57 (s, 2H), 2.31 (s, 6H), 2.00 (s, 12H), 1.52 (s, 6H).  
13
C NMR (75 MHz, CD2Cl2) δ 189.7, 152.9, 149.4, 140.4, 138.6, 137.3, 135.2, 134.2, 134.1, 134.0, 
131.6, 131.1, 130.2, 129.3, 127.5, 127.1, 127.0, 127.0, 126.9, 126.3, 126.0, 125.2, 122.7, 117.9, 111.9, 
21.0, 17.5, 17.3, 3.7.  
19
F NMR (282 MHz, CD2Cl2) δ -62.90, -71.13, -73.65.  
IR (film): ν (cm
1
) 1612, 1492, 1426, 1322, 1255, 1166, 1117, 1069, 823, 689, 552. 
3) Synthesis of enantiomerically pure ruthenium catalysts 
 
Chiral ruthenium complex Λ-(S)-Ru3 was synthesized following our published procedure with slight 
modifications.
2 
A mixture of rac-Ru3 (124.7 mg, 0.11 mmol), chiral auxiliary (S)-Aux4b (45.6 mg, 
0.22 mmol) and triethylamine (153 µL, 1.09 mmol) in CH2Cl2 (1.8 mL) was heated at 60 °C for 18 h. 
The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was 
subjected to a flash silica gel chromatography (CH3CN/CH2Cl2 = 1:600 to 1:50) to isolate one 
diastereomer (orange solid, 33.8 mg, 0.03 mmol, yield: 28%) which was assigned as Λ-(S)-Ru3.
  
1
H NMR (500 MHz, CD2Cl2) δ 8.74 (d, J = 2.0 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.95 (d, J = 2.3 Hz, 
1H), 7.92 (dd, J = 8.6, 2.2 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.74 (dd, J = 8.6, 2.2 Hz, 1H), 7.54-7.43 
(m, 7H), 7.42-7.38 (m, 3H), 7.37-7.31 (m, 3H), 7.00 (ddd, J = 8.7, 6.9, 1.9 Hz, 1H), 6.89 (d, J = 2.3 
Hz, 1H), 6.84 (d, J = 2.2 Hz, 1H), 6.56 (s, 1H), 6.51 (s, 1H), 6.50-6.45 (m, 3H), 6.24-6.18 (m, 1H), 
4.29 (dd, J = 9.3, 3.2 Hz, 1H), 4.12 (t, J = 9.1 Hz, 1H), 3.91 (dt, J = 8.9, 3.1 Hz, 1H), 2.28 (s, 3H), 
2.05 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H), 1.61 (s, 3H), 1.42 (s, 3H), 0.55 (d, J = 7.0 Hz, 3H), 0.30-0.19 
(m, 1H), -0.03 (d, J = 6.8 Hz, 3H).  
13
C NMR (126 MHz, CD2Cl2) δ 197.5, 196.2, 172.0, 165.2, 153.0, 152.9, 148.5, 148.0, 139.5, 137.3, 
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135.8, 135.4, 135.1, 135.0, 134.7, 134.4, 134.2, 133.9, 133.9, 133.6, 133.4, 130.2, 129.8, 129.6, 129.4, 
129.4, 129.1, 129.0, 126.4, 125.6, 125.1, 123.8, 116.6, 115.9, 112.7, 110.8, 110.5, 110.0, 74.9, 66.6, 
30.1, 30.0, 20.9, 20.9, 18.8, 18.5, 17.9, 17.9, 17.4, 13.5.  
19
F NMR (282 MHz, CD2Cl2) δ -71.73, -74.25.  
HRMS (ESI, m/z) calcd. for C58H56RuN7O2 [M-PF6]
+
: 984.3549, found: 984.3565.  
IR (film): ν (cm
1
) 1605, 1537, 1507, 1471, 1413, 1355, 1322, 1250, 1222, 1067, 969, 921, 836, 756, 
685, 580, 553.  




) 478 (7), 408 (+33), 365 (0), 334 (+20), 315 (+10), 291 (-2), 269 
(+13).
 
Following the above procedure, Λ-(S)-Ru6 (45.9 mg, 0.037 mmol, yield: 34%) was obtained as an 
orange solid from rac-Ru6 (139 mg, 0.11 mmol).  
1
H NMR (300 MHz, CD2Cl2) δ
 
8.73 (d, J = 2.0 Hz, 1H), 8.20 (d, J = 1.9 Hz, 1H), 7.95-7.82 (m, 3H), 
7.75 (dd, J = 8.6, 2.1 Hz, 1H), 7.49 (dt, J = 20.9, 9.3 Hz, 6H), 7.40-7.22 (m, 5H), 6.99 (ddd, J = 8.7, 
6.9, 1.9 Hz, 1H), 6.87 (dd, J = 13.1, 2.3 Hz, 2H), 6.61-6.37 (m, 5H), 6.22 (t, J = 7.1 Hz, 1H), 4.29 (dd, 
J = 9.2, 3.2 Hz, 1H), 4.15 (t, J = 9.0 Hz, 1H), 3.96-3.87 (m, 1H), 2.28 (s, 3H), 2.06 (s, 3H), 1.99 (s, 
3H), 1.93 (s, 3H), 1.60 (s, 3H), 1.42 (s, 3H), 1.39 (s, 9H), 1.35 (s, 9H), 0.55 (d, J = 6.9 Hz, 3H), 
0.33-0.16 (m, 1H), -0.03 (d, J = 6.8 Hz, 3H).  
13
C NMR (75 MHz, CD2Cl2) δ 197.1, 195.9, 171.7, 165.0, 152.7, 152.7, 152.4, 152.3, 148.1, 147.7, 
139.5, 139.5, 137.2, 135.0, 134.9, 134.7, 134.3, 134.1, 133.9, 133.8, 133.4, 133.3, 132.6, 132.4, 130.1, 
129.7, 129.4, 129.4, 129.0, 126.8, 126.5, 126.0, 126.0, 125.5, 125.0, 123.8, 116.6, 115.8, 112.6, 110.8, 
110.5, 109.9, 74.9, 66.5, 35.0, 34.9, 31.4, 31.3, 30.0, 20.9, 20.8, 18.8, 18.5, 17.9, 17.9, 17.4, 13.5.  
19
F NMR (282 MHz, CD2Cl2) δ -71.68, -74.19.  
IR (film): ν (cm
1
) 2958, 1607, 1486, 1420, 1372, 1320, 1251, 1151, 1068, 1032, 926, 836, 747, 688, 
553.  
HRMS (ESI, m/z) calcd. for C66H72RuN7O2 [M-PF6]
+
: 1096.4804, found: 1096.4824.  




) 469 (8), 405 (+43), 366 (-5), 332 (+22), 293 (-60), 270 (+58), 250 
(-17), 225 (+21). 
Following the above procedure, Λ-(S)-Ru7 (56.7 mg, 0.045 mmol, yield: 41%) was obtained as an 
orange solid from rac-Ru7 (142 mg, 0.11 mmol).  




H NMR (300 MHz, CD2Cl2) δ 8.78 (d, J = 2.2 Hz, 1H), 8.22-8.17 (m, 1H), 8.02-7.99 (m, 1H), 7.97 
(dd, J = 8.6, 1.9 Hz, 1H), 7.93-7.89 (m, 1H), 7.82-7.76 (m, 3H), 7.73 (s, 1H), 7.71 (s, 1H), 7.58 (d, J = 
8.7 Hz, 1H), 7.53-7.41 (m, 6H), 7.05-6.97 (m, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 
6.58 (s, 1H), 6.54 (s, 1H), 6.51-6.44 (m, 3H), 6.28-6.22 (m, 1H), 4.33-4.27 (m, 1H), 4.10 (t, J = 9.1 Hz, 
1H), 3.92-3.85 (m, 1H), 2.27 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.96 (s, 3H), 1.61 (s, 3H), 1.43 (s, 3H), 
0.55 (d, J = 7.0 Hz, 3H), 0.270.15 (m, 1H), 0.04 (d, J = 6.9 Hz, 3H).  
13
C NMR (75 MHz, CD2Cl2) δ 197.5, 196.12 172.0, 165.3, 153.8, 153.6, 148.7, 148.2, 139.6, 139.5, 
139.0, 137.2, 135.2, 134.9, 134.7, 134.7, 134.5, 134.4, 134.1, 134.0, 132.1, 131.8, 130.9, 130.8, 130.7, 
130.5, 130.1, 129.9, 129.6, 129.2, 128.8, 126.9, 126.8, 126.8, 126.6, 126.6, 126.6, 126.5, 125.75, 
125.56, 125.54, 125.34, 123.79, 123.40, 123.38, 116.84, 116.13, 112.87, 110.82, 110.32, 74.8, 66.6, 
30.1, 20.9, 20.9, 18.8, 18.5, 17.9, 17.8, 17.4, 13.5.  
19
F NMR (282 MHz, CD2Cl2) δ -63.02, -63.04, -71.64, -74.16.  
IR (film): ν (cm
1
) 2925, 1608, 1531, 1489, 1422, 1379, 1322, 1285, 1251, 1166, 1117, 1068, 1018, 
925, 836, 757, 686, 596, 553, 507, 458, 429.  
HRMS (ESI, m/z) calcd. for C60H54RuF6N7O2 [M-PF6]
+
: 1120.3298, found: 1120.3317.  




) 484 (6), 411 (+25), 369 (+1), 338 (+12), 316 (0), 304 (+6), 288 
(-5), 262 (+11). 
 
To a suspension of Λ-(S)-Ru3 (50 mg, 0.044 mmol) in CH3CN (4.4 mL) was added trifluoroacetic acid 
(32.6 µL, 0.44 mmol, 10 equiv) dropwise and stirred at room temperature for 0.5 h, followed by the 
addition of an excess of NH4PF6 (215 mg, 1.32 mmol, 30 equiv), and then stirred at room temperature 
for another 0.5 h. The mixture was filtered by a thin pad of silica gel, the pale yellow filtrate was 
concentrated, and then subjected to the column chromatography on silica gel (CH3CN/CH2Cl2 = 50:1 
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to 5:1) to give the enantiopure catalyst Λ-Ru3 (44.8 mg, 0.039 mmol, 88% yield) as a yellow solid. 




) 345 (+8), 326 (0), 305 (+39), 289 (-14), 266 (+69), 235 (-63), 216 
(-28). All the other spectroscopic data of enantiopure ruthenium catalyst Λ-Ru3 were in agreement 
with the racemic catalyst rac-Ru3. 
Following the above procedure, Λ-Ru6 (46.0 mg, 0.036 mmol, yield: 82%) was obtained as a yellow 
solid from Λ-(S)-Ru6 (54.7 mg, 0.044 mmol).  




) 344 (+13), 328 (+7), 309 (+34), 292 (-11), 270 (+87), 238 (-82), 
220 (-25). All the other spectroscopic data of enantiopure ruthenium catalyst Λ-Ru6 were in 
agreement with the racemic catalyst rac-Ru6. 
Following the above procedure, Λ-Ru7 (54.0 mg, 0.042 mmol, yield: 95%) was obtained as a yellow 
solid from Λ-(S)-Ru7 (55.8 mg, 0.044 mmol).  




) 353 (+7), 324 (-5), 302 (+40), 287 (-1), 266 (+60), 240 (-52), 212 
(-19). All the other spectroscopic data of enantiopure ruthenium catalyst Λ-Ru7 were in agreement 
with the one of racemic catalyst rac-Ru7. 
5.3.2 Synthesis of Organic Azide Substrates 
CAUTION: Organic azides are known to be potentially explosive compounds. All azidation reactions 
and subsequent workups should be performed carefully. Once isolated, organic azides were stored in a 
-20 ºC freezer. 
Organic azides 9a, 9e, 9r and 9y were synthesized according to published procedures.
3,4,5
 
Procedure A:  
 
To a solution of the desired alkyl carboxylic acid (10 mmol, 1 equiv) in THF (0.5 M) was added 
LiAlH4 (1.5 g, 40 mmol, 4 equiv) portionwise at 0 °C under N2 atmosphere. Then the solution was 
stirred at 25 °C for 24 h. After that, to the reaction was added H2O (0.2 mL), aqueous 1 M NaOH (0.2 
mL), H2O (0.5 mL) consecutively at 0 °C to quench the reaction, and then filtered. The aqueous phase 
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was extracted three times with diethyl ether, the combined organic phases were dried over Na2SO4, 
and concentrated in vacuo to get the alcohol compound which was directly used for the next step 
without further purification. 
To the above alcohol compound (1 equiv) in diethyl ether (0.9 M) was added PBr3 (0.5 equiv) 
dropwise at 0 °C under N2 atmosphere. The solution was stirred at 25 °C for 20 h. After the alcohol 
compound was totally consumed, the reaction was quenched by slowly by adding H2O at 0 °C. The 
aqueous phase was extracted three times with diethyl ether, the combined organic phases were washed 
with saturated aqueous solution of NaHCO3 and brine, dried over Na2SO4 and concentrated in vacuo to 
get the alkyl bromide compound which was directly used for next step without further purification. 
To a solution of the above alkyl bromide (1 equiv) in DMF (0.5 M) was added sodium azide (1.2 
equiv), and the solution was stirred for 24 h at 80 °C. A 1:1 mixture of H2O/diethyl ether was added to 
the reaction mixture, and the aqueous phase was extracted three times with diethyl ether. The 
combined organic phases were washed several times with H2O to remove DMF, then brine, and dried 
over Na2SO4. After removal of the solvent under reduced pressure, the crude mixture was purified by 
flash column chromatography on a silica gel column resulted in the analytically pure azides. 
Procedure B:  
 
To a solution of the desired aryl bromide (10 mmol, 1 equiv) in diethyl ether (0.5 M) was added nBuLi 
(12 mmol, 1.2 equiv) dropwise at 0 °C, followed by 1,4-dibromobutane. The mixture was then 
refluxed for 4 h. After cooling to room temperature, the reaction was quenched by slowly adding H2O 
at 0 °C. The aqueous phase was extracted three times with diethyl ether. The combined organic phases 
were dried over Na2SO4. After removal of the solvent under reduced pressure, the crude mixture was 
purified by flash column chromatography on silica gel column resulted in the desired alkyl bromide. 
To a solution of the above alkyl bromide (1 equiv) in DMF (0.5 M) was added sodium azide (1.2 
equiv), and the solution was stirred for 24 h at 80 °C. A 1:1 mixture of H2O/diethyl ether was added to 
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the reaction mixture, and the aqueous phase was extracted three times with diethyl ether. The 
combined organic phases were washed several times with H2O to remove DMF, then brine, and dried 
over Na2SO4. After removal of the solvent under reduced pressure, the crude mixture was purified by 
flash column chromatography on a silica gel column which resulted in the analytically pure azides. 
1-(4-Azidobutyl)-4-methylbenzene (9b) 
 
Compound 9b (927 mg, 4.9 mmol) was synthesized from 4-(p-tolyl)butanoic acid (1.78 g, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 49%.  
1
H NMR (300 MHz, CDCl3) δ 7.17-6.99 (m, 4H), 3.28 (t, J = 6.5 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H), 
2.33 (s, 3H), 1.80-1.55 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 138.9, 135.5, 129.2, 128.4, 51.5, 35.1, 28.7, 28.6, 21.1.  
IR (film): ν (cm
1




Compound 9c (965 mg, 5.1 mmol) was synthesized from 4-(m-tolyl)butanoic acid (1.78 g, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 51%.  
1
H NMR (300 MHz, CDCl3) δ 7.22-7.14 (m, 1H), 7.05-6.94 (m, 3H), 3.29 (t, J = 6.5 Hz, 2H), 2.62 (t, 
J = 7.2 Hz, 2H), 2.34 (s, 3H), 1.78-1.57 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 141.9, 138.1, 129.3, 128.4, 126.8, 125.5, 51.5, 35.4, 28.6, 28.6, 21.5.  
IR (film): ν (cm
1
) 3019, 2933, 2861, 2089, 1607, 1487, 1454, 1349, 1257, 1165, 1095, 1039, 884, 
778, 696, 556, 437. 
1-(4-Azidobutyl)-2-methylbenzene (9d) 




Compound 9d (852 mg, 4.5 mmol) was synthesized from 4-(o-tolyl)butanoic acid (1.78 g, 10 mmol) 
according to the above Procedure A and obtained as a colorless oil. Yield: 45%.  
1
H NMR (300 MHz, CDCl3) δ 7.22-7.07 (m, 4H), 3.32 (t, J = 6.3 Hz, 2H), 2.65 (dd, J = 8.7, 5.8 Hz, 
2H), 2.33 (s, 3H), 1.79-1.59 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 140.1, 135.9, 130.4, 128.9, 126.2, 126.1, 51.5, 32.9, 28.9, 27.4, 19.4.  
IR (film): ν (cm
1




Compound 9f (1.53 g, 6.1 mmol) was synthesized from 4-bromo-1,1'-biphenyl (1.86 g, 8 mmol) 
according to the above Procedure B and obtained as a colorless oil. Yield: 76%.  
1
H NMR (300 MHz, CDCl3) δ 7.64-7.48 (m, 4H), 7.44 (dd, J = 10.2, 4.8 Hz, 2H), 7.37-7.29 (m, 1H), 
7.27 (s, 1H), 7.24 (s, 1H), 3.31 (t, J = 6.6 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 1.83-1.60 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 141.2, 141.1, 139.1, 128.9, 128.9, 127.3, 127.2, 127.1, 51.5, 35.1, 28.6, 
28.6.  
IR (film): ν (cm
1
) 3027, 2934, 2860, 2089, 1602, 1486, 1453, 1407, 1349, 1257, 1115, 1073, 1004, 
832, 757, 695, 590, 552, 503. 
1-(4-Azidobutyl)-4-methoxybenzene (9g) 
 
Compound 9g (1.29 g, 5.5 mmol) was synthesized from 4-(3,4-dimethoxyphenyl)butanoic acid (2.24 g, 
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10 mmol) according to the above Procedure A and obtained as a pale yellow oil. Yield: 55%.  
1
H NMR (300 MHz, CDCl3) δ 6.80 (d, J = 8.7 Hz, 1H), 6.74-6.68 (m, 2H), 3.88 (s, 3H), 3.86 (s, 3H), 
3.29 (t, J = 6.5 Hz, 2H), 2.60 (t, J = 7.2 Hz, 2H), 1.77-1.57 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 149.1, 147.5, 134.6, 120.3, 111.9, 111.5, 56.1, 56.0, 51.5, 35.1, 28.8, 
28.6.  
HRMS (ESI, m/z) calcd. for C12H17N3O2Na [M+Na]
+
: 258.1213, found: 258.1222.  
IR (film): ν (cm
1
) 2999, 2935, 2861, 2090, 1590, 1512, 1457, 1417, 1257, 1234, 1145, 1026, 931, 
853, 804, 760, 632, 597, 556. 
(4-(4-Azidobutyl)phenyl)(methyl)sulfane (9h) 
 
Compound 9h (288 mg, 1.3 mmol) was synthesized from (4-bromophenyl)(methyl)sulfane (2.03 g, 10 
mmol) according to the above Procedure B and obtained as a colorless oil. Yield: 13%.  
1
H NMR (300 MHz, CDCl3) δ 7.24–7.17 (m, 2H), 7.14–7.06 (m, 2H), 3.28 (t, J = 6.5 Hz, 2H), 2.61 (t, 
J = 7.2 Hz, 2H), 2.47 (s, 3H), 1.75–1.56 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 139.1, 135.6, 129.0, 127.4, 51.5, 34.9, 28.5, 16.5.  
IR (film): ν (cm
1
) 2924, 2857, 2091, 1492, 1442, 1349, 1259, 1094, 1016, 962, 885, 806, 738, 658, 
627, 527, 489. 
4-(4-Azidobutyl)-N,N-dimethylaniline (9i) 
 
Compound 9i (327 mg, 1.5 mmol) was synthesized from 4-bromo-N,N-dimethylaniline (2.0 g, 10 
mmol) according to the above Procedure B and obtained as a colorless oil. Yield: 15%.  
1
H NMR (300 MHz, CDCl3) δ 7.06 (d, J = 8.5 Hz, 2H), 6.72 (d, J = 8.5 Hz, 2H), 3.28 (t, J = 6.4 Hz, 
2H), 2.92 (s, 6H), 2.56 (t, J = 7.0 Hz, 2H), 1.75–1.55 (m, 4H).  




C NMR (75 MHz, CDCl3) δ 149.2, 129.1, 113.3, 51.6, 41.1, 34.5, 28.8, 28.6.  
IR (film): ν (cm
1
) 2930, 2857, 2798, 2089, 1614, 1519, 1449, 1342, 1259, 1161, 1130, 1062, 946, 
887, 808, 743, 673, 554, 516. 
4-(4-Azidobutyl)phenyl diethyl phosphate (9j) 
Compound 9j was synthesized according to the method below.  
 
To the above 4-(4-bromobutyl)phenol (2.29 g, 10 mmol, 1 equiv) in dry CH2Cl2 (20 mL, 0.5 M) was 
added triethylamine (2.8 mL, 20 mmol, 2 equiv), followed by diethyl phosphorochloridate (1.6 mL, 11 
mmol, 1.1 equiv) dropwise at 0 °C under N2 atmosphere. The solution was stirred at 25 °C overnight. 
The reaction was quenched by slowly adding HCl aqueous (1 M). The aqueous phase was extracted 
with CH2Cl2, the combined organic phases were washed with saturated aqueous solution of NaHCO3 
and brine, dried over Na2SO4. The crude mixture was purified by flash column chromatography on a 
silica gel column resulting in the analytically pure alkyl bromide. 
To a solution of the above alkyl bromide (475 mg, 1.3 mmol, 1 equiv) in DMF (2.6 mL,0.5 M) was 
added sodium azide (104 mg, 1.6 mmol, 1.2 equiv), and the solution was stirred for 24 h at 80 °C. A 
1:1 mixture of H2O/ethyl acetate was added to the reaction mixture, and the aqueous phase was 
extracted five times with ethyl acetate. The combined organic phases were washed several times with 
H2O to remove DMF, then brine, and dried over Na2SO4. After removal of the solvent under reduced 
pressure, the crude mixture was purified by flash column chromatography on a silica gel column 
resulted in the analytically pure alkyl azides 9j as a colorless oil (393 mg, 1.2 mmol). Yield: 12% for 
two steps.  
1
H NMR (300 MHz, CDCl3) δ 7.12 (s, 4H), 4.20 (p, J = 7.3 Hz, 4H), 3.27 (t, J = 6.4 Hz, 2H), 2.61 (t, 
J = 7.2 Hz, 2H), 1.71–1.54 (m, 4H), 1.34 (t, J = 7.1 Hz, 6H).  
13
C NMR (75 MHz, CDCl3) δ 149.2, 149.1, 138.6, 129.6, 120.0, 120.0, 64. 7, 64.6, 51.4, 34.7, 28.6, 
28.5, 16.3, 16.2.  
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IR (film): ν (cm
1
) 2985, 2935, 2864, 2093, 1606, 1506, 1451, 1365, 1274, 1215, 1165, 1101, 1024, 
955, 933, 812, 765, 689, 637, 545, 511. 
1-(4-Azidobutyl)-4-(benzyloxy)benzene (9k) 
Compound 9k was synthesized according to the method below.  
 
A mixture of 4-(4-bromobutyl)phenol (2.29 g, 10 mmol, 1 equiv), K2CO3 (2.76 g, 20 mmol, 2 equiv) 
and benzyl bromide (1.71 g, 10 mmol, 1 equiv) in acetone (100 mL, 0.1 M) was stirred at 50 °C 
overnight. After the reaction was finished, acetone was removed under reduced pressure. A 1:1 
mixture of H2O/CH2Cl2 was added to the residue, and the organic phase washed with water for several 
times, then brine, dried over Na2SO4. The crude mixture was purified by flash column chromatography 
on a silica gel column resulting in the analytically pure alkyl bromide. 
To a solution of the above alkyl bromide (2.23 g, 7.0 mmol, 1 equiv) in DMF (14 mL, 0.5 M) was 
added sodium azide (546 mg, 8.4 mmol, 1.2 equiv), and the solution was stirred for 24 h at 80 °C. A 
1:1 mixture of H2O/ethyl acetate was added to the reaction mixture, and the aqueous phase was 
extracted five times with ethyl acetate. The combined organic phases were washed several times with 
H2O to remove DMF, then brine, and dried over Na2SO4. After removal of the solvent under reduced 
pressure, the crude mixture was purified by flash column chromatography on a silica gel column 
resulting in the analytically pure alkyl azides 9k as a colorless oil (1.74 g, 6.5 mmol). Yield: 62% for 
two steps.  
1
H NMR (300 MHz, CDCl3) δ 7.12 (s, 4H), 4.20 (p, J = 7.3 Hz, 4H), 3.27 (t, J = 6.4 Hz, 2H), 2.61 (t, 
J = 7.2 Hz, 2H), 1.71–1.54 (m, 4H), 1.34 (t, J = 7.1 Hz, 6H).  
13
C NMR (75 MHz, CDCl3) δ 149.2, 149.1, 138.6, 129.6, 120.0, 120.0, 64. 7, 64.6, 51.4, 34.7, 28.6, 
28.5, 16.3, 16.2.  
IR (film): ν (cm
1
) 3032, 2933, 2861, 2090, 1610, 1583, 1508, 1456, 1378, 1350, 1293, 1233, 1175, 
1112, 1077, 1018, 912, 859, 824, 735, 695, 642, 611, 552, 510, 455. 





Compound 9l (928 mg, 4.8 mmol) was synthesized from 4-(4-fluorophenyl)butanoic acid (1.46 g, 8 
mmol) according to the above Procedure A and obtained as a colorless oil. Yield: 60%.  
1
H NMR (300 MHz, CDCl3) δ 7.18-7.06 (m, 2H), 7.04-6.91 (m, 2H), 3.29 (t, J = 6.5 Hz, 2H), 2.62 (t, 
J = 7.2 Hz, 2H), 1.75-1.55 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 163.1, 159.9, 137.6, 137.5, 129.9, 129.8, 115.4, 115.1, 51.5, 34.7, 28.7, 
28.5.  
19
F NMR (282 MHz, CDCl3) δ -117.64.  
IR (film): ν (cm
1
) 2937, 2863, 2090, 1602, 1507, 1456, 1350, 1221, 1156, 1100, 1013, 826, 759, 703, 
637, 547, 500, 422. 
1-(4-Azidobutyl)-4-chlorobenzene (9m) 
 
Compound 9m (1.17 g, 5.6 mmol) was synthesized from 4-(4-chlorophenyl)butanoic acid (1.99 g, 10 
mmol) according to the above Procedure A and obtained as a colorless oil. Yield: 56%.  
1
H NMR (300 MHz, CDCl3) δ 7.25 (dd, J = 6.5, 1.9 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 3.28 (t, J = 6.5 
Hz, 2H), 2.62 (t, J = 7.3 Hz, 2H), 1.79-1.55 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 140.4, 131.8, 129.8, 128.6, 51.4, 34.9, 28.51, 28.49.  
IR (film): ν (cm
1
) 2936, 2862, 2090, 1490, 1457, 1407, 1349, 1255, 1091, 1014, 887, 811, 711, 661, 
630, 525, 485. 
2-(4-Azidobutyl)naphthalene (9n) 
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Compound 9n (1.35 g, 6.0 mmol) was synthesized from 2-bromonaphthalene (2.07 g, 10 mmol) 
according to the above Procedure B and obtained as a colorless oil. Yield: 60%.  
1
H NMR (300 MHz, CDCl3) δ 7.87 (dd, J = 10.1, 7.9 Hz, 3H), 7.68 (s, 1H), 7.58-7.47 (m, 2H), 7.39 
(dd, J = 8.4, 1.5 Hz, 1H), 3.33 (t, J = 6.7 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H), 1.92-1.79 (m, 2H), 
1.78-1.64 (m, 2H).  
13
C NMR (75 MHz, CDCl3) δ 139.4, 133.7, 132.1, 128.0, 127.7, 127.5, 127.2, 126.5, 126.0, 125.3, 
51.4, 35.5, 28.5, 28.3.  
IR (film): ν (cm
1
) 3052, 2935, 2860, 2088, 1632, 1599, 1507, 1455, 1353, 1261, 1151, 1075, 1015, 
954, 891, 853, 814, 744, 643, 555, 473, 403. 
2-(4-Azidobutyl)dibenzo[b,d]thiophene (9o) 
 
Compound 9o (985 mg, 3.5 mmol) was synthesized from 2-bromodibenzo[b,d]thiophene (2.63 g, 10 
mmol) according to the above Procedure B and obtained as a colorless oil. Yield: 35%.  
1
H NMR (300 MHz, CDCl3) δ 8.20-8.11 (m, 1H), 7.96 (d, J = 0.9 Hz, 1H), 7.89-7.82 (m, 1H), 7.77 (d, 
J = 8.2 Hz, 1H), 7.51-7.41 (m, 2H), 7.29 (dd, J = 8.2, 1.6 Hz, 1H), 3.32 (t, J = 6.7 Hz, 2H), 2.83 (t, J = 
7.5 Hz, 2H), 1.82 (tt, J = 8.1, 7.0 Hz, 2H), 1.75-1.63 (m, 2H).  
13
C NMR (75 MHz, CDCl3) δ 140.0, 138.4, 137.2, 135.9, 135.6, 127.6, 126.8, 124.4, 123.0, 122.8, 
121.7, 121.3, 51.5, 35.6, 29.0, 28.6.  
IR (film): ν (cm
1
) 2932, 2859, 2088, 1464, 1428, 1349, 1262, 1156, 1069, 1022, 933, 884, 810, 762, 
729, 674, 610, 556, 505, 417. 
2-(4-Azidobutyl)dibenzo[b,d]furan (9p) 
 
Compound 9p (557 mg, 2.1 mmol) was synthesized from 2-bromodibenzo[b,d]furan (2.47 g, 10 mmol)  
according to the above Procedure B and obtained as a colorless oil. Yield: 21%.  




H NMR (300 MHz, CDCl3) δ 7.94 (dd, J = 7.6, 0.7 Hz, 1H), 7.75 (d, J = 1.3 Hz, 1H), 7.56 (d, J = 
8.2 Hz, 1H), 7.45 (dt, J = 8.3, 5.0 Hz, 2H), 7.37-7.25 (m, 2H), 3.32 (t, J = 6.7 Hz, 2H), 2.81 (t, J = 7.4 
Hz, 2H), 1.89-1.60 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 156.7, 155.0, 136.5, 127.7, 127.2, 124.5, 124.4, 122.7, 120.7, 120.2, 
111.8, 111.5, 51.5, 35.5, 29.2, 28.6.  
IR (film): ν (cm
1
) 3050, 2934, 2861, 2089, 1594, 1478, 1445, 1347, 1270, 1248, 1191, 1114, 1074, 
1018, 930, 884, 841, 810, 746, 649, 617, 559, 421. 
2-(4-Azidobutyl)thiophene (9q) 
 
Compound 9q (870 mg, 4.8 mmol) was synthesized from 4-(thiophen-2-yl)butanoic acid (1.70 g, 10 
mmol) according to the above Procedure A and obtained as a colorless oil. Yield: 48%.  
1
H NMR (300 MHz, CDCl3) δ 7.13 (dd, J = 5.1, 1.2 Hz, 1H), 6.92 (dd, J = 5.1, 3.4 Hz, 1H), 
6.82-6.76 (m, 1H), 3.30 (t, J = 6.6 Hz, 2H), 2.87 (t, J = 7.1 Hz, 2H), 1.84-1.60 (m, 4H).  
13
C NMR (75 MHz, CDCl3) δ 144.7, 126.9, 124.4, 123.3, 51.4, 29.5, 29.0, 28.4.  
IR (film): ν (cm
1




Compound 9s (1.73 g, 6.2 mmol) was synthesized from 3-bromo-9-methyl-9H-carbazole (2.60 g, 10 
mmol) according to the above Procedure B and obtained as a pale yellow oil. Yield: 62%.  
1
H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 7.7 Hz, 1H), 7.90 (s, 1H), 7.48 (t, J = 7.6 Hz, 1H), 
7.42-7.27 (m, 3H), 7.23 (t, J = 7.4 Hz, 1H), 3.84 (s, 3H), 3.31 (t, J = 6.8 Hz, 2H), 2.85 (t, J = 7.4 Hz, 
2H), 1.89-1.62 (m, 4H).  




C NMR (75 MHz, CDCl3) δ 141.5, 139.8, 132.5, 126.5, 125.7, 123.1, 122.8, 120.4, 119.9, 118.8, 
108.5, 108.4, 51.6, 35.6, 29.4, 29.2, 28.6.  
IR (film): ν (cm
1
) 3051, 3021, 2930, 2858, 2089, 1602, 1483, 1355, 1326, 1244, 1148, 1122, 1058, 
1015, 924, 883, 847, 800, 773, 741, 681, 623, 589, 559, 423. 
5.3.3 Catalytic Enantioselective Intramolecular C-H Amination of Aliphatic Azides 
1) General procedure for the initial optimization of the intramolecular C-H amination reaction 
(for Tables 3-6 in Chapter 3.2) 
 
A dried 10 mL Schlenk tube was charged with azides 9a (17.5 mg, 0.1 mmol, 1 equiv) and rac-Ru1 
(or Λ-Ru1-7) under an atmosphere of nitrogen. The indicated solvent and corresponding additive were 
added then, followed by Boc2O. The reaction mixture was stirred at indicated temperature for 
indicated time under an atmosphere of nitrogen. The crude mixture was cooled down to room 
temperature and transferred to a 25 mL flask. All volatiles were removed from the solution via rotary 
evaporation. The residue was then analyzed by 
1
H NMR spectroscopy using Cl2CHCHCl2 as internal 
standard to determine the conversion, yield of 10a and 11. The analytically pure product 10a for the 
determination of the enantiomeric excess was obtained by preparative TLC. Enantiomeric excess was 
determined by HPLC analysis on chiral stationary phase. 
2) Standard procedure for the substrate scope of the C-H amination reaction 
A dried 10 mL Schlenk tube was charged with azides 9a-u (0.2 mmol) and Λ-Ru7 (2.6 mg, 0.002 
mmol, 1 mol%) under an atmosphere of nitrogen. A solution of P(4-F-Ph)3 (0.5 mL, 0.002 mmol, 4 
mM in 1,2-dichlorobenzene) was added via syringe, followed by Boc2O (45.8 µL, 0.2 mmol, 1 equiv). 
The reaction mixture was stirred at 95 °C for 60 h under an atmosphere of nitrogen. Afterwards, the 
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mixture was concentrated under reduced pressure, and the residue was purified by flash 
chromatography on silica gel (n-hexane/EtOAc = 60:1 to 15:1) to afford the analytically pure products 
10a-u. Enantiomeric excess was determined by HPLC analysis on chiral stationary phase. The 








Starting from 9a (35.0 mg, 0.20 mmol) according to the general procedure to provide 10a as a white 
solid (25.0 mg, 0.102 mmol, 51% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 95%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV 
detection at 220 nm, mobile phase n-hexane/isopropanol = 97:3, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 9.6 min, tr (minor) = 10.4 min. []D
22
 = 82.9 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.34-7.26 (m, 2H), 7.24-7.14 (m, 3H), 5.05-4.65 (br, m, 1H), 3.74-3.45 
(br, m, 2H), 2.41-2.19 (br, m, 1H), 1.99-1.78 (m, 3H), 1.55-1.11 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 154.7, 145.3, 128.3, 126.6, 125.6, 79.3, 61.5, 60.9, 47.3, 36.1, 34.9, 
28.3, 23.4.  
HRMS (ESI, m/z) calcd. for C15H21NO2Na [M+Na]
+





Starting from 9b (37.9 mg, 0.20 mmol) according to the general procedure to give 10b as a white solid 
(27.1 mg, 0.104 mmol, 52% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 93%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 13.0 min, tr (minor) = 15.9 min. []D
22
 = 91.6 (c = 1.0, CH2Cl2).  




H NMR (300 MHz, CDCl3) δ 7.13-7.01 (m, 4H), 5.04-4.64 (br, m, 1H), 3.70-3.42 (br, m, 2H), 
2.38-2.20 (m, 4H), 1.97-1.75 (m, 3H), 1.53-1.12 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 154.7, 142.2, 136.1, 128.9, 125.5, 79.2, 61.2, 47.2, 36.1, 28.4, 23.3, 
21.1.  
HRMS (ESI, m/z) calcd. for C16H23NO2Na [M+Na]
+





Starting from 9c (37.9 mg, 0.2 mmol) according to the general procedure to give 10c as a white solid 
(26.1 mg, 0.10 mmol, 50% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 91%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 14.6 min, tr (minor) = 16.6 min. []D
22
 = 83.5 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.22-7.12 (m, 1H), 7.05-6.92 (m, 3H), 5.04-4.59 (br, m, 1H), 3.75-3.37 
(br, m, 2H), 2.38-2.22 (m, 4H), 1.98-1.74 (m, 3H), 1.53-1.09 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 154.8, 145.2, 137.8, 128.2, 127.3, 126.4, 122.8, 79.3, 61.5, 47.3, 36.1, 
28.3, 23.4, 21.6.  
HRMS (ESI, m/z) calcd. for C16H23NO2Na [M+Na]
+





Starting from 9d (37.9 mg, 0.2 mmol) according to the general procedure to give 10d as a white solid 
(7.8 mg, 0.03 mmol, 15% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 90%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 13.9 min, tr (minor) = 15.4 min. []D
22
 = 89.1 (c = 1.0, CH2Cl2).  




H NMR (300 MHz, CDCl3) δ 7.18-7.02 (m, 4H), 5.20-4.89 (br, m, 1H), 3.75-3.39 (br, m, 2H), 
2.40-2.21(m, 4H), 2.00-1.65 (m, 3H), 1.50-1.10 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ
 
154.6, 143.5, 134.0, 130.1, 126.4, 126.0, 124.6, 79.2, 58.2, 47.3, 34.3, 
33.0, 28.6, 28.2, 23.3, 19.4.  
HRMS (ESI, m/z) calcd. for C16H23NO2Na [M+Na]
+





Starting from 9e (41.1 mg, 0.2 mmol) according to the general procedure to give 10e as a white solid 
(29.3 mg, 0.106 mmol, 53% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 99%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(minor) = 26.3 min, tr (major) = 28.2 min. []D
22
 = 108.6 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.15-7.03 (m, 2H), 6.90-6.76 (m, 2H), 5.05-4.57 (br, m, 1H), 3.79 (s, 
3H), 3.69-3.40 (br, m, 2H), 2.37-2.16 (m, 1H), 1.99-1.73 (m, 3H), 1.48-1.13 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 158.4, 154.8, 129.4, 126.7, 113.7, 79.2, 60.8, 55.4, 47.2, 36.2, 28.4, 
23.4.  
HRMS (ESI, m/z) calcd. for C16H23NO3Na [M+Na]
+





Starting from 9f (50.3 mg, 0.2 mmol) according to the general procedure to give 10f as a white solid 
(32.2 mg, 0.10 mmol, 50% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 94%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
254 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 21.2 min, tr (minor) = 27.2 min. []D
22
 = 69.7 (c = 1.0, CH2Cl2).  




H NMR (300 MHz, CDCl3) δ 7.64-7.51 (m, 4H), 7.48-7.40 (m, 2H), 7.37-7.30 (m, 1H), 7.28-7.22 
(m, 2H), 5.11-4.71 (br, m, 1H), 3.77-3.45 (br, m, 2H), 2.46-2.21 (m, 1H), 2.05-1.79 (m, 3H), 1.48 (br, s, 
3H), 1.22 (br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.7, 144.4, 141.1, 139.6, 128.8, 127.2, 127.1, 127.0, 126.1, 79.4, 
61.2, 47.3, 36.1, 28.4, 23.4.  
HRMS (ESI, m/z) calcd. for C21H25NO2Na [M+Na]
+





Starting from 9g (47 mg, 0.2 mmol) according to the general procedure to give 10g as a white solid 
(31.3 mg, 0.102 mmol, 51% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 94%. HPLC conditions: Chiralpak IC column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, 
tr (major) = 17.1 min, tr (minor) = 20.6 min. []D
22
 = 75.6 c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 6.85-6.76 (m, 1H), 6.75-6.62 (m, 2H), 5.05-4.60 (br, m, 1H), 3.85 (s, 
6H), 3.68-3.43 (br, m, 2H), 2.40-2.15 (m, 1H), 1.98-1.75 (m, 3H), 1.50-1.13 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 154.8, 149.0, 147.8, 138.0, 117.7, 111.2, 109.1, 79.3, 61.1, 56.1, 56.0, 
47.3, 36.1, 28.4, 23.4.  
HRMS (ESI, m/z) calcd. for C17H25NO4Na [M+Na]
+
: 330.1676, found: 330.1673. 
tert-Butyl (R)-2-(4-(methylthio)phenyl)pyrrolidine-1-carboxylate (10h) 
 
Starting from 9h (44.3 mg, 0.2 mmol) according to the general procedure to give 10h as a colourless 
oil (29.9 mg, 0.102 mmol, 51% yield). (Note: The side product tert-butyl 
(4-(4-(methylthio)phenyl)butyl)carbamate could not be removed from the target product.) 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 94%. HPLC 
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conditions: Chiralpak IG column (4.6  250 mm), UV detection at 220 nm, mobile phase 
n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr (major) = 24.7 min, tr 
(minor) = 30.1 min. []D
22
 = 28.2 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.23-7.17 (m, 2H), 7.12-7.06 (m, 2H), 5.04-4.65 (br, m, 1H), 3.72-3.39 
(br, m, 2H), 2.47 (s, 3H), 2.33-2.21 (m, 1H), 1.94-1.73 (m, 3H), 1.44 (br, s, 3H), 1.21 (br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.7, 136.3, 129.1, 127.4, 126.2, 79.4, 60.9, 47.3, 35.6, 28.5, 23.4, 
16.4.  
IR (film): ν (cm
1
) 2972, 2926, 2874, 1689, 1490, 1445, 1390, 1251, 1161, 1112, 1016, 967, 901, 871, 
818, 774, 569, 521.  
HRMS (ESI, m/z) calcd. for C16H23NSO2Na[M+Na]
+
: 316.1342, found: 316.1342. 
tert-Butyl (R)-2-(4-(dimethylamino)phenyl)pyrrolidine-1-carboxylate (10i) 
 
Starting from 9i (43.6 mg, 0.2 mmol) according to the general procedure to give 10i as a white solid 
(32.0 mg, 0.11 mmol, 55% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 77%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
254 nm, mobile phase n-hexane/isopropanol = 95:5, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 12.1 min, tr (minor) = 15.2 min. []D
22
 = 86.2 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.03 (d, J = 8.5 Hz, 2H), 6.68 (d, J = 8.7 Hz, 2H), 5.05-4.51 (br, m, 
1H), 3.70-3.40 (br, m, 2H), 2.92 (s, 6H), 2.35-2.11 (m, 1H), 1.98-1.74 (m, 3H), 1.44 (br, s, 3H), 1.23 
(br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.8, 149.7, 133.3, 126.5, 112.7, 79.1, 60.8, 47.1, 41.0, 36.0, 28.5, 
23.3.  
IR (film): ν (cm
1
) 2964, 2924, 2862, 2803, 2095, 1678, 1614, 1565, 1520, 1480, 1450, 1394, 1353, 
1226, 1159, 1106, 1026, 946, 895, 865, 816, 769, 696, 611, 571, 529, 469, 432.  
HRMS (ESI, m/z) calcd. for C17H27N2O2 [M+H]
+
: 291.2067, found: 291.2065. 
tert-Butyl (R)-2-(4-((diethoxyphosphoryl)oxy)phenyl)pyrrolidine-1-carboxylate (10j) 




Starting from 9j (65.3 mg, 0.2 mmol) according to the general procedure to give 10j as a colourless oil 
(25.6 mg, 0.064 mmol, 32% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 92%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 80:20, flow rate 1.0 mL/min, column temperature = 25 °C, 
tr (minor) = 19.0 min, tr (major) = 20.8 min. []D
22
 = 54.7 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.17-7.09 (m, 4H), 5.05-4.60 (br, m, 1H), 4.27-4.13 (m, 4H), 3.72-3.40 
(br, m, 2H), 2.39-2.18 (m, 1H), 1.95-1.72 (m, 3H), 1.45-1.10 (m, 15H).  
13
C NMR (75 MHz, CDCl3) δ 154.7, 149.5, 149.5, 129.7, 126.9, 119.9, 119.8, 79.5, 64.7, 64.6, 60.6, 
47.3, 36.1, 28.4, 23.4, 16.3, 16.2.  
IR (film): ν (cm
1
) 2977, 2932, 1691, 1506, 1451, 1391, 1274, 1216, 1162, 1109, 1025, 958, 872, 833, 
803, 767, 697, 632, 538.  
HRMS (ESI, m/z) calcd. for C19H30NPO6Na [M+Na]
+
: 422.1703, found: 422.1698. 
tert-Butyl (R)-2-(4-(benzyloxy)phenyl)pyrrolidine-1-carboxylate (10k) 
 
Starting from 9k (56.3 mg, 0.2 mmol) according to the general procedure to give 10k as a white solid 
(29.5 mg, 0.084 mmol, 42% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 92%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 98:2, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 16.5 min, tr (minor) = 17.6 min. []D
22
 = 66.7 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.47-7.28 (m, 5H), 7.08 (d, J = 8.5 Hz, 2H), 6.95-6.86 (m, 2H), 5.05 (s, 
2H), 4.98-4.65 (br, m, 1H), 3.70-3.40 (br, m, 2H), 2.37-2.17 (m, 1H), 1.99–1.74 (m, 3H), 1.44 (br, s, 
3H), 1.20 (br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 157.6, 154.8, 137.3, 128.7, 128.0, 127.6, 126.7, 114.8, 79.3, 70.2, 60.9, 
Chapter 5. Experimental Part 
131 
 
47.2, 36.2, 28.4, 23.4.  
IR (film): ν (cm
1
) 2968, 2925, 2880, 1689, 1609, 1508, 1453, 1390, 1246, 1159, 1098, 1039, 969, 
877, 821, 768, 734, 695, 636, 552, 506, 462, 436.  
HRMS (ESI, m/z) calcd. for C22H27NO3Na [M+Na]
+





Starting from 9l (38.6 mg, 0.2 mmol) according to the general procedure to give 10l as a white solid 
(21.1 mg, 0.08 mmol, 40% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 94%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 14.5 min, tr (minor) = 16.1 min. []D
22
 = 76.3 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.17-7.05 (m, 2H), 7.02-6.92 (m, 2H), 5.03-4.63 (br, m, 1H), 3.69-3.42 
(br, m, 2H), 2.39-2.18 (m, 1H), 1.96-1.71 (m, 3H), 1.45-1.08 (br, m, 9H).  
13
C NMR (126 MHz, CDCl3) δ 162.7, 160.7, 154.6, 141.0, 127.1, 127.1, 115.1, 114.9, 79.5, 60.9, 
60.3, 47. 5, 47.2, 36.2, 35.0, 28.7, 28.3, 23.6, 23.3.  
HRMS (ESI, m/z) calcd. for C15H20FNO2Na [M+Na]
+





Starting from 9m (41.9 mg, 0.2 mmol) according to the general procedure to give 10m as a white solid 
(25.3 mg, 0.09 mmol, 45% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 95%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 13.8 min, tr (minor) = 17.1 min. []D
22
 = 72.0 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.29-7.24 (m, 2H), 7.13-7.07 (m, 2H), 4.98-4.63 (br, m, 1H), 3.70-3.42 
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(br, m, 2H), 2.39-2.18 (m, 1H), 1.96-1.71 (m, 3H), 1.43 (br, m, 3H), 1.20 (br, m, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.6, 143.9, 132.3, 128. 5, 127.0, 79.6, 60.9, 47.3, 36.1, 28.4, 23.3.  
HRMS (ESI, m/z) calcd. for C15H20NO2ClNa [M+Na]
+





Starting from 9m (45.0 mg, 0.2 mmol) according to the general procedure to give 10m as a white solid 
(34.0 mg, 0.114 mmol, 57% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 96%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 19.4 min, tr (minor) = 25.3 min. []D
22
 = 103.2 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.88-7.74 (m, 3H), 7.59 (s, 1H), 7.51-7.39 (m, 2H), 7.36-7.28 (m, 1H), 
5.23-4.83 (br, m, 1H), 3.84-3.52 (br, m, 2H), 2.47-2.26 (m, 1H), 2.04-1.82 (m, 3H), 1.48 (br, s, 3H), 
1.16 (br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.8, 142.6, 133.5, 132.6, 128.2, 127.8, 127.7, 126.1, 125.5, 124.3, 
124.0, 79.4, 61.5, 47.3, 36.0, 28.3, 23.3.  
HRMS (ESI, m/z) calcd. for C19H23NO2Na [M+Na]
+
: 320.1621, found: 320.1622. 
tert-Butyl (R)-2-(dibenzo[b,d]thiophen-2-yl)pyrrolidine-1-carboxylate (10o) 
 
Starting from 9o (56.3 mg, 0.2 mmol) according to the general procedure to give 10o as a pale yellow 
oil (34.5 mg, 0.098 mmol, 49% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 95%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV 
detection at 220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column 
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temperature = 25 °C, tr (major) = 11.7 min, tr (minor) = 19.3 min. []D
22
 = 62.0 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 8.22-8.07 (m, 1H), 7.94 (s, 1H), 7.87-7.73 (m, 2H), 7.44 (dd, J = 5.7, 
2.9 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 5.25-4.85 (br, m, 1H), 3.83-3.53 (br, m, 2H), 2.50-2.30 (m, 1H), 
2.07-1.85 (m, 3H), 1.49 (br, s, 3H), 1.17 (br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.7, 141.8, 139.8, 137.5, 135.6, 126.6, 124.6, 124.4, 122.9, 122.6, 
121.5, 118.4, 79.4, 61.3, 47.3, 36.4, 28.3, 23.4.  
IR (film): ν (cm
1
) 2971, 2928, 2874, 1686, 1469, 1390, 1256, 1160, 1111, 1078, 1022, 911, 876, 810, 
764, 731, 624, 523, 421.  
HRMS (ESI, m/z) calcd. for C21H23NO2SNa [M+Na]
+
: 376.1342, found: 376.1341. 
tert-Butyl (R)-2-(dibenzo[b,d]furan-2-yl)pyrrolidine-1-carboxylate (10p) 
 
Starting from 9p (53.1 mg, 0.2 mmol) according to the general procedure to give 10p as a pale yellow 
oil (34.3 mg, 0.102 mmol, 51% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 80%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV 
detection at 220 nm, mobile phase n-hexane/isopropanol = 95:5, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 10.7 min, tr (minor) = 16.5 min. []D
22
 = 22.4 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 7.3 Hz, 1H), 7.74 (d, J = 1.0 Hz, 1H), 7.60-7.40 (m, 3H), 
7.38-7.26 (m, 2H), 5.24-4.83 (br, m, 1H), 3.87-3.43 (br, m, 1H), 2.53-2.22 (m, 1H), 2.05-1.84 (m, 3H), 
1.47 (br, s, 3H), 1.17 (br, s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 156.7, 155.3, 154.8, 139.9, 127.2, 125.0, 124.4, 124.2, 122.7, 120.7, 
117.5, 111.8, 111.4, 79.4, 61.4, 47.4, 36.4, 28.4, 23.4.  
IR (film): ν (cm
1
) 2971, 2928, 2874, 1687, 1478, 1447, 1390, 1250, 1192, 1161, 1110, 1021, 972, 912, 
871, 844, 811, 748, 659, 626, 545, 424.  
HRMS (ESI, m/z) calcd. for C21H23NO3Na [M+Na]
+








Starting from 9q (36.3 mg, 0.2 mmol) according to the general procedure to give 10q as a yellow oil 
(25.3 mg, 0.10 mmol, 50% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 90%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 95:5, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(major) = 16.7 min, tr (minor) = 19.3 min. []D
22
 = 69.6 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.20-7.06 (m, 1H), 6.97-6.75 (m, 2H), 5.29-4.96 (br, m, 1H), 3.64-3.35 
(br, m, 2H), 2.35-2.16 (m, 1H), 2.10-1.85 (m, 3H), 1.52-1.25 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 154. 6, 149.0, 126.5, 123.4, 123.2, 79.7, 56.9, 46.4, 35.7, 28.5, 23.3.  
HRMS (ESI, m/z) calcd. for C13H19SNO2Na [M+Na]
+





Starting from 9r (33.0 mg, 0.2 mmol) according to the general procedure to give 10r as a pale yellow 
oil (17.0 mg, 0.072 mmol, 36% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 76%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV 
detection at 220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 12.4 min, tr (minor) = 13.4 min. []D
22
 = 31.0 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.29 (dd, J = 1.8, 0.8 Hz, 1H), 6.27 (dd, J = 3.1, 1.8 Hz, 1H), 6.07 (s, 
1H), 5.10-4.70 (br, m, 1H), 3.62-3.28 (m, 2H), 2.21-1.79 (m, 4H), 1.51-1.26 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 154.5, 141.2, 110.2, 105.5, 79.5, 54.8, 46.3, 32.3, 28.5, 23.6.  
HRMS (ESI, m/z) calcd. for C13H19O3NNa [M+Na]
+
: 260.1257, found: 260.1258. 
tert-Butyl (R)-2-(9-methyl-9H-carbazol-3-yl)pyrrolidine-1-carboxylate (10s) 




Starting from 9s (55.7 mg, 0.2 mmol) according to the general procedure to give 10s as a pale yellow 
solid (35.0 mg, 0.10 mmol, 50% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 93%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 90:10, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 12.1 min, tr (minor) = 24.7 min. []D
22
 = 76.5 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 7.7 Hz, 1H), 7.89 (s, 1H), 7.48 (t, J = 7.5 Hz, 1H), 
7.42-7.28 (m, 3H), 7.22 (d, J = 7.3 Hz, 1H), 5.26-4.85 (br, m, 1H), 3.90-3.60 (m, 5H), 2.50-2.28 (m, 
1H), 2.08-1.82 (m, 3H), 1.59-1.08 (br, m, 9H).  
13
C NMR (75 MHz, CDCl3) δ 155.0, 141.5, 140.2, 135.9, 125.7, 123.7, 122.9, 122.7, 120.3, 118.8, 
117.2, 108.5, 108.2, 79.2, 61.7, 47.4, 36.6, 29.2, 28.4, 23.4.  
IR (film): ν (cm
1
) 3045, 2965, 2925, 2857, 1679, 1600, 1478, 1397, 1357, 1330, 1248, 1153, 1115, 
1022, 971, 915, 875, 826, 770, 743, 706, 631, 598, 563, 545, 456, 427.  
HRMS (ESI, m/z) calcd. for C22H26O2N2Na [M+Na]
+
: 373.1886, found: 373.1899. 
tert-Butyl (S)-1-phenylisoindoline-2-carboxylate (10t) 
 
Starting from 9t (44.7 mg, 0.2 mmol) according to the general procedure to give 10t as a pale yellow 
solid (27.7 mg, 47% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 80%. HPLC conditions: Chiralpak IG column (4.6  250 mm), UV detection at 
254 nm, mobile phase n-hexane/isopropanol = 95:5, flow rate 1.0 mL/min, column temperature = 25 °C, tr 
(minor) = 9.4 min, tr (major) = 13.0 min. []D
22
 = 142.3 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ
 
7.36-7.18 (m, 8H), 7.02 (dd, J = 17.1, 7.3 Hz, 1H), 6.06-5.81 (br, m, 
1H), 4.99-4.84 (m, 2H), 1.48 (s, 3H), 1.25 (s, 6H).  




C NMR (75 MHz, CDCl3) δ 154.6, 144.3, 142.0, 135.8, 128.7, 128.4, 127.8, 127.3, 126.8, 123.7, 
122.9, 80.0, 67.7, 67.4, 53.1, 52.7, 28.7, 28.3.  
IR (film): ν (cm
1
) 2977, 2925, 2883, 1680, 1598, 1468, 1394, 1310, 1261, 1176, 1121, 1028, 894, 
870, 829, 786, 740, 704, 628, 597, 559, 459, 418.  
HRMS (ESI, m/z) calcd. for C19H21O2N1Na [M+Na]
+
: 318.1465, found: 318.1472. 
tert-Butyl (S)-1-phenyl-1,3-dihydro-2H-benzo[f]isoindole-2-carboxylate (10u) 
 
Starting from 9u (54.7 mg, 0.2 mmol) according to the general procedure with slight modifications 
(85 °C and 0.2 mL 1,2-dichlorobenzene were used) to give 10u as a white solid (31.0 mg, 45% yield). 
Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 94%. HPLC 
conditions: Chiralpak IG column (4.6  250 mm), UV detection at 254 nm, mobile phase 
n-hexane/isopropanol = 95:5, flow rate 1.0 mL/min, column temperature = 25 °C, tr (minor) = 13.4 min, tr 
(major) = 20.3 min. []D
22
 = 35.4 (c = 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.77 (dd, J = 35.3, 7.8 Hz, 3H), 7.53-7.37 (m, 3H), 7.35-7.21 (m, 5H), 
6.26-5.92 (br, m, 1H), 5.19-4.95 (m, 2H), 1.51 (s, 3H), 1.28 (s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 154.6, 144.7, 141.1, 134.7, 133.4, 128.5, 128.1, 127.9, 127.4, 126.8, 
126.0, 125.8, 122.5, 121.4, 80.1, 67.1, 52.2, 28.4.  
IR (film): ν (cm
1
) 2975, 2924, 1681, 1606, 1476, 1379, 1312, 1255, 1175, 1121, 1079, 1025, 959, 
889, 862, 818, 772, 741, 700, 633, 601, 554, 519, 478, 431, 399.  
HRMS (ESI, m/z) calcd. for C23H23O2N1Na [M+Na]
+
: 368.1621, found: 368.1630. 
5.3.4 Mechanism Study 
1) Preparation of iminophosphorane 
 
A mixture of azide 9a (35 mg, 0.2 mmol) and P(4-F-Ph)3 (63 mg, 0.2 mmol) in toluene (0.2 mL, 1 M) 
were stirred at 95 °C for 6 h under an atmosphere of nitrogen. Afterwards, the mixture was 
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concentrated under reduced pressure to remove the solvent. The analytically pure iminophosphorane 
12 was obtained as a colorless oil (29.4 mg, 0.2 mmol, 100% yield).  
1
H NMR (300 MHz, C6D6) δ 7.61-7.48 (m, 6H), 7.24 (dd, J = 9.6, 6.4 Hz, 5H), 6.88-6.79 (m, 6H), 
3.41 (dt, J = 16.2, 6.2 Hz, 2H), 2.74 (t, J = 7.3 Hz, 2H), 2.09-1.90 (m, 4H).  
13
C NMR (75 MHz, C6D6) δ 166.6, 166.5, 163.3, 163.2, 143.4, 135.1, 135.0, 134.9, 134.8, 129.7, 
129.6, 128.8, 128.6, 125.9, 116.0, 115.8, 115.8, 115.7, 115.5, 45.2, 45.2, 36.4, 35.9, 35.6, 29.8.  
19
F NMR (282 MHz, C6D6) δ -109.14.  
IR (film): ν (cm
1
) 3062, 3029, 2927, 2852, 2809, 2127, 1674, 1588, 1495, 1457, 1395, 1358, 1296, 
1225, 1157, 1103, 1014, 826, 745, 701, 659, 573, 528, 473.  
HRMS (ESI, m/z) calcd. for C28H26F3NP [M+H]
+
: 464.1749, found: 464.1763. 
2) Catalytic asymmetric C-H amination using iminophosphorane 12 as the co-catalyst 
 
A dried 10 mL Schlenk tube was charged with azide 9a (35 mg, 0.2 mmol) and Λ-Ru7 (2.6 mg, 0.002 
mmol, 1 mol%) under an atmosphere of nitrogen. A solution of iminophosphorane 12 (0.5 mL, 0.002 
mmol, 4 mM in 1,2-dichlorobenzene) was added via syringe, followed by Boc2O (45.8 µL, 0.2 mmol). 
The reaction mixture was stirred at 95 °C for 30 h under an atmosphere of nitrogen. Afterwards, the 
mixture was concentrated under reduced pressure, and the residue was analized by 
1
H NMR to 
determine the yield using Cl2CHCHCl2 as internal standard. Analytically pure product was obtained by 
preparative TLC for chiral HPLC analysis to determine the enantiomeric excess. 
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3) Comparison of 1,2-hydride shift of benzyl azide and standard substrate 9a 
 
A dried 10 mL Schlenk tube was charged with benzyl azide or 9a (8.8 mg, 0.05 mmol) and rac-Ru1 
(10.3 mg, 0.0075 mmol, 15 mol%) under an atmosphere of nitrogen. A solution of P(4-F-Ph)3 (0.15 
mL, 0.001 mmol, 6.7 mM in CH2Cl2) was added via syringe. The reaction mixture was stirred at 50 °C 
for 20 h under an atmosphere of nitrogen. Afterwards, the mixture was concentrated under reduced 
pressure, and the residue was analized by 
1
H NMR to determine the conversion of the imine.
8
 See the 
1
H NMR spectrum below. 
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4) Reaction rates of electronically distinct substrates 
 
A dried 10 mL Schlenk tube was charged with azide 9e or 9l (0.2 mmol) and rac-Ru1 (2.8 mg, 0.002 
mmol, 1 mol%) under an atmosphere of nitrogen. A solution of P(4-F-Ph)3 (0.5 mL, 0.002 mmol, 4 
mM in 1,2-dichlorobenzene) was added via syringe, followed by Boc2O (46 µL, 0.2 mmol). Then 
10µL Cl2CHCHCl2 was added as the internal standard. The reaction mixture was stirred at 95 °C under 
an atmosphere of nitrogen. Aliquots were taken at time intervals as indicated in the figure below. The 
aliquot was analyzed by 
1
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5) KIE experiments 






A dried 10 mL Schlenk tube was charged with azide 9a' (35.2 mg, 0.2 mmol) and rac-Ru7 (2.6 mg, 
0.002 mmol, 1 mol%) under an atmosphere of nitrogen. A solution of P(4-F-Ph)3 (0.5 mL, 0.002 mmol, 
4 mM in 1,2-dichlorobenzene) was added via syringe, followed by Boc2O (46 µL, 0.2 mmol). The 
reaction mixture was stirred at 95 °C for 40 h under an atmosphere of nitrogen. Afterwards, the 
mixture was concentrated under reduced pressure, and the residue was purified by a short silica gel 
column. The ratio of kD/kH was determined by 
1
H NMR by integration of the methine proton against 
the methylene protons at the 2- and 4-positions, respectively. A intramolecular KIE value of 1.3 was 
obtained. See the 
1
H NMR spectrum below. 
 





The intermolecular KIE (noncompetitive) was obtained by measuring the initial reaction rates with 9a 
and 9a'' following the procedure below. 
A dried 10 mL Schlenk tube was charged with azide 9a (35.0 mg, 0.2 mmol) or 9a'' (35.4 mg, 0.2 
mmol), and rac-Ru7 (2.6 mg, 0.002 mmol, 1 mol%) under an atmosphere of nitrogen. A solution of 
P(4-F-Ph)3 (0.5 mL, 0.002 mmol, 4 mM in 1,2-dichlorobenzene) was added via syringe, followed by 
Boc2O (46 µL, 0.2 mmol). Then 10µL Cl2CHCHCl2 was added as the internal standard. The reaction 
mixture was stirred at 95 °C under an atmosphere of nitrogen. Aliquots were taken at time intervals as 
indicated in the figure below. The aliquot was analyzed by 
1
H NMR spectroscopy for the formation of 
product (square for 9a, triangle for 9a'').  








The intermolecular KIE (competitive) was obtained by taking a 1:1 mixture of the non- and 
bis-deuterated substrate and looking at the ratio of products. 
A dried 10 mL Schlenk tube was charged with azides 9a (17.5 mg, 0.1 mmol), 9a'' (17.7 mg, 0.1 
mmol), and rac-Ru7 (2.6 mg, 0.002 mmol, 1 mol%) under an atmosphere of nitrogen. A solution of 
P(4-F-Ph)3 (0.5 mL, 0.002 mmol, 4 mM in 1,2-dichlorobenzene) was added via syringe, followed by 
Boc2O (46 µL, 0.2 mmol). The reaction mixture was stirred at 95 °C for 30 h under an atmosphere of 
nitrogen. Afterwards, the mixture was concentrated under reduced pressure, and the residue was 
purified by a short silica gel column. The ratio of kH/kD was determined by 
1
H NMR by integration of 
the methine proton against the methylene protons at the 2- and 4-positions, respectively. A KIE value 
of 3.9 was obtained. See the 
1
H NMR below. 
 
c) Stereospecificity of the intramolecular C-H amination 
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A dried 10 mL Schlenk tube was charged with azide (R)-9y or (S)-9y (37.9 mg, 0.2 mmol) and 
rac-Ru7 or Λ-Ru7 (2.6 mg, 0.002 mmol, 1 mol%) under an atmosphere of nitrogen. A solution of 
P(4-F-Ph)3 (0.5 mL, 0.002 mmol, 4 mM in 1,2-dichlorobenzene) was added via syringe, followed by 
Boc2O (46 µL, 0.2 mmol). The reaction mixture was stirred at 95 °C for 35 h under an atmosphere of 
nitrogen. Afterwards, the mixture was concentrated under reduced pressure, and the residue was 
analized by 
1
H NMR to determine the yield using Cl2CHCHCl2 as internal standard. Analytically pure 
product was obtained by preparative TLC. Enantiomeric excess was determined by HPLC analysis on 
a chiral stationary phase. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection at 
220 nm, mobile phase n-hexane/isopropanol = 99:1, flow rate 0.7 mL/min, column temperature = 25 °C. 
See the chromatographys of (R)-10y or (S)-10y
10
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5.4 Ruthenium Catalyzed Asymmetric Oxidative Homocoupling of 2-Acyl Imidazoles 
5.4.1 Synthesis of Substrates 
 
To a solution of N-phenylimidazole (1.1 equiv) in THF at 78 C was added nBuLi (1.1 equiv) 
dropwise. The mixture was stirred at 78 C for 30 min, then stirred at room temperature for another 
30 min. The corresponding Weinreb amide (1.0 equiv, 0.4 M in THF) was added dropwise to the flask 
after the reaction was cooled back down to 78 C. The reaction was allowed to warm to room 
temperature slowly (over a period of 3-4 h) and stirred overnight. The reaction was quenched with 
AcOH (6.0 equiv) at room temperature and extracted with EtOAc. The organic layer was washed with 
aqueous saturated NaHCO3 and brine. The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:5) to produce 13a-o. 
The experimental data of unknown compound 13g and 13m are shown below. The other 2-acyl 





Following the general procedure, 2-acyl imidazole 13g (870 mg, 3.0 mmol, yield: 75%) was obtained 
as a yellow oil from the corresponding Weinreb amide (829 mg, 4.0 mmol).  
1
H NMR (300 MHz, CDCl3) δ 7.45-7.39 (m, 3H), 7.34- 7.30 (m, 1H), 7.28-7.21 (m, 2H), 7.19 (d, J = 
1.0 Hz, 1H), 6.94 (s, 2H), 6.87 (s, 1H), 4.38 (s, 2H), 2.28 (s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 188.9, 143.1, 138.5, 138.0, 134.3, 129.9, 129.1, 128.8, 128.7, 127.9, 
127.5, 126.0, 45.6, 21.4.  
IR (film): ν (cm
1
) 3110, 3016, 2916, 1683, 1600, 1496, 1446, 1397, 1336, 1304, 1216, 1147, 1100, 
1044, 962, 910, 854, 792, 761, 691, 636, 551, 521, 492, 419.  
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: 291.1492, found: 291.1494. 
1-(1-Phenyl-1H-imidazol-2-yl)-2-(3-(trifluoromethyl)phenyl)ethan-1-one (13m) 
 
Following the general procedure, 2-acyl imidazole 13m (793 mg, 2.4 mmol, yield: 60%) was obtained 
as a white solid from the corresponding Weinreb amide (989 mg, 4.0 mmol).  
1
H NMR (300 MHz, CDCl3) δ 7.60 (s, 1H), 7.55-7.48 (m, 2H), 7.47-7.41 (m, 4H), 7.35 (d, J = 0.7 Hz, 
1H), 7.28-7.22 (m, 3H), 4.54 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ 187.7, 142.7, 138.3, 135.5, 133.6, 130.9 (q, J = 31.9 Hz), 130.1, 129.1, 
129.0, 128.9, 127.9, 126.8 (q, J = 3.8 Hz), 126.0, 123.8 (q, J = 3.8 Hz), 122.5, 45.3.  
19
F NMR (282 MHz, CDCl3) δ -62.53 (s, 3F).  
IR (film): ν (cm
1
) 3120, 1678, 1595, 1496, 1451, 1397, 1330, 1302, 1204, 1163, 1125, 1072, 1027, 
961, 910, 877, 821, 787, 771, 696, 657, 621, 591, 536, 420.  




: 353.0872, found: 353.0874. 
5.4.2 Ruthenium Catalyzed Asymmetric Homocoupling of 2-Acyl Imidazoles 
1) General procedure for the optimization of the reaction conditions (for Table 9 in Chapter 
3.3) 
A dried 10 mL Schlenk tube was charged with the corresponding 2-acyl imidazoles substrate (0.20 
mmol, 1.0 equiv), the corresponding ruthenium catalyst (2 mol%) and the corresponding base (0.22 
mmol, 1.1 equiv). The corresponding solvent was added, then was BrCCl3. The reaction mixture was 
degassed via freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial 
was sealed and put in pre-heated silicone oil bath. The reaction was stirred at indicated temperature for 
the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was 
concentrated under reduced pressure, and the residue was purified by flash chromatography on silica 
gel (EtOAc/hexane = 1:5 to 1:3) to afford the analytically pure product. Enantiomeric excess was 
determined by HPLC analysis on chiral stationary phase. 
2) Standard procedure for the substrate scope of the ruthenium-catalyzed homocoupling  
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A dried 10 mL Schlenk tube was charged with Phebox-Ru1 (2.5 mg, 0.004 mmol, 2 mol%), NaHCO3 
(18.5 mg, 0.22 mmol, 1.1 equiv) and the corresponding 2-acyl imidazoles (0.20 mmol, 1.0 equiv). 
MeOH/THF (1 mL, the volume ratio of MeOH/THF is 4:1) was added, then was BrCCl3 (19.6 µL, 
0.20 mmol, 1.0 equiv). The reaction mixture was degassed via freeze-pump-thaw for three cycles. 
After the mixture was thoroughly degassed, the vial was sealed and put in pre-heated silicone oil bath. 
The reaction was stirred at 40 C for the indicated time (monitored by TLC) under nitrogen 
atmosphere. Afterwards, the mixture was concentrated under reduced pressure, and the residue was 
purified by flash chromatography on silica gel (EtOAc/hexane = 1:5 to 1:3) to afford the analytically 




Starting from 13a (40 mg, 0.20 mmol) according to the general procedure to give 15a as a white solid 
(18.7 mg, 0.047 mmol, 47% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 45%. HPLC conditions: Chiralpak OJ-H column (4.6  250 mm), UV detection 
at 254 nm, mobile phase n-hexane/isopropanol = 80: 20, flow rate 1.0 mL/min, column temperature = 
25 °C, tr (minor) = 9.4 min, tr (major) = 10.8 min. []D
20
 = -16.2 (c 0.05, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.31-7.27 (m, 2H), 7.26-7.24 (m, 2H), 7.16-7.04 (m, 8H), 6.92 (s, 2H), 
5.91 (s, 2H), 3.90 (s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 191.6, 142.8, 136.7, 129.7, 129.5, 128.4, 127.0, 126.9, 57.2, 36.1.  
IR (film): ν (cm
1
) 2922, 2854, 2175, 2022, 1965, 1663, 1594, 1456, 1397, 1328, 1285, 1251, 1153, 
1076, 1009, 967, 908, 888, 778, 740, 695, 665, 623, 585, 561, 520.  




: 399.1816, found: 399.1819. 
(2R,3R)-1,4-Bis(1-isopropyl-1H-imidazol-2-yl)-2,3-diphenylbutane-1,4-dione (15b) 




Starting from 13b (45.7 mg, 0.2 mmol) according to the general procedure to give 15b as a white solid 
(18.7 mg, 0.041 mmol, 41% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 58%. HPLC conditions: Chiralpak IA column (4.6  250 mm), UV detection at 
254 nm, mobile phase n-hexane/isopropanol = 85: 15, flow rate 1.0 mL/min, column temperature = 25 °C, 
tr (major) = 6.3 min, tr (minor) = 8.7 min. []D
20
 = -118.1 (c 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.26-7.21 (m, 4H), 7.17-7.03 (m, 10H), 5.89 (s, 2H), 5.53-5.40 (m, 
2H), 1.36 (d, J = 6.6 Hz, 6H), 1.26 (d, J = 6.7 Hz, 6H).  
13
C NMR (75 MHz, CDCl3) δ
 
191.9, 142.3, 137.0, 130.1, 129.4, 128.3, 126.9, 120.9, 58.1, 49.1, 23.7, 
23.6.  
IR (film): ν (cm
1
) 2971, 2929, 2181, 1664, 1595, 1493, 1458, 1391, 1333, 1253, 1195, 1154, 1081, 
1004, 964, 918, 888, 816, 776, 748, 697, 671, 645, 600, 572, 522, 447, 406.  




: 477.2261, found: 477.2264. 
(2R,3R)-2,3-Diphenyl-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15c) 
 
Starting from 13c (52.4 mg, 0.20 mmol) according to the general procedure to give 15c as a white 
solid (38.1 mg, 0.073 mmol, 73% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 94%. HPLC conditions: Chiralpak IA column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 85: 15, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 9.7 min, tr (minor) = 17.7 min. []D
20
 = -310.6 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.45-7.36 (m, 6H), 7.27-7.23 (m, 4H), 7.22-7.07 (m, 12H), 7.00 (s, 
2H), 5.81 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ
 
189.7, 142.7, 138.5, 136.5, 129.9, 129.5, 128.9, 128.5, 128.4, 127.1, 
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126.6, 125.6, 57.6.  
IR (film): ν (cm
1
) 2175, 2012, 1974, 1676, 1594, 1494, 1447, 1396, 1305, 1147, 1071, 1030, 980, 
955, 906., 887, 818, 756, 692, 663, 603, 545, 517, 450, 411.  




: 523.2129, found: 523.2133. 
(2R,3R)-1,4-Bis(1-phenyl-1H-imidazol-2-yl)-2,3-di-m-tolylbutane-1,4-dione (15d) 
 
Starting from 13d (55.2 mg, 0.20 mmol) according to the general procedure to give 15d as a white 
solid (37.4 mg, 0.068 mmol, 68% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 93%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 8.8 min, tr (minor) = 10.9 min. []D
20
 = -270.5 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.43-7.36 (m, 6H), 7.20-7.15 (m, 2H), 7.13-7.09 (m, 4H), 7.08-7.04 
(m, 3H), 7.03-6.90 (s, 7H), 5.69 (s, 2H), 2.23 (s, 6H). 
13
C NMR (75 MHz, CDCl3) δ 190.0, 142.9, 138.6, 137.9, 136.4, 129.9, 129.9, 129.0, 128.6, 128.3, 
127.9, 126.9, 126.5, 125.7, 57.6, 21.4. 
IR (film): ν (cm
1
) 2922, 2854, 2175, 2022, 1965, 1663, 1594, 1456, 1397, 1328, 1285, 1251, 1153, 
1076, 1009, 967, 908, 888, 778, 740, 695, 665, 623, 585, 561, 520.  




: 573.2261, found: 573.2267. 
(2R,3R)-1,4-Bis(1-phenyl-1H-imidazol-2-yl)-2,3-di-p-tolylbutane-1,4-dione (15f) 
 
Starting from 13f (55.2 mg, 0.20 mmol) according to the general procedure to give 15f as a white solid 
(25.3 mg, 0.046 mmol, 46% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
Chapter 5. Experimental Part 
151 
 
stationary phase, ee = 87%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection 
at 254 nm, mobile phase n-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, column temperature = 
25 °C, tr (major) = 9.9 min, tr (minor) = 12.2 min. []D
20
 = -359.5 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.41-7.36 (m, 6H), 7.17-7.16 (m, 2H), 7.13-7.06 (m, 8H), 6.99-6.94 
(m, 6H), 5.72 (s, 2H), 2.22 (s, 6H).  
13
C NMR (75 MHz, CDCl3) δ 190.0, 142.8, 138.6, 136.6, 133.4, 129.9, 129.4, 129.2, 129.0, 128.5, 
126.5, 125.7, 57.1, 21.2.  
IR (film): ν (cm
1
) 3131, 2230, 2200, 2146, 1672, 1595, 1497, 1446, 1399, 1342, 1307, 1237, 1144, 
1081, 1029, 955, 910, 890, 761, 693, 644, 597, 532, 486, 409.  




: 573.2261, found: 573.2263.  
(2R,3R)-2,3-Bis(3,5-dimethylphenyl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15g) 
 
Starting from 13g (58.2 mg, 0.20 mmol) according to the general procedure to give 15g as a white 
solid (34.8 mg, 0.060 mmol, 60% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 92%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 6.9 min, tr (minor) = 8.1 min. []D
20
 = -306.3 (c 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.43-7.36 (m, 6H), 7.17 (d, J = 0.9 Hz, 2H), 7.13-7.06 (m, 4H), 6.99 (d, 
J = 0.9 Hz, 2H), 6.79 (s, 4H), 6.73 (s, 2H), 5.59 (s, 2H), 2.17 (s, 12H).  
13
C NMR (75 MHz, CDCl3) δ 190.2, 143.1, 138.6, 137.6, 136.2, 129.9, 129.0, 128.8, 128.6, 127.3, 
126.4, 125.7, 57.6, 21.3.  
IR (film): ν (cm
1
) 2960, 2916, 2050, 1678, 1599, 1495, 1446, 1399, 1340, 1304, 1263, 1205, 1148, 
1096, 1029, 968, 911, 812, 760, 694, 602, 556, 517, 479, 398.  




: 601.2574, found: 601.2581. 
(2R,3R)-2,3-Di([1,1'-biphenyl]-4-yl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15h) 




Starting from 13h (67.7 mg, 0.20 mmol) according to the general procedure to give 15h as a yellow 
solid (43.9 mg, 0.065 mmol, 65% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 90%. HPLC conditions: Chiralpak AD-H column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 80: 20, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (minor) = 17.1 min, tr (major) = 22.6 min. []D
20
 = -433.4 (c 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.55-7.50 (m, 4H), 7.44-7.27 (m, 20H), 7.23-7.19 (m, 2H), 7.17-7.09 
(m, 4H), 7.04-7.01 (m, 2H), 5.86 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ 190.0, 142.8, 140.7, 139.8, 138.6, 135.6, 130.0, 129.9, 129.0, 128.8, 
128.6, 127.3, 127.1, 127.0, 126.7, 125.8, 57.2.  
IR (film): ν (cm
1
) 3098, 1684, 1591, 1487, 1449, 1400, 1337, 1307, 1209, 1144, 1105, 1076, 1034, 
1008, 954, 913, 863, 792, 756, 691, 597, 542, 515, 491, 413.  




: 697.2574, found: 697.2575.  
(2R,3S)-2,3-Bis(4-methoxyphenyl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15i) 
 
Starting from 13i (58.5 mg, 0.20 mmol) according to the general procedure to give 15i as a white solid 
(20.4 mg, 0.035 mmol, 35% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 94%. HPLC conditions: Chiralpak IA column (4.6  250 mm), UV detection at 
254 nm, mobile phase n-hexane/isopropanol = 80: 20, flow rate 1.0 mL/min, column temperature = 25 °C, 
tr (minor) = 15.8 min, tr (major) = 20.3 min. []D
20
 = -304.2 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.40-7.35 (m, 6H), 7.18-7.05 (m, 10H), 7.00-6.98 (m, 2H), 6.72-6.67 
(m, 4H), 5.66 (s, 2H), 3.71 (s, 6H).  




C NMR (75 MHz, CDCl3) δ 190.1, 158.7, 142.9, 138.6, 130.6, 129.9, 129.0, 128.6, 128.6, 126.5, 
125.7, 114.0, 56.7, 55.2.  
IR (film): ν (cm
1
) 2932, 2835, 1723, 1676, 1603, 1503, 1446, 1398, 1341, 1302, 1248, 1176, 1148, 
1102, 1029, 957, 911, 889, 833, 799, 760, 692, 646, 599, 537, 444.  




: 605.2159, found: 605.2164.  
(2R,3R)-2,3-Bis(4-fluorophenyl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15j) 
 
Starting from 13j (56.1 mg, 0.20 mmol) according to the general procedure to give 15j as a white solid 
(38.1 mg, 0.068 mmol, 68% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 82%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV detection 
at 254 nm, mobile phase n-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, column temperature = 
25 °C, tr (major) = 9.6 min, tr (minor) = 12.2 min. []D
20
 = -260.1 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.45-7.36 (m, 6H), 7.22-7.14 (m, 6H), 7.13-7.06 (m, 4H), 7.02 (d, J = 
1.0 Hz, 2H), 6.90-6.80 (m, 4H), 5.71 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ 189.4, 163.7, 160.5, 142.5, 138.5, 132.3, 132.3, 131.0, 130.9, 130.1, 
129.1, 128.7, 126.9, 125.7, 115.7, 115.4, 56.8.  
19
F NMR (282 MHz, CDCl3) δ -115.28 (s, 2F).  
IR (film): ν (cm
1
) 3051, 2150, 2063, 2027, 1996, 1677, 1597, 1500, 1446, 1397, 1342, 1306, 1224, 
1154, 1087, 1029, 957, 911, 891, 815, 790, 761, 692, 646, 598, 535, 494, 472, 415.  




: 581.1760, found: 581.1764. 
(2R,3R)-2,3-Bis(4-bromophenyl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15k) 




Starting from 13k (68.2 mg, 0.20 mmol) according to the general procedure to give 15k as a white 
solid (48.9 mg, 0.072 mmol, 72% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 58%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 10.4 min, tr (minor) = 12.4 min. []D
20
 = -250.2 (c 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.44-7.37 (m, 6H), 7.33-7.26 (m, 4H), 7.18-7.16 (m, 2H), 7.14-7.06 
(m, 8H), 7.03 (d, J = 0.9 Hz, 2H), 5.70 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ
 
188.9, 142.4, 138.4, 135.5, 131.8, 131.1, 130.1, 129.1, 128.8, 127.0, 
125.7, 121.5, 56.7.  
IR (film): ν (cm
1
) 3064, 2192, 2083, 1996, 1940, 1680, 1593, 1488, 1445, 1397, 1340, 1307, 1235, 
1208, 1149, 1074, 1032, 1009, 952, 915, 887, 823, 763, 692, 598, 531, 404.  




:703.0141, found: 703.0140. 
(2R,3R)-2,3-Bis(4-chlorophenyl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15l) 
 
Starting from 13l (59.4 mg, 0.20 mmol) according to the general procedure to give 15l as a white solid 
(42.6 mg, 0.072 mmol, 72% yield). Enantiomeric excess was determined by HPLC analysis on a chiral 
stationary phase, ee = 75%. HPLC conditions: Chiralpak IA column (4.6  250 mm), UV detection at 
254 nm, mobile phase n-hexane/isopropanol = 85: 15, flow rate 1.0 mL/min, column temperature = 25 °C, 
tr (major) = 12.2 min, tr (minor) = 20.5 min. []D
20
 = -244.3 (c 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.44-7.36 (m, 6H), 7.20-7.06 (m, 14H), 7.02 (s, 2H), 5.71 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ 189.0, 142.4, 138.4, 135.0, 133.3, 130.8, 130.1, 129.1, 128.9, 128.8, 
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127.0, 125.7, 56.7.  
IR (film): ν (cm
1
) 3108, 2038, 1905, 1677, 1595, 1492, 1447, 1398, 1308, 1234, 1150, 1090, 1018, 
955, 913, 889, 826, 785, 760, 692, 591, 533, 484, 409.  








Starting from 13m (66.1 mg, 0.20 mmol) according to the general procedure to give 15m as a white 
solid (36.2 mg, 0.055 mmol, 55% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 57%. HPLC conditions: Chiralpak OD-H column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 7.5 min, tr (minor) = 9.6 min. []D
20
 = -147.9 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.47-7.30 (m, 12H), 7.28-7.23 (m, 2H), 7.20-7.16 (m, 2H), 7.15-7.07 
(m, 4H), 7.03-7.04 (m, 2H), 5.81 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ
 
188.5, 142.4, 138.3, 137.5, 133.1, 131.0 (q, J = 32.2 Hz), 130.3, 129.2, 
128.1, 128.9, 127.1, 125.8, 125.7, 124.2 (q, J = 3.9 Hz), 122.2, 57.2.  
19
F NMR (282 MHz, CDCl3) δ -62.69 (s, 6F).  
IR (film): ν (cm
1
) 3049, 3130, 2285, 2215, 2158, 1982, 1904, 1679, 1595, 1495, 1446, 1398, 1324, 
1164, 1121, 1072, 1031, 958, 910, 831, 786, 761, 695, 653, 572, 521, 484, 409.  




: 681.1696, found: 681.1708. 
(2R,3R)-2,3-Di(naphthalen-2-yl)-1,4-bis(1-phenyl-1H-imidazol-2-yl)butane-1,4-dione (15n) 




Starting from 13n (62.5 mg, 0.20 mmol) according to the general procedure to give 15n as a white 
solid (46.7 mg, 0.075 mmol, 75% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 80%. HPLC conditions: Chiralpak IA column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 80: 20, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 10.1 min, tr (minor) = 15.0 min. []D
20
 = -429.9 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.80 (s, 2H), 7.72-7.62 (m, 4H), 7.59 (s, 1H), 7.56 (s, 1H), 7.42-7.34 
(m, 12H), 7.19-7.15 (m, 2H), 7.12-7.05 (m, 4H), 6.99-6.96 (m, 2H), 6.10 (s, 2H).  
13
C NMR (75 MHz, CDCl3) δ 189.6, 142.8, 138.5, 134.0, 133.5, 132.6, 130.0, 129.0, 128.6, 128.5, 
128.2, 128.0, 127.8, 127.6, 126.7, 125.9, 125.8, 125.7, 57.6.  
IR (film): ν (cm
1
) 3054, 1677, 1595, 1496, 1445, 1398, 1304, 1148, 1030, 959, 912, 844., 793, 756, 
691, 656, 535, 474.  




: 645.2261, found: 645.2270. 
(2R,3R)-1,4-Bis(1-phenyl-1H-imidazol-2-yl)-2,3-di(thiophen-3-yl)butane-1,4-dione (15o) 
 
Starting from 13o (53.7 mg, 0.20 mmol) according to the general procedure to give 15o as a white 
solid (28.9 mg, 0.054 mmol, 54% yield). Enantiomeric excess was determined by HPLC analysis on a 
chiral stationary phase, ee = 75%. HPLC conditions: Chiralpak AD-H column (4.6  250 mm), UV 
detection at 254 nm, mobile phase n-hexane/isopropanol = 85: 15, flow rate 1.0 mL/min, column 
temperature = 25 °C, tr (major) = 15.5 min, tr (minor) = 18.0 min. []D
20
 = -167.2 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.42-7.34 (m, 6H), 7.21-7.18 (m, 2H), 7.15-7.04 (m, 8H), 7.04-7.01 
(m, 2H), 6.96-6.90 (m, 2H), 5.90 (s, 2H).  




C NMR (75 MHz, CDCl3) δ 189.2, 142.6, 138.5, 136.9, 130.0, 129.0, 128.6, 128.1, 126.8, 125.7, 
125.4, 123.7, 52.5.  
IR (film): ν (cm
1
) 3102, 1676, 1594, 1495, 1446, 1397, 1338, 1304, 1260, 1203, 1146, 1078, 1029, 
958, 913, 866, 822, 760, 689, 649, 572, 544, 515, 484, 455, 417.  




: 557.1076, found: 557.1080. 
5.4.3 Determination of the Absolute Configuration of the Homocoupling Product 
 
4 Å MS (167 mg, 100 mg/0.1 mmol of 15c) was added to a solution of 15c (87.8 mg, 0.167 mmol) in 
CH3CN (1.7 mL, 0.1 M) under nitrogen atmosphere. The suspension was stirred vigorously under a 
positive pressure of nitrogen for 3 h at 0 C. Then methyl trifluoromethansulfonate (30.3 mg, 0.184 
mmol, 1.1 equiv) was added dropwise at 0 C. After being stirred at 0 C for 6 h, EtOH (1.0 mL) and 
DBU (28.0 mg, 0.184 mmol, 1.1 equiv) were subsequently added to the reaction mixture at 0 C. After 
being stirred at 0 C for 60 min, 10 mL of saturated NaHCO3 aqueous solution was added. And the 
mixture was extracted with CH2Cl2, washed with NaHCO3 aqueous solution, water. The organic layer 
was dried and the solvent was evaporated and the residue was purified by flash chromatography on 
silica gel to give 18 (27.8 mg, 0.085 mmol, 51% yield) as a white solid.
4
 Compound 18 was further 
reduced to 19 (17.4 mg, 0.072 mmol, 85% yield) according to a reported procedure
5
 using LiAlH4 as 
the reductant. The optical rotation of 19 is determined as []D
20
 = -45.8 (c 1.0, CH2Cl2), which 




 +47 (c = 0.25, CHCl3) for (2S,3S)-19}. Thus the 
homocoupling product is (2R,3R)-15c. 
5.4.4 Mechanism Study 
1) Preparation of ruthenium enolate intermediate 




The ruthenium enolate complex was obtained by reacting substrate 13l (14.6 mg, 0.049 mmol) with 
Phebox-Ru1 (30.0 mg, 0.048 mmol) at 60 
o
C for 24 h in CHCl3 (0.8 mL) under N2 atmosphere. After 
removing the solvent, the residue was recrystallized in the mixture solvent of CH2Cl2 and n-hexane. 
The analytically pure ruthenium enolate complex 16 (27.5 mg, 0.034 mmol, 70% yield) was obtained 
as crystals after several days. 
1
H NMR (300 MHz, CD2Cl2) δ 7.57-7.48 (m, 3H), 7.31-7.22 (m, 5H), 7.20-7.14 (m, 2H), 7.06-6.85 
(m, 9H), 6.81 (s, 1H), 6.55-6.47 (m, 2H), 5.10-5.00 (m, 1H), 4.53-4.95 (m, 2H), 4.60-4.50 (m, 1H), 
4.48-4.39 (m, 1H), 4.38-4.29 (m, 2H), 2.68 (s, 3H), 2.67 (s, 3H). 
13
C NMR (75 MHz, CD2Cl2) δ 205.0, 195.6, 176.9, 176.1, 157.0, 149.8, 140.4, 140.3, 140.2, 140.1, 
134.0, 139.0, 130.7, 130.5, 129.8, 129.5, 128.9, 128.8, 128.6, 128.3, 128.3, 128.0, 127.9, 127.9, 127.5, 
127.5, 127.4, 126.8, 122.8, 100.1, 78.6, 78.2, 69.8, 67.1, 54.7, 54.6, 54.4, 54.2, 54.0, 53.8, 53.6, 53.3, 
19.7, 19.6. 
IR (film): ν (cm
1
) 3030, 2952, 1890, 1654, 1585, 1542, 1477, 1448, 1374, 1317, 1255, 1211, 1161, 
1088, 1054, 1015, 941, 872, 831, 759, 692, 624, 597, 548, 517, 476, 438. 




: 821.1472, found: 821.1480. 
2) Ruthenium enolate intermediate 16 as catalyst for the catalytic homocoupling of 13l 
 
A dried 10 mL Schlenk tube was charged with the catalyst 16 (3.3 mg, 0.004 mmol, 2 mol%), 
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NaHCO3 (18.5 mg, 0.22 mmol, 1.1 equiv) and 13l (59.4 mg, 0.20 mmol, 1.0 equiv). MeOH/THF (1 
mL, the volume ratio of MeOH/THF is 4:1) was added, then was BrCCl3 (19.6 µL, 0.20 mmol, 1.0 
equiv). The reaction mixture was degassed via freeze-pump-thaw for three cycles. After the mixture 
was thoroughly degassed, the vial was sealed and put in pre-heated silicone oil bath. The reaction was 
stirred at 40 C for 48 h under nitrogen atmosphere. Afterwards, the mixture was concentrated under 
reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc/hexane = 
1:5 to 1:3) to afford the analytically pure product 15l as a white solid (38.4 mg, 0.065 mmol, 65% 
yield). Enantiomeric excess was determined by HPLC analysis on a chiral stationary phase, ee = 75%. 
HPLC conditions: Chiralpak IA column (4.6  250 mm), UV detection at 254 nm, mobile phase 
n-hexane/isopropanol = 85: 15, flow rate 1.0 mL/min, column temperature = 25 °C, tr (major) = 12.2 min, 
tr (minor) = 20.5 min. 




A dried 10 mL Schlenk tube was charged with Phebox-Ru1 (3.7 mg, 0.006 mmol, 2 mol%), NaHCO3 
(27.8 mg, 0.33 mmol, 1.1 equiv) and 13c (78.7 mg, 0.30 mmol, 1.0 equiv). 1.1 mL MeOH and 0.4 mL 
THF were added, then was BrCCl3 (29.4 µL, 0.30 mmol, 1.0 equiv). The reaction mixture was 
degassed via freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial 
was sealed and put in pre-heated silicone oil bath. The reaction was stirred at 40 C under nitrogen 
atmosphere. The reaction was monitored by 
1
H NMR analysis of aliquots taken out from the reaction 
mixture via syringe at indicated time with Cl2CHCHCl2 as internal standard (see the below profile). 




4) Heterocoupling of brominated compound 17 with 2-acyl imidazole 13c or 13d 
 
A dried 10 mL Schlenk tube was charged with Phebox-Ru1 (3.7 mg, 0.006 mmol, 2 mol%), NaHCO3 
(27.8 mg, 0.33 mmol, 1.1 equiv), 17 (122.8 mg, 0.36 mmol, 1.2 equiv) and 13c (78.7 mg, 0.30 mmol, 
1.0 equiv), then 1.1 mL MeOH and 0.4 mL THF were added. The reaction mixture was degassed via 
freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and 
put in pre-heated silicone oil bath. The reaction was stirred at 40 C under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure, and the residue was purified by 
flash chromatography on silica gel (EtOAc/hexane = 1:5 to 1:3) to afford the analytically pure 
heterocoupling product 15c (87.8 mg, 0.168 mmol, 56% yield). Enantiomeric excess was determined 
by HPLC analysis on chiral stationary phase.  
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Following the above procedure, three coupling products (30.2 mg, 0.056 mmol, 56% yield, 15d: 15c: 
15cd = 1.3: 1.0: 2.0) were obtained between the reaction of 17 (40.9 mg, 0.12 mmol, 1.2 equiv) and 
13d (27.6 mg, 0.10 mmol, 1.0 equiv). These three products could only be isolated as a mixture but 
could be analyzed by 
1
H NMR and MS. 
 
5) EPR experiments 
EPR spectra were recorded at room temperature using DMPO (5,5-dimethyl-1-pyrroline N-oxide) as 
free radical spin trapping agent.  
A dried 10 mL Schlenk tube was charged with Phebox-Ru1 (1.3 mg, 0.002 mmol, 2 mol%), NaHCO3 
H   H+H   H 
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(9.3 mg, 0.11 mmol, 1.1 equiv), 17 (40.9 mg, 0.12 mmol, 1.2 equiv) and 13c (26.2 mg, 0.10 mmol, 1.0 
equiv), then 0.37 mL MeOH and 0.13 mL THF were added. The reaction mixture was degassed via 
freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and 
put in pre-heated silicone oil bath. The reaction was stirred at 40 C under nitrogen atmosphere for 1 
hour. 10 µL the reaction solution was taken out to a vial, followed by the addition of 10 µL DMPO 
(5,5-dimethylM-1-pyrroline N-oxide) solution (1 M in H2O). The resulting mixture was stirred for 5 
min. Then, a portion of the reaction mixture was taken out to an EPR tube and measured by EPR 
(9.17965 GHz; Mod. Frequency = 100 kHz; Mod. Ampl. = 0.12 mT).  
The EPR experiment was also performed for the standard catalytic reaction according to the above 
same procedure.  
 
6) Catalytic homocoupling reaction with 17 as the substrate 
 
A dried 10 mL Schlenk tube was charged with Phebox-Ru1 (3.7 mg, 0.006 mmol, 2 mol%), NaHCO3 
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(27.8 mg, 0.33 mmol, 1.1 equiv) and 17 (102.3 mg, 0.30 mmol, 1.0 equiv), then 1.1 mL MeOH and 
0.4 mL THF were added. The reaction mixture was degassed via freeze-pump-thaw for three cycles. 
After the mixture was thoroughly degassed, the vial was sealed and put in pre-heated silicone oil bath. 
The reaction was stirred at 40 C for 48 hours under nitrogen atmosphere. Afterwards, the mixture was 
concentrated under reduced pressure, and the residue was purified by flash chromatography on silica 
gel (EtOAc/hexane = 1:5 to 1:3) to afford the analytically pure homocoupling product 15c (11.8 mg, 
0.023 mmol, 12% yield). 
5.4.5 Single Crystal X-Ray Diffraction Study of Ruthenium Enolate 16 
Crystals of ruthenium enolate 16 was obtained by slow diffusion from a solution of the compounds in 
CH2Cl2 layered with n-hexane at room temperature for several days.  
Crystal data and details of the structure determination are presented in Table 11. X-ray data were 
collected with a Bruker 3 circuit D8 Quest diffractometer with MoKa radiation (microfocus tube with 
multilayer optics) and Photon 100 CMOS detector at 115 K. Scaling and absorption correction was 
performed by using the SADABS
6 
software package of Bruker. Structures were solved using direct 
methods in SHELXS or SHELXT
7 
and refined using the full matrix least squares procedure in 
SHELXL-2014
8
. The hydrogen atoms were placed in calculated positions and refined as riding on 
their respective C atom, and Uiso(H) was set at 1.2 Ueq(Csp
2
) and 1.5 Ueq(Csp
3
). Disorder of PF6 ions, 
solvent molecules or phenyl and tert-butyl groups was refined using restraints for both the geometry 
and the anisotropic displacement factors. 




Figure 38. Crystal structure of ruthenium enolate 16. ORTEP drawing with 50% probability thermal 
ellipsoids. 
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Table 11. Crystal data and details of the structure determination of ruthenium enolate 16. 
Empiric formula C44H35ClN4O4Ru 
Formula weight 820.28 
Crystal system, space group 
Orthorhombic, 
P212121 
a, b, c (Å) 13.4250(9), 13.8917(10), 19.6840(13) 







Crystal size (mm) 0.333 x 0.187 x 0.143 
Tmax, Tmin 0.93, 0.86 
No. of measured, independent and observed [I > 2 (I)] 
reflections 








), S 0.0308, 0.0697, 1.051 
No. of used reflections 8519 
No. of parameters 489 
No. of restraints 0 
max, min (e Å
-3
) 0.725, -0.561 
Absolute structure parameter -0.039(19) 
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6.1 List of Abbreviations 
1
H NMR proton nuclear magnetic resonance spectroscopy 
13
C NMR carbon nuclear magnetic resonance spectroscopy 
9











ppm parts per million 
AcOH acetic acid 
Al aluminum 
APCI atmospheric pressure chemical ionization 
aq aqueous 
Aux auxiliary 
CD circular dichroism 












DMSO dimethyl sulfoxide 
dr diastereomeric ratio 
ee enantiomeric excesses 
e.g. exempli gratia (lat.: for example) 
equiv equivalent 
et al. et alii (lat.: and others) 
ESI electrospray ionization 
EtOH ethanol 
Et2O diethyl ether 
Et3N triethyl amine 
EtOAc ethyl acetate 
GC gas chromatography 
HAT hydrogen atom transfer 
h hour(s) 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
IR spectra infrared spectra 
Ir iridium 
L liter(s) 
LDA lithium diisopropylamide 
















ppm parts per million 
rac racemate 
Rh rhodium 
r.t. room temperature 
Ru ruthenium 
SET single-electron transfer 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
Tol toluene 
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6.2 List of Figures 
Figure 1. General mechanism of a binary catalytic system for the kinetic resolution of epoxides with 
CO2. 
Figure 2. Kinetic resolution of epoxides with CO2 catalyzed by chiral cobalt Schiff base catalysts.  
Figure 3. Kinetic resolution of N-(2,3-epoxypropyl)diphenylamine with CO2 catalyzed by Al(salen) 
and Cr(salen). 
Figure 4. Kinetic resolution of epoxides with CO2 catalyzed by organocatalysts. 
Figure 5. General process of C-H amination through metal-imido intermediate. 
Figure 6. Transition-metal catalyzed enantioselective intramolecular C-H amination of sulfamate 
esters in the presence of stoichiometric amount of oxidant. 
Figure 7. Transition-metal catalyzed enantioselective intramolecular C-H amination of sulfonyl 
azides. 
Figure 8. Enantioselective intramolecular C-H amination of sulfonyl azides catalyzed by enzymes. 
Figure 9. Transition-metal catalyzed enantioselective intermolecular C-H amination with 
[N-(p-toluenesulfonyl)imino] phenyliodinane (PhINTs) as the aminating reagent. 
Figure 10. Transition-metal catalyzed enantioselective intermolecular C-H amination with 
electron-deficient organic azides as the aminating reagents. 
Figure 11. a) General scheme for oxidative coupling of carbonyl compounds; b) Mechanisms for the 
formation of the coupling product; c) Ideal way for oxidative coupling of carbonyl compounds. 
Figure 12. Chiral auxiliary-mediated asymmetric oxidative enolate coupling. 
Figure 13. Chiral transition metal catalysts with chiral or achiral ligand and representative 
chiral-at-metal catalysts developed by the Meggers group. 
Figure 14. Aim1: Expand the catalytic properties of chiral-at-metal iridium catalysts. 
Figure 15. Aim 2: Expand the catalytic properties of chiral-at-metal ruthenium catalysts. 
Figure 16. Aim 3: Expand the catalytic properties of chiral cyclometalated ruthenium catalysts. 
Figure 17. a) Enantioselective Friedel-Crafts alkylation of substrate with two-point binding; b) ATH 
reaction of substrate with one-point binding; c) Kinetic resolution of epoxide with CO2. 
Figure 18. Asymmetric coupling of various epoxides with CO2. 
a
MB = mass balance. 
 b
 Reaction 
time was 70 h.. 
c
2 mol% nBu4NBr, 1 mol% -IrO(Carb) and 45 h were used instead. 
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Figure 19. Additional experiments. a) Investigation of match and mismatch of chiral catalyst 
and epoxide substrate. b) Dependence of enantioselectivity and s-factor on the conversion. 
Reaction conditions: glycidyl ether 4b (0.2 mmol) with -IrO(Carb) (2.0 mol%), Et4NBr (3.0 
mol%) in 1,4-dioxane (57 µL) at room temperature under 20 bar CO2. c) Stoichiometric 
reaction of IrO(Carb) with nBu4NBr. 
Figure 20. Proposed mechanism for the kinetic resolution of epoxides with CO2. 
Figure 21. Transformations via the ruthenium imido intermediate. 
Figure 22. Previous work on ring-closing C(sp
3
)-H aminations of primary aliphatic azides. 
Figure 23. Substrate scope for the enantioselective intramolecular C-H amination of aliphatic azide 
with isolated yield. 
a
Recovered starting materials were showed in parentheses. 
b
0.1 M 
1,2-dichlorobenzene and 85 °C were used instead. 
Figure 24. Synthesis of anti-tumor alkaloid (R)-(+)-crispine A from pyrrolidine (R)-10g. 
Figure 25. Mechanism studies for the enantioselective intramolecular C-H amination of aliphatic 
azide. 
Figure 26. Proposed mechanism for the enantioselective intramolecular C-H amination of aliphatic 
azide. 
Figure 27. Asymmetric transformations catalyzed by chiral cyclometalated ruthenium complex 
(Phebox-Ru1). 
Figure 28. a) General strategy for oxidative homocoupling of carbonyl compounds; b) Previous report 
on direct asymmetric oxidative homocoupling of carbonyl compounds. 
Figure 29. Substrate scope of direct asymmetric oxidative homocoupling of 2-acyl imidazoles with 
isolated yields. 
Figure 30. a) Preparation of the chiral ruthenium enolate intermediate; b) The chiral ruthenium enolate 
intermediate as the catalyst for the homocoupling of 13l. 
Figure 31. a) Monitor the reation by 
1
H NMR; b) Heterocoupling of 17 with 13c or 13d. 
Figure 32. a) EPR experiment; b) Catalytic reaction with 17 as the substrate. 
Figure 33. Proposed mechanism for the homocoupling of 2-acyl imidazoles. 
Figure 34. Kinetic resolution of epoxides with CO2 catalyzed by -IrO(Carb). 
Figure 35. Enantioselective intramolecular C-H amination of aliphatic azides by dual ruthenium and 
phosphine catalysis. 
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Figure 36. Asymmetric direct oxidative homocoupling of 2-acyl imidazole catalyzed by 
cyclometalated ruthenium complex. 
Figure 37. Crystal structure of Ir complex -IrO(Carb). ORTEP drawing with 50% probability 
thermal ellipsoids. 




H NMR (in CD3CN) and 
13
C NMR (in CD2Cl2) spectrum of IrO(Carb). 
Figure 40. 
1
H NMR and 
13
C NMR spectrum of Ru1 in CD2Cl2. 
Figure 41. 
1
H NMR and 
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C NMR spectrum of Ru4 in CD2Cl2. 
Figure 42. 
1
H NMR and 
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C NMR spectrum of Ru7 in CD2Cl2. 
Figure 44. HPLC traces of rac-5a and (R)-5a (81% ee). 
Figure 45. HPLC traces of rac-5b and (R)-5b (82% ee). 
Figure 46. HPLC traces of rac-5c and (R)-5c (82% ee). 
Figure 47. HPLC traces of rac-5d and (R)-5d (82% ee). 
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Figure 61. HPLC traces of rac-5r and (S)-5r (86% ee). 
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Figure 63. GC traces of rac-5t and (R)-5t (70% ee). 
Figure 64. HPLC traces of rac-5v and (R)-5v (74% ee). 
Figure 65. HPLC traces of (R)-10a (95% ee) and rac-10a. 
Figure 66. HPLC traces of (R)-10b (93% ee) and rac-10b. 
Figure 67. HPLC traces of (R)-10c (91% ee) and rac-10c. 
Figure 68. HPLC traces of (R)-10d (90% ee) and rac-10d.  
Figure 69. HPLC traces of (R)-10e (99% ee) and rac-10e.  
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Figure 72. HPLC traces of (R)-10h (94% ee) and rac-10h. 
Figure 73. HPLC traces of (R)-10i (77% ee) and rac-10i. 
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Figure 93. HPLC traces of rac-15h and (2R, 3R)-15h (91% ee). 
Figure 94. HPLC traces of rac-15i and (2R, 3R)-15i (94% ee). 
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6.5 List of Synthesized Compounds 
1) Chapter 3.1 and its Experimental Part 
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2) Chapter 3.2 and its Experimental Part 
 









3) Chapter 3.3 and its Experimental Part 
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6.6 List of Spectra of Complexes 





H NMR (in CD3CN) and 
13
C NMR (in CD2Cl2) spectrum of Λ-IrO(Carb). 







H NMR and 
13
C NMR spectrum of rac-Ru1 in CD2Cl2. 







H NMR and 
13
C NMR spectrum of rac-Ru4 in CD2Cl2. 
 







H NMR and 
13
C NMR spectrum of rac-Ru6 in CD2Cl2. 
 









C NMR spectrum of rac-Ru7 in CD2Cl2. 
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2) Chromatography on chiral stationary phase 




Figure 44. HPLC traces of rac-5a and (R)-5a (81% ee). 







Figure 45. HPLC traces of rac-5b and (R)-5b (82% ee). 







Figure 46. HPLC traces of rac-5c and (R)-5c (82% ee). 
 







Figure 47. HPLC traces of rac-5d and (R)-5d (82% ee). 







Figure 48. HPLC traces of rac-5e and (R)-5e (80% ee). 







Figure 49. HPLC traces of rac-5f and (R)-5f (80% ee). 
 
 







Figure 50. HPLC traces of rac-5g and (R)-5g (80% ee). 







Figure 51. HPLC traces of rac-5h and (R)-5h (78% ee). 







Figure 52. HPLC traces of rac-5i and (R)-5i (80% ee). 
 







Figure 53. HPLC traces of rac-5j and (R)-5j (82% ee). 
 







Figure 54. HPLC traces of rac-5k and (R)-5k (82% ee). 



















Figure 56. HPLC traces of rac-5m and (R)-5m (76% ee). 
 







Figure 57. HPLC traces of rac-5n and (R)-5n (74% ee). 
 







Figure 58. HPLC traces of rac-5o and (R)-5o (78% ee). 
 







Figure 59. GC traces of rac-5p and (S)-5p (74% ee). 







Figure 60. GC traces of rac-5q and (S)-5q (68% ee). 







Figure 61. HPLC traces of rac-5r and (S)-5r (86% ee). 
 







Figure 62. HPLC traces of rac-5s and (S)-5s (80% ee). 
 







Figure 63. GC traces of rac-5t and (R)-5t (70% ee). 
 







Figure 64. HPLC traces of rac-5v and (R)-5v (74% ee). 







Figure 65. HPLC traces of (R)-10a (95% ee) and rac-10a. 







Figure 66. HPLC traces of (R)-10b (93% ee) and rac-10b. 







Figure 67. HPLC traces of (R)-10c (91% ee) and rac-10c. 
 







Figure 68. HPLC traces of (R)-10d (90% ee) and rac-10d.  
 






Figure 69. HPLC traces of (R)-10e (99% ee) and rac-10e.  
 







Figure 70. HPLC traces of (R)-10f (94% ee) and rac-10f. 







Figure 71. HPLC traces of (R)-10g (94% ee) and rac-10g. 







Figure 72. HPLC traces of (R)-10h (94% ee) and rac-10h. 







Figure 73. HPLC traces of (R)-10i (77% ee) and rac-10i. 







Figure 74. HPLC traces of (R)-10j (92% ee) and rac-10j. 







Figure 75. HPLC traces of (R)-10k (92% ee) and rac-10k. 







Figure 76. HPLC traces of (R)-10l (94% ee) and rac-10l.  







Figure 77. HPLC traces of (R)-10m (95% ee) and rac-10m.  
 







Figure 78. HPLC traces of (R)-10n (96% ee) and rac-10n.  







Figure 79. HPLC traces of (R)-10o (95% ee) and rac-10o. 







Figure 80. HPLC traces of (R)-10p (80% ee) and rac-10p.  







Figure 81. HPLC traces of (R)-10q (90% ee) and rac-10q.  
 







Figure 82. HPLC traces of (R)-10r (76% ee) and rac-10r.  
 








Figure 83. HPLC traces of (R)-10s (93% ee) and rac-10s.  







Figure 84. HPLC traces of (S)-10t (80% ee) and rac-10t.  







Figure 85. HPLC traces of (S)-10u (94% ee) and rac-10u.  







Figure 86. HPLC traces of (R)-10y (46% ee) and rac-10y.  
 







Figure 87. HPLC traces of rac-15a and (2R, 3R)-15a (45% ee). 







Figure 88. HPLC traces of rac-15b and (2R, 3R)-15b (67% ee). 







Figure 89. HPLC traces of rac-15c and (2R, 3R)-15c (94% ee). 






Figure 90. HPLC traces of rac-15d and (2R, 3R)-15d (93% ee). 







Figure 91. HPLC traces of rac-15e and (2R, 3R)-15e (87% ee). 





Figure 92. HPLC traces of rac-15g and (2R, 3R)-15g (92% ee). 





Figure 93. HPLC traces of rac-15h and (2R, 3R)-15h (91% ee). 







Figure 94. HPLC traces of rac-15i and (2R, 3R)-15i (94% ee). 





Figure 95. HPLC traces of rac-15j and (2R, 3R)-15j (82% ee). 







Figure 96. HPLC traces of rac-15k and (2R, 3R)-15k (58% ee). 







Figure 97. HPLC traces of rac-15l and (2R, 3R)-15l (75% ee). 






Figure 98. HPLC traces of rac-15m and (2R, 3R)-15m (57% ee). 







Figure 99. HPLC traces of rac-15n and (2R, 3R)-15n (80% ee). 
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